WO2010059836A1 - Substituted aza-bridged bicyclics for cardiovascular and cns disease - Google Patents
Substituted aza-bridged bicyclics for cardiovascular and cns disease Download PDFInfo
- Publication number
- WO2010059836A1 WO2010059836A1 PCT/US2009/065162 US2009065162W WO2010059836A1 WO 2010059836 A1 WO2010059836 A1 WO 2010059836A1 US 2009065162 W US2009065162 W US 2009065162W WO 2010059836 A1 WO2010059836 A1 WO 2010059836A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nhc
- compound according
- optionally substituted
- alkyl
- nitrogen
- Prior art date
Links
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 17
- 201000010099 disease Diseases 0.000 title claims description 13
- 125000002619 bicyclic group Chemical group 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 140
- 238000000034 method Methods 0.000 claims abstract description 47
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 32
- 241000124008 Mammalia Species 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 208000010125 myocardial infarction Diseases 0.000 claims abstract description 7
- 230000004968 inflammatory condition Effects 0.000 claims abstract description 6
- -1 3-nitrophenyl Chemical group 0.000 claims description 98
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 75
- 125000000217 alkyl group Chemical group 0.000 claims description 61
- 229910052757 nitrogen Inorganic materials 0.000 claims description 59
- 229910052739 hydrogen Inorganic materials 0.000 claims description 47
- 239000001257 hydrogen Substances 0.000 claims description 45
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 44
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 43
- 125000001424 substituent group Chemical group 0.000 claims description 32
- 235000001014 amino acid Nutrition 0.000 claims description 29
- 150000001413 amino acids Chemical class 0.000 claims description 29
- 125000003118 aryl group Chemical group 0.000 claims description 28
- 239000003795 chemical substances by application Substances 0.000 claims description 28
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 23
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 22
- 229910052799 carbon Inorganic materials 0.000 claims description 20
- 125000001072 heteroaryl group Chemical group 0.000 claims description 19
- 229910052760 oxygen Inorganic materials 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 17
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 15
- 125000005842 heteroatom Chemical group 0.000 claims description 15
- 125000004076 pyridyl group Chemical group 0.000 claims description 15
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 10
- 125000001188 haloalkyl group Chemical group 0.000 claims description 10
- 125000003107 substituted aryl group Chemical group 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 8
- 150000001408 amides Chemical class 0.000 claims description 8
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 8
- 125000004043 oxo group Chemical group O=* 0.000 claims description 8
- 125000003282 alkyl amino group Chemical group 0.000 claims description 7
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 7
- 208000006673 asthma Diseases 0.000 claims description 7
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 7
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 6
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims description 6
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 6
- 201000000980 schizophrenia Diseases 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 5
- 206010065687 Bone loss Diseases 0.000 claims description 5
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 208000020358 Learning disease Diseases 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 5
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 5
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 5
- 201000003723 learning disability Diseases 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 206010063057 Cystitis noninfective Diseases 0.000 claims description 4
- 206010037211 Psychomotor hyperactivity Diseases 0.000 claims description 4
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims description 4
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims description 4
- 125000004442 acylamino group Chemical group 0.000 claims description 4
- 125000004945 acylaminoalkyl group Chemical group 0.000 claims description 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 4
- 125000000676 alkoxyimino group Chemical group 0.000 claims description 4
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 4
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 4
- 125000005518 carboxamido group Chemical group 0.000 claims description 4
- 230000019771 cognition Effects 0.000 claims description 4
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 4
- 125000004984 dialkylaminoalkoxy group Chemical group 0.000 claims description 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 4
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 4
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 4
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 4
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 claims description 4
- 125000004497 pyrazol-5-yl group Chemical group N1N=CC=C1* 0.000 claims description 4
- 125000003396 thiol group Chemical class [H]S* 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 claims description 3
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 206010005063 Bladder pain Diseases 0.000 claims description 3
- 206010022562 Intermittent claudication Diseases 0.000 claims description 3
- 206010034576 Peripheral ischaemia Diseases 0.000 claims description 3
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 3
- 229910006074 SO2NH2 Inorganic materials 0.000 claims description 3
- 208000007718 Stable Angina Diseases 0.000 claims description 3
- 208000007536 Thrombosis Diseases 0.000 claims description 3
- 208000002223 abdominal aortic aneurysm Diseases 0.000 claims description 3
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 3
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 3
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 claims description 3
- 208000007474 aortic aneurysm Diseases 0.000 claims description 3
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims description 3
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 claims description 3
- 125000005110 aryl thio group Chemical group 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims description 3
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 3
- 208000021156 intermittent vascular claudication Diseases 0.000 claims description 3
- VMWJCFLUSKZZDX-UHFFFAOYSA-N n,n-dimethylmethanamine Chemical compound [CH2]N(C)C VMWJCFLUSKZZDX-UHFFFAOYSA-N 0.000 claims description 3
- 125000000160 oxazolidinyl group Chemical group 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 125000000335 thiazolyl group Chemical group 0.000 claims description 3
- VGJVKLWPZBTZIL-UHFFFAOYSA-N 1-phenylmethoxyazetidine Chemical compound C=1C=CC=CC=1CON1CCC1 VGJVKLWPZBTZIL-UHFFFAOYSA-N 0.000 claims description 2
- YSGASDXSLKIKOD-UHFFFAOYSA-N 2-amino-N-(1,2-diphenylpropan-2-yl)acetamide Chemical compound C=1C=CC=CC=1C(C)(NC(=O)CN)CC1=CC=CC=C1 YSGASDXSLKIKOD-UHFFFAOYSA-N 0.000 claims description 2
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims description 2
- ZQPQGKQTIZYFEF-WCVJEAGWSA-N Huperzine Natural products C1([C@H]2[C@H](O)C(=O)N[C@H]2[C@@H](O)C=2C=CC=CC=2)=CC=CC=C1 ZQPQGKQTIZYFEF-WCVJEAGWSA-N 0.000 claims description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 235000006708 antioxidants Nutrition 0.000 claims description 2
- 108010079785 calpain inhibitors Proteins 0.000 claims description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 2
- 239000005515 coenzyme Substances 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 229960003530 donepezil Drugs 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- FWUQWDCOOWEXRY-ZDUSSCGKSA-N lanicemine Chemical compound C([C@H](N)C=1C=CC=CC=1)C1=CC=CC=N1 FWUQWDCOOWEXRY-ZDUSSCGKSA-N 0.000 claims description 2
- 229950003165 lanicemine Drugs 0.000 claims description 2
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims description 2
- 229960004640 memantine Drugs 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- OGZQTTHDGQBLBT-UHFFFAOYSA-N neramexane Chemical compound CC1(C)CC(C)(C)CC(C)(N)C1 OGZQTTHDGQBLBT-UHFFFAOYSA-N 0.000 claims description 2
- 229950004543 neramexane Drugs 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 229950000659 remacemide Drugs 0.000 claims description 2
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960001685 tacrine Drugs 0.000 claims description 2
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 230000003920 cognitive function Effects 0.000 claims 4
- 125000006706 (C3-C6) carbocyclyl group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical group 0.000 claims 2
- 235000010290 biphenyl Nutrition 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 abstract description 5
- APXRHPDHORGIEB-UHFFFAOYSA-N 1H-pyrazolo[4,3-d]pyrimidine Chemical class N1=CN=C2C=NNC2=C1 APXRHPDHORGIEB-UHFFFAOYSA-N 0.000 abstract description 3
- OAYOKHKMIWKLTD-UHFFFAOYSA-N pyrazolo[4,3-d]triazin-4-one Chemical class O=C1N=NN=C2C=NN=C12 OAYOKHKMIWKLTD-UHFFFAOYSA-N 0.000 abstract description 3
- 150000005229 pyrazolopyridines Chemical class 0.000 abstract description 3
- 150000008523 triazolopyridines Chemical class 0.000 abstract description 3
- 150000005232 imidazopyridines Chemical class 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 126
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 100
- 239000000203 mixture Substances 0.000 description 85
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 70
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 69
- 239000007787 solid Substances 0.000 description 55
- 239000011541 reaction mixture Substances 0.000 description 51
- 230000015572 biosynthetic process Effects 0.000 description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 48
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 44
- 235000019439 ethyl acetate Nutrition 0.000 description 43
- 238000003786 synthesis reaction Methods 0.000 description 41
- 229940093499 ethyl acetate Drugs 0.000 description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 39
- 238000009472 formulation Methods 0.000 description 39
- 239000012267 brine Substances 0.000 description 38
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 38
- 239000007832 Na2SO4 Substances 0.000 description 37
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 37
- 229910052938 sodium sulfate Inorganic materials 0.000 description 37
- 235000011152 sodium sulphate Nutrition 0.000 description 37
- 238000005160 1H NMR spectroscopy Methods 0.000 description 33
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 32
- 239000000243 solution Substances 0.000 description 32
- 239000013058 crude material Substances 0.000 description 30
- 239000003480 eluent Substances 0.000 description 30
- 238000004440 column chromatography Methods 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 26
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 25
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 25
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 25
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 24
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 24
- 239000002904 solvent Substances 0.000 description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 19
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 18
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 16
- 235000017557 sodium bicarbonate Nutrition 0.000 description 16
- 239000000543 intermediate Substances 0.000 description 15
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 150000003840 hydrochlorides Chemical class 0.000 description 12
- 229910000027 potassium carbonate Inorganic materials 0.000 description 12
- TWKVUTXHANJYGH-UHFFFAOYSA-L allyl palladium chloride Chemical class Cl[Pd]CC=C.Cl[Pd]CC=C TWKVUTXHANJYGH-UHFFFAOYSA-L 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 239000001301 oxygen Substances 0.000 description 11
- 235000015320 potassium carbonate Nutrition 0.000 description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 description 9
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 description 9
- 239000000443 aerosol Substances 0.000 description 9
- 208000010877 cognitive disease Diseases 0.000 description 9
- 125000000753 cycloalkyl group Chemical group 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- MZFPAWGWFDGCHP-UHFFFAOYSA-N 5-diphenylphosphanylpentyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCCCP(C=1C=CC=CC=1)C1=CC=CC=C1 MZFPAWGWFDGCHP-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- LENLQGBLVGGAMF-UHFFFAOYSA-N tributyl([1,2,4]triazolo[1,5-a]pyridin-6-yl)stannane Chemical compound C1=C([Sn](CCCC)(CCCC)CCCC)C=CC2=NC=NN21 LENLQGBLVGGAMF-UHFFFAOYSA-N 0.000 description 6
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 229920005654 Sephadex Polymers 0.000 description 5
- 239000012507 Sephadex™ Substances 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 229950001653 cilomilast Drugs 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 5
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 5
- 230000002685 pulmonary effect Effects 0.000 description 5
- 238000007363 ring formation reaction Methods 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 4
- BJRXZMCJFCAZDL-UHFFFAOYSA-N 2-bromopropanal Chemical compound CC(Br)C=O BJRXZMCJFCAZDL-UHFFFAOYSA-N 0.000 description 4
- YFTAUNOLAHRUIE-UHFFFAOYSA-N 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(N)N=C1 YFTAUNOLAHRUIE-UHFFFAOYSA-N 0.000 description 4
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 4
- 0 CP(*(C(**)=*1)NC(*)*)C(*)(*)N1N* Chemical compound CP(*(C(**)=*1)NC(*)*)C(*)(*)N1N* 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 229960001456 adenosine triphosphate Drugs 0.000 description 4
- 125000004452 carbocyclyl group Chemical group 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 229940126142 compound 16 Drugs 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 4
- OTZRAYGBFWZKMX-JUDRUQEKSA-N leukotriene E4 Chemical compound CCCCCC=CCC=C\C=C\C=C\[C@@H](SC[C@H](N)C(O)=O)[C@@H](O)CCCC(O)=O OTZRAYGBFWZKMX-JUDRUQEKSA-N 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 208000027061 mild cognitive impairment Diseases 0.000 description 4
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 4
- 229950005741 rolipram Drugs 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 229960001866 silicon dioxide Drugs 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 3
- OJBYZWHAPXIJID-UHFFFAOYSA-N (6-fluoropyridin-3-yl)boronic acid Chemical compound OB(O)C1=CC=C(F)N=C1 OJBYZWHAPXIJID-UHFFFAOYSA-N 0.000 description 3
- OSSMJQGXYASWSA-UHFFFAOYSA-N 2,2,2-trichloroethylphosphane Chemical compound PCC(Cl)(Cl)Cl OSSMJQGXYASWSA-UHFFFAOYSA-N 0.000 description 3
- HYCRIDFDPOZBTQ-UHFFFAOYSA-N 5-(bromomethyl)-1h-pyrazole Chemical compound BrCC=1C=CNN=1 HYCRIDFDPOZBTQ-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000002281 Adenylate kinase Human genes 0.000 description 3
- 108020000543 Adenylate kinase Proteins 0.000 description 3
- 208000000044 Amnesia Diseases 0.000 description 3
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 3
- 201000011240 Frontotemporal dementia Diseases 0.000 description 3
- OTZRAYGBFWZKMX-SHSCPDMUSA-N Leukotriene E4 Natural products CCCCCC=C/CC=C/C=C/C=C/C(SCC(N)C(=O)O)C(O)CCCC(=O)O OTZRAYGBFWZKMX-SHSCPDMUSA-N 0.000 description 3
- 208000026139 Memory disease Diseases 0.000 description 3
- 229910020667 PBr3 Inorganic materials 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 102000013009 Pyruvate Kinase Human genes 0.000 description 3
- 108020005115 Pyruvate Kinase Proteins 0.000 description 3
- 238000006619 Stille reaction Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 3
- 208000024823 antisocial personality disease Diseases 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000006984 memory degeneration Effects 0.000 description 3
- 208000023060 memory loss Diseases 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- DTBNBXWJWCWCIK-UHFFFAOYSA-K phosphonatoenolpyruvate Chemical compound [O-]C(=O)C(=C)OP([O-])([O-])=O DTBNBXWJWCWCIK-UHFFFAOYSA-K 0.000 description 3
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- XXAFQSGWAGUKDT-UHFFFAOYSA-N (4-aminophenyl)boronic acid;2,3-dimethylbutane-2,3-diol Chemical compound CC(C)(O)C(C)(C)O.NC1=CC=C(B(O)O)C=C1 XXAFQSGWAGUKDT-UHFFFAOYSA-N 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- FWNHUZOBVQZERU-UHFFFAOYSA-N 5-methyl-1h-pyrazole-3-carbohydrazide Chemical compound CC1=CC(C(=O)NN)=NN1 FWNHUZOBVQZERU-UHFFFAOYSA-N 0.000 description 2
- GXWNSJYVSIJRLS-UHFFFAOYSA-N 6-bromo-8-methylimidazo[1,2-a]pyrazine Chemical compound CC1=NC(Br)=CN2C=CN=C12 GXWNSJYVSIJRLS-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 101150041968 CDC13 gene Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 208000031124 Dementia Alzheimer type Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 208000032274 Encephalopathy Diseases 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000007126 N-alkylation reaction Methods 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000036752 Schizophrenia, paranoid type Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
- 229950006790 adenosine phosphate Drugs 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000005111 carboxyalkoxy group Chemical group 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 210000001652 frontal lobe Anatomy 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- PHAOQQLUFOSENJ-UHFFFAOYSA-N methyl 6-amino-5-(3-chlorophenyl)pyridine-3-carboxylate Chemical compound COC(=O)C1=CN=C(N)C(C=2C=C(Cl)C=CC=2)=C1 PHAOQQLUFOSENJ-UHFFFAOYSA-N 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 125000002524 organometallic group Chemical group 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012746 preparative thin layer chromatography Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- XFTQRUTUGRCSGO-UHFFFAOYSA-N pyrazin-2-amine Chemical compound NC1=CN=CC=N1 XFTQRUTUGRCSGO-UHFFFAOYSA-N 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 2
- 229960002586 roflumilast Drugs 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000003478 temporal lobe Anatomy 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- CFOAUYCPAUGDFF-UHFFFAOYSA-N tosmic Chemical class CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 2
- 235000019798 tripotassium phosphate Nutrition 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- SDEAGACSNFSZCU-UHFFFAOYSA-N (3-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(Cl)=C1 SDEAGACSNFSZCU-UHFFFAOYSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 1
- KMJTVTWYQBINHU-UHFFFAOYSA-N (6-aminopyridin-3-yl)boronic acid;2,3-dimethylbutane-2,3-diol Chemical compound CC(C)(O)C(C)(C)O.NC1=CC=C(B(O)O)C=N1 KMJTVTWYQBINHU-UHFFFAOYSA-N 0.000 description 1
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- FBZVZUSVGKOWHG-UHFFFAOYSA-N 1,1-dimethoxy-n,n-dimethylethanamine Chemical compound COC(C)(OC)N(C)C FBZVZUSVGKOWHG-UHFFFAOYSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- 150000000185 1,3-diols Chemical class 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- HKDFRDIIELOLTJ-UHFFFAOYSA-N 1,4-dithianyl Chemical group [CH]1CSCCS1 HKDFRDIIELOLTJ-UHFFFAOYSA-N 0.000 description 1
- NVNPLEPBDPJYRZ-UHFFFAOYSA-N 1-(bromomethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CBr)C=C1 NVNPLEPBDPJYRZ-UHFFFAOYSA-N 0.000 description 1
- MONVOHRDPXYPGQ-UHFFFAOYSA-N 1-diphenylphosphanylpentyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)C(CCCC)P(C=1C=CC=CC=1)C1=CC=CC=C1 MONVOHRDPXYPGQ-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- ZKAMEFMDQNTDFK-UHFFFAOYSA-N 1h-imidazo[4,5-b]pyrazine Chemical class C1=CN=C2NC=NC2=N1 ZKAMEFMDQNTDFK-UHFFFAOYSA-N 0.000 description 1
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 1
- GOWXFLLEOIKUCC-UHFFFAOYSA-N 2,3-dimethylbutane-2,3-diol;(6-methoxycarbonylpyridin-3-yl)boronic acid Chemical compound CC(C)(O)C(C)(C)O.COC(=O)C1=CC=C(B(O)O)C=N1 GOWXFLLEOIKUCC-UHFFFAOYSA-N 0.000 description 1
- MVAXDKDOPWPFML-UHFFFAOYSA-N 2-(dimethylamino)acetyl chloride;hydrochloride Chemical compound [Cl-].C[NH+](C)CC(Cl)=O MVAXDKDOPWPFML-UHFFFAOYSA-N 0.000 description 1
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 description 1
- QSKPIOLLBIHNAC-UHFFFAOYSA-N 2-chloro-acetaldehyde Chemical compound ClCC=O QSKPIOLLBIHNAC-UHFFFAOYSA-N 0.000 description 1
- DILXLMRYFWFBGR-UHFFFAOYSA-N 2-formylbenzene-1,4-disulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(S(O)(=O)=O)C(C=O)=C1 DILXLMRYFWFBGR-UHFFFAOYSA-N 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- CAAMSDWKXXPUJR-UHFFFAOYSA-N 3,5-dihydro-4H-imidazol-4-one Chemical compound O=C1CNC=N1 CAAMSDWKXXPUJR-UHFFFAOYSA-N 0.000 description 1
- ONNMDRQRSGKZCN-UHFFFAOYSA-N 3-aminopropyl(butyl)phosphinic acid Chemical compound CCCCP(O)(=O)CCCN ONNMDRQRSGKZCN-UHFFFAOYSA-N 0.000 description 1
- BNBOUFHCTIFWHN-UHFFFAOYSA-N 3-bromobutan-2-one Chemical compound CC(Br)C(C)=O BNBOUFHCTIFWHN-UHFFFAOYSA-N 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical class C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- YCIPQJTZJGUXND-UHFFFAOYSA-N Aglaia odorata Alkaloid Natural products C1=CC(OC)=CC=C1C1(C(C=2C(=O)N3CCCC3=NC=22)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 YCIPQJTZJGUXND-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 208000029197 Amphetamine-Related disease Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 206010002820 Antisocial behaviour Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 102000007371 Ataxin-3 Human genes 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- AFWTZXXDGQBIKW-UHFFFAOYSA-N C14 surfactin Natural products CCCCCCCCCCCC1CC(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O1 AFWTZXXDGQBIKW-UHFFFAOYSA-N 0.000 description 1
- ZRJJMUDVHYYASC-ULKAAYNESA-N CC(C)[C@@H](C)NC1NC(CO)CC1C(C1)=C[C@@H](C)CC1Cl Chemical compound CC(C)[C@@H](C)NC1NC(CO)CC1C(C1)=C[C@@H](C)CC1Cl ZRJJMUDVHYYASC-ULKAAYNESA-N 0.000 description 1
- LDCDYOCLKGVKIY-JLHYYAGUSA-N CC1(C)N/C=C(/CN2CCCC2)\CCCNC1 Chemical compound CC1(C)N/C=C(/CN2CCCC2)\CCCNC1 LDCDYOCLKGVKIY-JLHYYAGUSA-N 0.000 description 1
- HSGRVYNGKSNHCW-UHFFFAOYSA-N CCOC(Nc1ncc(Cc2c[n]3nc(C)nc3c(-c3cc(Cl)ccc3)c2)cc1)=O Chemical compound CCOC(Nc1ncc(Cc2c[n]3nc(C)nc3c(-c3cc(Cl)ccc3)c2)cc1)=O HSGRVYNGKSNHCW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000004894 Camptocormia Diseases 0.000 description 1
- 201000001601 Capgras syndrome Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007270 Carcinoid syndrome Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- QAIOFVDIUOSPQH-UHFFFAOYSA-N Cc1c[n](cc(cc2-c3cc(Cl)ccc3)C(Nc3cccnc3)=O)c2n1 Chemical compound Cc1c[n](cc(cc2-c3cc(Cl)ccc3)C(Nc3cccnc3)=O)c2n1 QAIOFVDIUOSPQH-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- XXGMIHXASFDFSM-UHFFFAOYSA-N Delta9-tetrahydrocannabinol Natural products CCCCCc1cc2OC(C)(C)C3CCC(=CC3c2c(O)c1O)C XXGMIHXASFDFSM-UHFFFAOYSA-N 0.000 description 1
- 206010012245 Delusion of replacement Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- 208000009396 Group II Malformations of Cortical Development Diseases 0.000 description 1
- INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 208000003698 Heroin Dependence Diseases 0.000 description 1
- 208000000903 Herpes simplex encephalitis Diseases 0.000 description 1
- 101000988419 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4D Proteins 0.000 description 1
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 description 1
- 208000005031 Hyperostosis Frontalis Interna Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020853 Hypertonic bladder Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 208000006264 Korsakoff syndrome Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000008763 Mercury poisoning Diseases 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000022750 Morgagni-Stewart-Morel syndrome Diseases 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 208000009507 Nervous System Mercury Poisoning Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 241000255964 Pieridae Species 0.000 description 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 208000007432 Roifman syndrome Diseases 0.000 description 1
- 229910020008 S(O) Inorganic materials 0.000 description 1
- 208000018642 Semantic dementia Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041243 Social avoidant behaviour Diseases 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 208000014604 Specific Language disease Diseases 0.000 description 1
- 201000010829 Spina bifida Diseases 0.000 description 1
- 208000006097 Spinal Dysraphism Diseases 0.000 description 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- DHCOPPHTVOXDKU-UHFFFAOYSA-N Tofimilast Chemical compound C1CN2C(C=3SC=CC=3)=NN=C2C2=C1C(CC)=NN2C1CCCC1 DHCOPPHTVOXDKU-UHFFFAOYSA-N 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 description 1
- 206010072731 White matter lesion Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- PBHFNBQPZCRWQP-QUCCMNQESA-N [(3ar,8bs)-3,4,8b-trimethyl-2,3a-dihydro-1h-pyrrolo[2,3-b]indol-7-yl] n-phenylcarbamate Chemical compound CN([C@@H]1[C@@](C2=C3)(C)CCN1C)C2=CC=C3OC(=O)NC1=CC=CC=C1 PBHFNBQPZCRWQP-QUCCMNQESA-N 0.000 description 1
- YPFLFUJKZDAXRA-UHFFFAOYSA-N [3-(carbamoylamino)-2-(2,4-dichlorobenzoyl)-1-benzofuran-6-yl] methanesulfonate Chemical compound O1C2=CC(OS(=O)(=O)C)=CC=C2C(NC(N)=O)=C1C(=O)C1=CC=C(Cl)C=C1Cl YPFLFUJKZDAXRA-UHFFFAOYSA-N 0.000 description 1
- BVWCMMVUJQHJJE-UHFFFAOYSA-N [4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]urea Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(NC(N)=O)C=C1 BVWCMMVUJQHJJE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- SATGEQMVIZSAFR-UHFFFAOYSA-N acetyloxysulfinyl acetate Chemical compound CC(=O)OS(=O)OC(C)=O SATGEQMVIZSAFR-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000005255 adrenal gland hyperfunction Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 1
- 125000004949 alkyl amino carbonyl amino group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- CHKQALUEEULCPZ-UHFFFAOYSA-N amino 2,4,6-trimethylbenzenesulfonate Chemical compound CC1=CC(C)=C(S(=O)(=O)ON)C(C)=C1 CHKQALUEEULCPZ-UHFFFAOYSA-N 0.000 description 1
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 1
- 229960003036 amisulpride Drugs 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 229940124604 anti-psychotic medication Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 238000010936 aqueous wash Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 1
- 229960002430 atomoxetine Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- IADUEWIQBXOCDZ-UHFFFAOYSA-N azetidine-2-carboxylic acid Chemical compound OC(=O)C1CCN1 IADUEWIQBXOCDZ-UHFFFAOYSA-N 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000030963 borderline personality disease Diseases 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 102100029170 cAMP-specific 3',5'-cyclic phosphodiesterase 4D Human genes 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000013172 carotid endarterectomy Methods 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 201000009151 chronic rhinitis Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000009189 diving Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 206010013932 dyslexia Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- BOTXQJAHRCGJEG-UHFFFAOYSA-N ethyl 5-methyl-1h-pyrazole-3-carboxylate Chemical compound CCOC(=O)C=1C=C(C)NN=1 BOTXQJAHRCGJEG-UHFFFAOYSA-N 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 238000010228 ex vivo assay Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- STTRYQAGHGJXJJ-LICLKQGHSA-N filaminast Chemical compound COC1=CC=C(C(\C)=N\OC(N)=O)C=C1OC1CCCC1 STTRYQAGHGJXJJ-LICLKQGHSA-N 0.000 description 1
- 229950006884 filaminast Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- OFBIFZUFASYYRE-UHFFFAOYSA-N flumazenil Chemical compound C1N(C)C(=O)C2=CC(F)=CC=C2N2C=NC(C(=O)OCC)=C21 OFBIFZUFASYYRE-UHFFFAOYSA-N 0.000 description 1
- 229960004381 flumazenil Drugs 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 229960002048 guanfacine Drugs 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 150000005828 hydrofluoroalkanes Chemical class 0.000 description 1
- 125000005113 hydroxyalkoxy group Chemical group 0.000 description 1
- HPMRFMKYPGXPEP-UHFFFAOYSA-N idazoxan Chemical compound N1CCN=C1C1OC2=CC=CC=C2OC1 HPMRFMKYPGXPEP-UHFFFAOYSA-N 0.000 description 1
- 229950001476 idazoxan Drugs 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- JNODQFNWMXFMEV-UHFFFAOYSA-N latrepirdine Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 JNODQFNWMXFMEV-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229950008462 lirimilast Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000008376 long-term health Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 201000003995 melancholia Diseases 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- LNTAAMVZKGYIIA-UHFFFAOYSA-N methyl 6-amino-5-bromopyridine-3-carboxylate Chemical compound COC(=O)C1=CN=C(N)C(Br)=C1 LNTAAMVZKGYIIA-UHFFFAOYSA-N 0.000 description 1
- IMAKHNTVDGLIRY-UHFFFAOYSA-N methyl prop-2-ynoate Chemical compound COC(=O)C#C IMAKHNTVDGLIRY-UHFFFAOYSA-N 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 125000004373 methylthiopropyl group Chemical group [H]C([H])([H])SC([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 229960001165 modafinil Drugs 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 125000006203 morpholinoethyl group Chemical group [H]C([H])(*)C([H])([H])N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- MQQNFDZXWVTQEH-UHFFFAOYSA-N nafamostat Chemical compound C1=CC(N=C(N)N)=CC=C1C(=O)OC1=CC=C(C=C(C=C2)C(N)=N)C2=C1 MQQNFDZXWVTQEH-UHFFFAOYSA-N 0.000 description 1
- 229950009865 nafamostat Drugs 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 125000004998 naphthylethyl group Chemical group C1(=CC=CC2=CC=CC=C12)CC* 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 201000003077 normal pressure hydrocephalus Diseases 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002450 orbitofrontal effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001979 organolithium group Chemical group 0.000 description 1
- 239000003987 organophosphate pesticide Substances 0.000 description 1
- 208000020629 overactive bladder Diseases 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- PENAXHPKEVTBLF-UHFFFAOYSA-L palladium(2+);prop-1-ene;dichloride Chemical compound [Pd+]Cl.[Pd+]Cl.[CH2-]C=C.[CH2-]C=C PENAXHPKEVTBLF-UHFFFAOYSA-L 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- BHTUNQYYFYCLDV-UHFFFAOYSA-N phenoxymethanediol Chemical compound OC(O)OC1=CC=CC=C1 BHTUNQYYFYCLDV-UHFFFAOYSA-N 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- RRRUXBQSQLKHEL-UHFFFAOYSA-N piclamilast Chemical compound COC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OC1CCCC1 RRRUXBQSQLKHEL-UHFFFAOYSA-N 0.000 description 1
- 229950005184 piclamilast Drugs 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 208000001282 primary progressive aphasia Diseases 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 125000006513 pyridinyl methyl group Chemical group 0.000 description 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 208000022610 schizoaffective disease Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 208000012672 seasonal affective disease Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 201000002959 specific language impairment Diseases 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 229960004940 sulpiride Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- NJGWOFRZMQRKHT-UHFFFAOYSA-N surfactin Natural products CC(C)CCCCCCCCCC1CC(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O1 NJGWOFRZMQRKHT-UHFFFAOYSA-N 0.000 description 1
- NJGWOFRZMQRKHT-WGVNQGGSSA-N surfactin C Chemical compound CC(C)CCCCCCCCC[C@@H]1CC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)O1 NJGWOFRZMQRKHT-WGVNQGGSSA-N 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- RHONTQZNLFIDCQ-UHFFFAOYSA-N tert-butyl n-(2-amino-2-oxoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC(N)=O RHONTQZNLFIDCQ-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000006090 thiamorpholinyl sulfone group Chemical group 0.000 description 1
- 125000006089 thiamorpholinyl sulfoxide group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 229950003899 tofimilast Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- OVCXRBARSPBVMC-UHFFFAOYSA-N triazolopyridine Chemical group C=1N2C(C(C)C)=NN=C2C=CC=1C=1OC=NC=1C1=CC=C(F)C=C1 OVCXRBARSPBVMC-UHFFFAOYSA-N 0.000 description 1
- 208000002271 trichotillomania Diseases 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 208000009999 tuberous sclerosis Diseases 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the invention relates to substituted imidazopyridines, pyrazolotriazinones, triazolopyridines, pyrazolopyridines and pyrazolopyrimidines that are useful for treating stroke, myocardial infarct, and cardiovascular inflammatory conditions, to pharmaceutical compositions comprising these compounds, and to methods for the treatment of stroke, myocardial infarct, and cardiovascular inflammatory conditions in a mammal.
- PDE4 is the major cAMP-metabolizing enzyme found in inflammatory and immune cells.
- PDE4 inhibitors have proven potential as anti-inflammatory drugs, especially in inflammatory pulmonary diseases such as asthma, COPD and rhinitis. They suppress the release of cytokines and other inflammatory signals and inhibit the production of reactive oxygen species.
- a large number of PDE4 inhibitors have been developed for a variety of clinical indications (Torphy and Page. 2000. TIPS 21, 157-159; Burnouf and Pruniaux. 2002. Curr. Pharm. Design 8, 1255-1296; Lipworth. 2005. Lancet 365, 167-175).
- PDE4 inhibitors have been in development as a novel anti- inflammatory therapy since the 1980s with asthma and chronic obstructive pulmonary disease (COPD) being primary indications.
- COPD chronic obstructive pulmonary disease
- PDE4 inhibitors of various structural classes including cilomilast, filaminast, lirimilast, piclamilast, tofimilast has been discontinued due to lack of efficacy.
- a primary problem is the low therapeutic ratio of these compounds, which severely limits the dose that can be given.
- the compounds of the present invention are non-competitive inhibitors of cAMP while being gene- specific inhibitors (PDE4D), and, based on the target rationale and in vitro potency, a person of skill in the art would expect the compounds to be useful as anti- inflammatory agents for the treatment, amelioration or prevention of inflammatory diseases and of complications arising therefrom.
- PDE4D gene- specific inhibitors
- P is chosen from nitrogen and carbon
- Q is chosen from nitrogen and carbon, with the provisos that one of P or Q must be nitrogen, but P and Q cannot both be nitrogen;
- R 1 is selected from hydrogen, (Ci-C 6 ) alkyl, haloalkyl, -CONHR 5 , lower alkoxy, alkylamino, dialkylamino, amino, -NHCOOR 2 and -OCONH 2 ;
- W is nitrogen or CR 2 ;
- R 2 is selected from hydrogen, (Ci-C 6 ) alkyl, haloalkyl and optionally substituted heterocyclyl;
- Y is CR 3 or nitrogen
- R 3 is selected from hydrogen, fluoro, hydroxyl and -OR 10 ;
- R 10 is selected from (Ci-C 6 ) alkyl optionally substituted with fluoro;
- X is selected from CR 4 , nitrogen and N + O " ;
- R 4 is selected from hydrogen, (Ci-C 6 ) alkyl, halogen, amino, alkoxy and hydroxyl;
- R 5 is selected from hydrogen and (Ci-C 6 ) alkyl
- R 8 and R 9 are independently selected from hydrogen, (Ci-C 6 ) alkyl, (Ci-C 6 ) hydroxyalkyl, (Cs-C 6 ) carbocyclyl and a 3- to 6-membered heterocyclyl; or R 8 and R 9 together form a 4-6 membered ring which optionally contains a heteroatom selected from -O-, -NR 5 and S(O) 0-2 ; or R 8 and R 9 together form an oxo group;
- Z is selected from -O-, -S(O) 0-2 , -NH-, -CH 2 - and a direct bond;
- Cy 1 is selected from optionally substituted (Cs-C 6 ) carbocyclyl and optionally substituted heterocyclyl;
- Cy 2 is selected from optionally substituted aryl and optionally substituted heteroaryl
- M is chosen from -CH 2 -, -CH 2 CH 2 -, -O-, -S(O) 0-2 , -OCH 2 , -CH 2 O, -CONH, -CONHCH 2 , -NHCO and -NHSO 2 .
- composition comprising a compound as described herein, and a pharmaceutically acceptable carrier, excipient or diluent therefore.
- the invention relates to methods for the treatment or prophylaxis of a disease or condition mediated by phosphodiesterase-4.
- the methods comprise administering to a mammal a therapeutically effective amount of a compound having the general formula of formula I or II above.
- the disease or condition may be related to allergic, acute or chronic inflammation.
- the disease may be, for example, atherosclerosis, thrombosis, stroke, acute coronary syndrome, stable angina, peripheral vascular disease, critical leg ischemia, intermittent claudication, abdominal aortic aneurysm or myocardial infarction.
- Selective PDE4 inhibitors of the invention are useful in improving cognition and thus useful for treating learning disorders, memory loss and other cognitive dysfunctions.
- Selective PDE4 inhibitors of the invention are also useful for treating asthma and Chronic Obstructive Pulmonary Disease (COPD).
- COPD Chronic Obstructive Pulmonary Disease
- Compounds of the invention, which inhibit tumor growth and metastases, also find utility in the treatment and prevention of cancer, including esophageal cancer, brain cancer, pancreatic cancer, and colon cancer.
- Selective PDE4 inhibitors of the invention are also thought to be useful for treating or preventing schizophrenia or Huntington's disease, bone loss, depression, anxiety, bladder inflammation, bladder pain and bladder overactivity.
- the invention relates to compounds of formula I or formula II
- P is nitrogen and Q is carbon.
- Y is CR 3 .
- X is CR 4 .
- X is nitrogen.
- W is CR 2 .
- W is nitrogen.
- P is carbon and Q is nitrogen.
- W is CR 2 .
- X is CR 4 .
- X is nitrogen.
- Y is CR .
- Y is nitrogen.
- P is carbon and Q is nitrogen.
- W can be nitrogen.
- W is CR 2 .
- cores include imidazolopyridines, triazolopyridines, pyrazolotriazinones and imidazolopyrazines:
- pyrazolopyridines examples include pyrazolopyrimidines:
- R 2 is selected from hydrogen and (Ci-C 6 ) alkyl, and in some embodiments, R 2 is hydrogen.
- X is CR 4 . In other embodiments, X is nitrogen.
- R 1 is selected from hydrogen and (Ci-C 6 ) alkyl. In some embodiments, R 1 is methyl.
- Z is a direct bond. In yet other embodiments, Z is selected from -O- and -S(O) 0-2 . In further embodiments, Z is -CH 2 -. In still other embodiments, Cy l is selected from optionally substituted aryl and heteroaryl.
- Cy 2 is selected from optionally substituted aryl and heteroaryl. In yet other embodiments, Cy 1 and Cy 2 are both optionally substituted phenyl.
- R 8 and R 9 are each independently selected from hydrogen and (Ci-C 6 ) alkyl. In further embodiments, R 8 and R 9 together form an oxo group. In still other embodiments, R 8 and R 9 together form a 4-6 membered ring, and this ring may optionally contain a heteroatom. In one embodiment, this heteroatom may be oxygen. In another embodiment, the heteroatom may be NR 5 . In still other embodiments, the heteroatom may be -S-, -S(O)- or -S(O) 2 -.
- Z is a direct bond.
- M is -CH 2 -.
- M is -CONH-.
- Cy 1 is selected from optionally substituted aryl and an optionally substituted 5- or 6-membered ring nitrogen heterocycle.
- Cy 1 is selected from optionally substituted phenyl and an optionally substituted 5- or 6-membered ring nitrogen heterocycle.
- Cy 1 is selected from optionally substituted phenyl, pyridinyl, morpholin-4-yl, piperazin-1-yl, piperidiny-1-yl, imidazol-1-yl, pyrazol-1-yl, and pyrazol-5-yl.
- Cy 2 is selected from optionally substituted phenyl and an optionally substituted 5- or 6-membered ring nitrogen heterocycle.
- Yet other embodiments include compounds in which Cy 2 is selected from phenyl, 3-chlorophenyl, 3-nitrophenyl, 3- bromophenyl, 3-acetylphenyl, 3-trichloromethylphenyl and 3-methylthiophenyl.
- Cy 2 is selected from phenyl and 3-chlorophenyl.
- Cy 1 is selected from phenyl and pyridinyl, each of which is optionally substituted with a substituent chosen from (1) hydrogen, halogen, halo alky 1, alkyl, acyl, alkoxyalkyl, hydroxyalkyl, hydroxyalkoxy, carbonyl, phenyl, heteroaryl, benzenesulfonyl, hydroxy, alkoxy, haloalkoxy, oxaalkyl, carboxy, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxycarbonylamino, carboxyalkyl, carboxyalkoxy, carboxy alky It hio, alkoxycarbonylaminoalkyl, carboxy alky lcarbonylamino, carboxamido, aminocarbonyloxy, alkylaminocarbonyl, dialkylaminocarbonyl, amino carbonylalkyl, cyano, acetoxy, nitro, amino,
- Cy 1 is selected from phenyl and pyridinyl, each of which is optionally substituted with a substituent chosen from -CH 3 , -CH 2 CF 3 , -CF 3 , -CHO, -COOH, -CN, halogen, -OH, , -OEt, -C(K))NH 2 , -C(K))NHEt, -C(K))NMe 2 -COOCH3, -COOEt, -CH 2 NHC(K))NH 2 , -CH(CH 3 )NHC(K))NH 2 , -CH 2 NHC(K))H, -CH 2 NHC(K))CH 3 , -CH 2 C(K))NH 2 , -CH 2 COOH, -CH 2 COOEt, -CH 2 NHC(K))OEt, -CH 2 NHC(K)O-C 6 H 5
- Cy 1 is selected from phenyl and pyridinyl, each of which is substituted with a monocyclic heterocycle, and the monocyclic heterocycle is optionally substituted with a substituent chosen from the foregoing list.
- An example of the embodiment in which Cy 1 is a pyridinyl substituted with a monocyclic heterocycle substituted with a carboxylic acid is found in example D-25 below:
- W is CR and R is selected from
- R > 2 is J is selected from O, S, S(O), SO 2 , NH and NCH 3 and L is C or N. In some of these embodiments, R 2 is hydrogen.
- R 4 is hydrogen. In other embodiments, R 3 is hydrogen.
- R 1 is selected from hydrogen and (Ci-C 6 ) alkyl. In some of these compounds, R 1 is methyl. In other embodiments, X is CH. In yet other embodiments, X is CF. Still other embodiments include compounds in which Cy l is selected from optionally substituted phenyl, pyridinyl, morpholin-4-yl, piperazin-1-yl, piperidiny-1-yl, imidazol-1-yl, pyrazol-1-yl, and pyrazol-5-yl. In other embodiments of the invention, Cy 1 is phenyl optionally substituted with a substituent selected from amino, urea, alkylurea, -
- NHCO 2 (C i-C 6 )alkyl azeditine acid, azeditine amide, an d J n further embodiments, Cy 2 is optionally substituted phenyl. In yet other embodiments, Z is a direct bond. In some embodiments, M is -CH 2 -.
- R 1 is selected from hydrogen and (Ci-C 6 ) alkyl;
- X is CH;
- Cy 1 is selected from optionally substituted phenyl, pyridinyl, morpholin- 4-yl, piperazin-1-yl, piperidiny-1-yl, imidazol-1-yl, pyrazol-1-yl, and pyrazol-5-yl;
- Cy 2 is optionally substituted phenyl;
- Z is a direct bond; and M is -CH 2 -.
- the compounds are of formula (A)
- Cy 1 is selected from optionally substituted (Cs-C 6 ) carbocyclyl and optionally substituted heterocyclyl;
- Cy 2 is selected from optionally substituted aryl and optionally substituted heteroaryl
- R 1 is selected from hydrogen, (Ci-C 6 ) alkyl, haloalkyl, -CONHR 5 , lower alkoxy, alkylamino, dialkylamino, amino, -NHCOOR 2 and -OCONH 2 ;
- R 2 is selected from hydrogen, (Ci-C 6 ) alkyl, haloalkyl and optionally substituted heterocyclyl;
- R 3 is selected from hydrogen, fluoro, hydroxyl and -OR 10 ;
- R 10 is selected from (Ci-C 6 ) alkyl optionally substituted with fluoro;
- R 4 is selected from hydrogen, (Ci-C 6 ) alkyl, halogen, amino, alkoxy and hydroxyl;
- M is chosen from -CH 2 -, -CH 2 CH 2 -, -O-, -S(O) 0-2 , -OCH 2 , -CH 2 O, -CONH, -CONHCH 2 , -
- Cy l is selected from optionally substituted phenyl, pyridinyl, morpholinyl, piperazinyl, piperidinyl, imidazolyl, pyrazolyl, oxazolidinyl, pyrrolidinyl, thiazolyl and benzo[c][l,2,5]oxadiazolyl.
- the compounds are of formula (A) wherein
- Cy 1 is selected from optionally substituted aryl and an optionally substituted 5- or 6-membered ring nitrogen heterocycle;
- Cy 2 is selected from optionally substituted phenyl and an optionally substituted 5- or 6- membered ring nitrogen heterocycle;
- R 1 is selected from hydrogen and (Ci-C 6 ) alkyl
- R 2 is selected from hydrogen, methyl, and wherein J is selected from O, S(0)o-2, NH and NCH 3 and L is selected from C and N
- R 3 is hydrogen
- R 4 is hydrogen
- M is -CH 2 -.
- the compounds are of formula (A) wherein Cy 1 is selected from phenyl and pyridinyl, each of which is optionally substituted with a substituent chosen from halogen, haloalkyl, alkyl, acyl, alkoxyalkyl, hydroxyalkyl, carbonyl, phenyl, heteroaryl, benzenesulfonyl, hydroxy, alkoxy, haloalkoxy, oxaalkyl, carboxy, alkoxycarbonyl, alkoxycarbonylamino, alkoxycarbonylaminoalkyl, carboxy alky lcarbonylamino, carboxamido, aminocarbonyloxy, alkylaminocarbonyl, dialkylaminocarbonyl, aminocarbonylalkyl, cyano, acetoxy, nitro, amino, alkylamino, dialkylamino, aminoalkyl, (alkyl)(aryl)a
- Cy 2 is selected from phenyl and 3-chlorophenyl.
- the compound is selected from the following (Table 1): [0029] Table 1.
- the compound is represented by the following (Table 2): [0031] Table 2.
- PDE4 inhibitors have been shown to be effective therapeutic agents in clinical studies. For example, administration of cilomilast and roflumilast (PDE4 inhibitors) to patients suffering from asthma and COPD showed initially excellent results, although the effect of cilomilast disappeared on long-term trial [Lipworth, Lancet 365. 167-175 (2005)]. L- 454,560, a selective PDE4 inhibitor has been shown to improve learning in a rat model in vivo [Huang et al. Biochemical Pharmacology 73, 1971-1981 (2007)]. This suggests that selective PDE4 inhibitors will be useful in treating learning disorders, memory loss (e.g. Alzheimer's disease) and other cognitive dysfunctions. Selective PDE4 inhibitors (e.g.
- rolipram are also useful for treating bone loss [Yao et al., J.Musculoskelet.Neuronal Interact. 7, 119-130 (2007)].
- a PDE4 inhibitor, YM976 was shown to ameliorate the effects of experimentally- induced interstitial cystitis in rats, resulting in a decrease in the frequency of urination and an increase in the volume of urine at each time of urination [Kitta et al., BJU Int. 102. 1472-1476 (2008)].
- PDE4 inhibitor IC485
- IC485 Another PDE4 inhibitor, IC485, was shown to be equally efficacious as tolteradine tartrate, a marketed drug for treating overactive bladder, in a rodent model of obstructive bladder [Kaiho et al. BJU Int. 101, 615-20 (2008)]. These findings suggest that PDE4 inhibitors will be useful in treating symptoms of bladder inflammation, such as overactivity and pain. [0034] Furthermore, the compounds, compositions and methods of the present invention are useful in treating cancer. Phosphodiesterase activity has been shown to be associated with hematological malignancies [Lerner et al., BiochemJ. 393, 21-41 (2006); Ogawa et al, Blood 99, 3390-3397 (2002)].
- Alkyl is intended to include linear, branched, or cyclic hydrocarbon structures and combinations thereof. A combination would be, for example, cyclopropylmethyl. When not otherwise restricted, the term refers to alkyl of 20 or fewer carbons. Lower alkyl refers to alkyl groups of 1, 2, 3, 4, 5 and 6 carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, s-and t-butyl and the like. Preferred alkyl and alkylene groups are those of Ci 0 or below (e.g.
- Cycloalkyl is a subset of alkyl and includes cyclic hydrocarbon groups of 3, 4, 5, 6, 7, and 8 carbon atoms. Examples of cycloalkyl groups include c-propyl, c-butyl, c-pentyl, norbornyl, adamantyl and the like.
- C 1 to C 20 Hydrocarbon (e.g. C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , C 10 , C 11 , C 12 , C 13 , C 14 , C 15 , C 16 , C 17 , C 18 , C 19 , C 20 ) includes alkyl, cycloalkyl, alkenyl, alkynyl, aryl and combinations thereof. Examples include benzyl, phenethyl, cyclohexylmethyl, camphoryl and naphthylethyl.
- phenylene refers to ortho, meta or para residues of the formulae:
- Hydrocarbon refers to any substituent comprised of hydrogen and carbon as the only elemental constituents.
- carbocycle (or “carbocyclyl”) is intended to include ring systems in which the ring atoms are all carbon but of any oxidation state.
- carbocycle refers to such systems as cyclopropane, benzene and cyclohexene;
- C 8 - Ci 2 carbopolycycle refers to such systems as norbornane, decalin, indane and naphthalene.
- Carbocycle not otherwise limited, refers to monocycles, bicycles and polycycles.
- Alkoxy or alkoxyl refers to groups of 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms of a straight, branched, cyclic configuration and combinations thereof attached to the parent structure through an oxygen. Examples include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy and the like. Lower-alkoxy refers to groups containing one to four carbons.
- alkoxy also includes methylenedioxy and ethylenedioxy in which each oxygen atom is bonded to the atom, chain or ring from which the methylenedioxy or ethylenedioxy group is pendant so as to form a ring.
- phenyl substituted by alkoxy may be, for example,
- Oxaalkyl refers to alkyl residues in which one or more carbons (and their associated hydrogens) have been replaced by oxygen. Examples include methoxypropoxy, 3,6,9- trioxadecyl and the like.
- the term oxaalkyl is intended as it is understood in the art [see Naming and Indexing of Chemical Substances for Chemical Abstracts, published by the American Chemical Society, 1196, but without the restriction of Tfl27(a)], i.e. it refers to compounds in which the oxygen is bonded via a single bond to its adjacent atoms (forming ether bonds). It does not refer to doubly bonded oxygen, as would be found in carbonyl groups.
- thiaalkyl and azaalkyl refer to alkyl residues in which one or more carbons have been replaced by sulfur or nitrogen, respectively. Examples include ethylaminoethyl and methylthiopropyl.
- Acyl refers to formyl and to groups of 1, 2, 3, 4, 5, 6, 7 and 8 carbon atoms of a straight, branched or cyclic configuration, saturated, unsaturated and aromatic and combinations thereof, attached to the parent structure through a carbonyl functionality.
- One or more carbons in the acyl residue may be replaced by nitrogen, oxygen or sulfur as long as the point of attachment to the parent remains at the carbonyl. Examples include acetyl, propionyl, isobutyryl, ⁇ -butoxycarbonyl, benzoyl, benzyloxycarbonyl and the like.
- Lower- acyl refers to groups containing one to four carbons.
- the double bonded oxygen when referred to as a substituent itself, is called "oxo".
- Aryl and heteroaryl refer to aromatic or heteroaromatic rings, respectively, as substituents.
- Aryl and heteroaryl mean (i) a phenyl group (or benzene) or a monocyclic 5- or 6-membered heteroaromatic ring containing 1-4 heteroatoms selected from O, N, or S; (ii) a bicyclic 9- or 10-membered aromatic or heteroaromatic ring system containing 0-4 heteroatoms selected from O, N, or S; or (iii) a tricyclic 13- or 14-membered aromatic or heteroaromatic ring system containing 0-5 heteroatoms selected from O, N, or S.
- Aromatic 6, 7, 8, 9, 10, 11, 12, 13 and 14-membered carbocyclic rings include, e.g., benzene, naphthalene, indane, tetralin, and fluorene and the 5, 6, 7, 8, 9 and 10-membered aromatic heterocyclic rings include, e.g., imidazole, pyridine, indole, thiophene, benzopyranone, thiazole, furan, benzimidazole, quinoline, isoquinoline, quinoxaline, pyrimidine, pyrazine, tetrazole and pyrazole.
- aryl refers to residues in which one or more rings are aromatic, but not all need be.
- Arylalkyl refers to a substituent in which an aryl residue is attached to the parent structure through alkyl. Examples are benzyl, phenethyl and the like. This is in contradistinction to alkylaryl, in which an aryl residue is attached to the parent structure through alkyl (e.g. a p-tolyl residue).
- Heteroarylalkyl refers to a substituent in which a heteroaryl residue is attached to the parent structure through alkyl. Examples include, e.g., pyridinylmethyl, pyrimidinylethyl and the like.
- Heterocyclylalkyl refers to a substituent in which a heterocyclyl residue is attached to the parent structure through alkyl. Examples include morpholinoethyl and pyrrolidinylmethyl.
- heterocycle means a monocyclic, bicyclic or tricyclic residue with 1 to 13 carbon atoms and 1 to 4 heteroatoms chosen from the group consisting of nitrogen, oxygen and sulfur.
- the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized.
- a heterocycle may be non-aromatic or aromatic.
- the heterocycle may be fused to an aromatic hydrocarbon radical.
- Suitable examples include pyrrolyl, pyridinyl, pyrazolyl, triazolyl, pyrimidinyl, pyridazinyl, oxazolyl, thiazolyl, imidazolyl, indolyl, thiophenyl, furanyl, tetrazolyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolindinyl, 1,3-dioxolanyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3- triazolyl, 1,3,4-thiadiazolyl, 2H-pyranyl, 4H-pyranyl, piperidinyl, 1,4-dithianyl, thiomorpholinyl, pyrazinyl, piperazinyl, 1,3,5-tria
- a nitrogen heterocycle is a heterocycle containing at least one nitrogen in the ring; it may contain additional nitrogens, as well as other heteroatoms. Examples include piperidine, piperazine, morpholine, pyrrolidine and thiomorpholine. It is to be noted that heteroaryl is a subset of heterocycle in which the heterocycle is aromatic; examples include pyridine, pyrrole and thiazole.
- heterocyclyl residues additionally include piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2- oxo-pyrrolidinyl, 2-oxoazepinyl, azepinyl, 4-piperidinyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, benzimidazolyl, thiadiazolyl, benzopyranyl, benzothiazolyl, tetrahydrofuryl, tetrahydropyranyl, thienyl, benzothienyl, thiamorpholinyl, thiamorpholinylsulfoxide, thiamorpholinylsulfone, oxadia
- An oxygen heterocycle is a heterocycle containing at least one oxygen in the ring; it may contain additional oxygens, as well as other heteroatoms.
- a sulphur heterocycle is a heterocycle containing at least one sulphur in the ring; it may contain additional sulphurs, as well as other heteroatoms.
- a nitrogen heterocycle is a heterocycle containing at least one nitrogen in the ring; it may contain additional nitrogens, as well as other heteroatoms.
- substituted alkyl, aryl, cycloalkyl, heterocyclyl, etc. refer to alkyl, aryl, cycloalkyl, or heterocyclyl wherein up to three H atoms in each residue are replaced with a specified radical.
- acyl alkoxyalkyl, benzenesulfonyl, cyano, carbonyl, nitro, amino, hydroxyalkyl, alkylamino, dialkylamino, aminoalkyl, (alkyl)(aryl)aminoalkyl, alkylaminoalkyl (including cycloalkylaminoalkyl), dialkylaminoalkyl, dialkylaminoalkoxy, heterocyclylalkoxy, mercapto, alkylthio, alkylsulfinyl, alkylsulfonyl, acylamino, diacylamino, acylaminoalkyl, acylaminoalkoxy,
- Haloakyl refers to an alkyl group in which one or more hydrogens are replaced by halogen, for example, trifluoromethyl, trifluoromethoxy, trichloroethyl, and difluoromethyl.
- Oxo is also included among the substituents referred to in "optionally substituted”; it will be appreciated by persons of skill in the art that, because oxo is a divalent radical, there are circumstances in which it will not be appropriate as a substituent (e.g. on phenyl).
- 1, 2 or 3 hydrogen atoms are replaced with a specified radical.
- Additional substituents that are considered within the scope of the term are the are the residues of amino acids, amino acid amides, protected residues of aminoacids and their amides, and N-methylated (mono- or di-, as appropriate) amino acids and amino acid amides.
- a residue of an amino acid, amino acid amide refers to an amino acid etc. minus the functional groups that are considered part of the bond to the parent structure.
- Fragment A illustrated below:
- halogen means fluorine, chlorine, bromine or iodine.
- haloalkyl and haloalkoxy mean alkyl or alkoxy, respectively, substituted with one or more halogen atoms.
- prodrug refers to a compound that is made more active in vivo. Commonly the conversion of prodrug to drug occurs by enzymatic processes in the liver or blood of the mammal. Many of the compounds of the invention may be chemically modified without absorption into the systemic circulation, and in those cases, activation in vivo may come about by chemical action (as in the acid-catalyzed cleavage in the stomach) or through the intermediacy of enzymes and microflora in the gastrointestinal GI tract.
- the compounds of this invention can exist in radiolabeled form, i.e., the compounds may contain one or more atoms containing an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Radioisotopes of hydrogen, carbon, phosphorous, fluorine, iodine and chlorine include 3 H, 14 C, 35 S, 18 F, 32 P, 33 P, 125 I, and 36 Cl, respectively. Compounds that contain those radioisotopes and/or other radioisotopes of other atoms are within the scope of this invention. Radiolabeled compounds described herein and prodrugs thereof can generally be prepared by methods well known to those skilled in the art. Conveniently, such radiolabeled compounds can be prepared by carrying out the procedures disclosed in the Examples and Schemes by substituting a readily available radiolabeled reagent for a non-radio labeled reagent.
- PDE4 inhibitors have been shown to be effective therapeutic agents in clinical studies. For example, administration of cilomilast and roflumilast (PDE4 inhibitors) to patients suffering from asthma and COPD showed initially excellent results, although the effect of cilomilast disappeared on long-term trial [Lipworth, Lancet 365, 167-175 (2005)]. L-454,560, a selective PDE4 inhibitor has been shown to improve learning in a rat model in vivo [Huang et al. Biochemical Pharmacology 73. 1971-1981 (2007)]. This suggests that selective PDE4 inhibitors will be useful in treating learning disorders, memory loss (e.g. Alzheimer's disease) and other cognitive dysfunctions.
- memory loss e.g. Alzheimer's disease
- Rolipram a selective PDE4 inhibitor has been shown to improve the outcome in two separate studies in mice in vivo in models accepted by persons of skill in the art as predictive of utility in schizophrenia [Kanes et al., Neuroscience 144. 239-246 (2007); Davis and Gould, Behav.Neurosci. 119. 595-602 (2005)]. Rolipram has also been shown to exhibit a neuroprotective effect in a rat model of Huntington's disease [DeMarch et al. Neurobiol.Dis. 25, 266-273 (2007)]. Selective PDE4 inhibitors (e.g. rolipram) are also useful for treating bone loss [Yao et al., J.Musculoskelet.Neuronal Interact. 7. 119-130 (2007)].
- the compounds, compositions and methods of the present invention are useful in treating cancer.
- Phosphodiesterase activity has been shown to be associated with hematological malignancies [Lerner et al., BiochemJ. 393. 21-41 (2006); Ogawa et al., Blood 99. 3390-3397 (2002)].
- the compounds may also be administered to overcome cognitive impairment induced by one or more of the following agents, alcohol, amphetamine, antipsychotic medication, anti-retroviral therapy, MDMA ( 3,4-methylenedioxy-N- methylamphetamine, cannabis, cocaine, delta-9 tetrahydrocannabinol, dexamphetamine, haloperidol, heroin and other opiates, ketamine and metamphetamine.
- MDMA 3,4-methylenedioxy-N- methylamphetamine
- cannabis cocaine, delta-9 tetrahydrocannabinol, dexamphetamine, haloperidol, heroin and other opiates, ketamine and metamphetamine.
- the compounds, compositions and methods of the present invention may be employed as imaging agents and in other ways for diagnosis and/or treatment.
- immobilization of compounds of the invention on solid support could be of utility for affinity purification and modification of compounds of the invention with chemically active groups may be used for protein labeling.
- cholinesterase inhibitors e.g. tacrine, huperzine, donepezil
- NMDA antagonists e.g. lanicemine, remacemide, neramexane, memantine
- calpain inhibitors e.g. CEP-3122
- antioxidants e.g. vitamin E, coenzyme QlO
- agents that have shown clinical efficacy but whose mechanism is unclear e.g. dimebon).
- Compounds of formula I or formula II may also be administered together with one or more of the following agents to improve cognition: amisulpride, atomoxetine, bromocryptine, buspirone, caffeine, chlorpromazine, clonidine, clozapine, diazepam, flumazenil, fluoxetine, galantamine, guanfacine, methylphenidate, idazoxan, modafinil, olanzapine, paroxetine, pergolide, phenserine, quetiapine, risperidone, rivastigmine, SGS742 and sulpiride.
- the terms "methods of treating or preventing” mean amelioration, prevention or relief from the symptoms and/or effects associated with lipid disorders.
- preventing refers to administering a medicament beforehand to forestall or obtund an acute episode or, in the case of a chronic condition to diminish the likelihood or seriousness of the condition.
- prevent is not an absolute term.
- reference to “treatment” of a patient is intended to include prophylaxis.
- mammal is used in its dictionary sense.
- the term “mammal” includes, for example, mice, hamsters, rats, cows, sheep, pigs, goats, and horses, monkeys, dogs (e.g., Canis familiaris), cats, rabbits, guinea pigs, and primates, including humans.
- the cognitive impairment to be treated may arise from one or more of the following disorders, which may not in themselves be necessarily associated with PDE4 abnormality: acute pain, AD/HD - Attention deficit hyperactivity disorder, AIDS dementia complex, alcoholism, amphetamine addiction, amygdalo-hippocampectomy, anorexia nervosa, anterior parietal damage, antisocial behavior, antisocial personality disorder, anxiety, autism, basal ganglia lesions, bipolar disorder, borderline personality disorder, camptocormia, capgras syndrome, carcinoid syndrome, carotid endarterectomy surgery, chronic drug misuse, chronic fatigue syndrome, chronic occupational solvent encephalopathy, chronic pain, brain ischemia, coronary artery bypass surgery, critical illness requiring intensive care, dementia Alzheimer- type (DAT), dementia Lewy Body type, dementia of frontal type, dementia caused by ischemia, dental pain, developmental dyslexia, diabetes, dorsolateral frontal cortical compression, Down's Syndrome, drug abuse, dysexecutive syndrome,
- Compounds described herein may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms.
- Each chiral center may be defined, in terms of absolute stereochemistry, as (R)- or (S)-.
- the present invention is meant to include all such possible isomers, as well as mixtures thereof, including racemic and optically pure forms.
- Optically active (R)- and (S)-, (-)- and (+)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques.
- the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included.
- a compound As used herein, and as would be understood by the person of skill in the art, the recitation of "a compound” is intended to include salts, solvates and inclusion complexes of that compound as well as any stereoisomeric form, or a mixture of any such forms of that compound in any ratio.
- a compound as described herein, including in the contexts of pharmaceutical compositions, methods of treatment, and compounds per se is provided as the salt form.
- the salt is a hydrochloride salt.
- solvate refers to a compound in the solid state, wherein molecules of a suitable solvent are incorporated in the crystal lattice.
- a suitable solvent for therapeutic administration is physiologically tolerable at the dosage administered. Examples of suitable solvents for therapeutic administration are ethanol and water. When water is the solvent, the solvate is referred to as a hydrate. Inclusion complexes are described in Remington: The Science and Practice of Pharmacy 19 th Ed. (1995) volume 1, page 176-177.
- pharmaceutically acceptable salt refers to salts prepared from pharmaceutically acceptable non-toxic acids or bases including inorganic acids and bases and organic acids and bases.
- salts may be prepared from pharmaceutically acceptable non-toxic acids including inorganic and organic acids.
- Suitable pharmaceutically acceptable acid addition salts for the compounds of the present invention include acetic, benzenesulfonic (besylate), benzoic, camphorsulfonic, carbonic, citric, ethanedisulfonic, ethanesulfonic, ethylenediaminetetraacetic, fumaric, glucoheptonic, gluconic, glutamic, hydrobromic, hydrochloric, hydroiodic, hydroxynaphthoic, isethionic, lactic, lactobionic, laurylsulfonic, maleic, malic, mandelic, methanesulfonic, mucic, naphthylenesulfonic, nitric, pamoic, pantothenic, phosphoric, polygalacturonic, salicylic, stearic, succinic, sulfuric, tannic, tartaric acid, teoclatic, p- toluenesulfonic, and the like.
- suitable pharmaceutically acceptable base addition salts for the compounds of the present invention include, but are not limited to, metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from lysine, arginine, N,N'- dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine.
- enantiomeric excess is related to the older term “optical purity” in that both are measures of the same phenomenon.
- the value of ee will be a number from 0 to 100, zero being racemic and 100 being pure, single enantiomer.
- a compound which in the past might have been called 98% optically pure is now more precisely described as 96% ee; in other words, a 90% ee reflects the presence of 95% of one enantiomer and 5% of the other in the material in question.
- a protecting group refers to a group which is used to mask a functionality during a process step in which it would otherwise react, but in which reaction is undesirable.
- the protecting group prevents reaction at that step, but may be subsequently removed to expose the original functionality. The removal or "deprotection” occurs after the completion of the reaction or reactions in which the functionality would interfere.
- Me, Et, Ph, Tf, Ts and Ms represent methyl, ethyl, phenyl, trifluoromethanesulfonyl, toluenesulfonyl and methanesulfonyl respectively.
- a comprehensive list of abbreviations utilized by organic chemists appears in the first issue of each volume of the Journal of Organic Chemistry. The list, which is typically presented in a table entitled “Standard List of Abbreviations" is incorporated herein by reference.
- a pharmaceutical composition comprising a compound of formula I or formula II or a pharmaceutically acceptable salt or solvate thereof, together with one or more pharmaceutically carriers thereof and optionally one or more other therapeutic ingredients.
- the carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
- the formulations include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous and intraarticular), rectal and topical (including dermal, buccal, sublingual and intraocular) administration.
- the most suitable route may depend upon the condition and disorder of the recipient.
- the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association a compound of formula I or formula II or a pharmaceutically acceptable salt or solvate thereof ("active ingredient”) with the carrier, which constitutes one or more accessory ingredients.
- active ingredient a compound of formula I or formula II or a pharmaceutically acceptable salt or solvate thereof
- the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
- Formulations suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
- the active ingredient may also be presented as a bolus, electuary or paste.
- a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free- flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent.
- Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- the tablets may optionally be coated or scored and may be formulated so as to provide sustained, delayed or controlled release of the active ingredient therein.
- the pharmaceutical compositions may include a "pharmaceutically acceptable inert carrier", and this expression is intended to include one or more inert excipients, which include starches, polyols, granulating agents, microcrystalline cellulose, diluents, lubricants, binders, disintegrating agents, and the like. If desired, tablet dosages of the disclosed compositions may be coated by standard aqueous or nonaqueous techniques, "Pharmaceutically acceptable carrier” also encompasses controlled release means.
- compositions may also optionally include other therapeutic ingredients, anti-caking agents, preservatives, sweetening agents, colorants, flavors, desiccants, plasticizers, dyes, and the like. Any such optional ingredient must be compatible with the compound of formula I or formula II to insure the stability of the formulation.
- the composition may contain other additives as needed, including for example lactose, glucose, fructose, galactose, trehalose, sucrose, maltose, raffinose, maltitol, melezitose, stachyose, lactitol, palatinite, starch, xylitol, mannitol, myoinositol, and the like, and hydrates thereof, and amino acids, for example alanine, glycine and betaine, and peptides and proteins, for example albumen.
- additives including for example lactose, glucose, fructose, galactose, trehalose, sucrose, maltose, raffinose, maltitol, melezitose, stachyose, lactitol, palatinite, starch, xylitol, mannitol, myoinositol, and the like, and hydrates thereof, and amino
- excipients for use as the pharmaceutically acceptable carriers and the pharmaceutically acceptable inert carriers and the aforementioned additional ingredients include, but are not limited to binders, fillers, disintegrants, lubricants, anti-microbial agents, and coating agents.
- the dose range for adult humans is generally from 0.005 mg to 10 g/day orally. Tablets or other forms of presentation provided in discrete units may conveniently contain an amount of compound of formula I or formula II which is effective at such dosage or as a multiple of the same, for instance, units containing 5 mg to 500 mg, usually around 10 mg to 200 mg.
- the precise amount of compound administered to a patient will be the responsibility of the attendant physician. However, the dose employed will depend on a number of factors, including the age and sex of the patient, the precise disorder being treated, and its severity.
- a dosage unit (e.g. an oral dosage unit) can include from, for example, 1 to 30 mg, 1 to 40 mg, 1 to 100 mg, 1 to 300 mg, 1 to 500 mg, 2 to 500 mg, 3 to 100 mg, 5 to 20 mg, 5 to 100 mg (e.g.
- the agents can be administered, e.g., by intravenous injection, intramuscular injection, subcutaneous injection, intraperitoneal injection, topical, sublingual, intraarticular (in the joints), intradermal, buccal, ophthalmic (including intraocular), intranasaly (including using a cannula), or by other routes.
- the agents can be administered orally, e.g., as a tablet or cachet containing a predetermined amount of the active ingredient, gel, pellet, paste, syrup, bolus, electuary, slurry, capsule, powder, granules, as a solution or a suspension in an aqueous liquid or a non-aqueous liquid, as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion, via a micellar formulation (see, e.g. WO 97/11682) via a liposomal formulation (see, e.g., EP 736299,WO 99/59550 and WO 97/13500), via formulations described in WO 03/094886 or in some other form.
- a micellar formulation see, e.g. WO 97/11682
- a liposomal formulation see, e.g., EP 736299,WO 99/59550 and WO 97/13500
- the agents can also be administered transdermally (i.e. via reservoir-type or matrix-type patches, microneedles, thermal poration, hypodermic needles, iontophoresis, electroporation, ultrasound or other forms of sonophoresis, jet injection, or a combination of any of the preceding methods (Prausnitz et al. 2004, Nature Reviews Drug Discovery 3: 115)).
- the agents can be administered locally, for example, at the site of injury to an injured blood vessel.
- the agents can be coated on a stent.
- the agents can be administered using high-velocity transdermal particle injection techniques using the hydrogel particle formulation described in U.S. 20020061336.
- WO 00/45792 An example of a transdermal formulation containing plaster and the absorption promoter dimethylisosorbide can be found in WO 89/04179.
- WO 96/11705 provides formulations suitable for transdermal administration.
- the agents can be administered in the form a suppository or by other vaginal or rectal means.
- the agents can be administered in a transmembrane formulation as described in WO 90/07923.
- the agents can be administered non-invasively via the dehydrated particles described in U.S. 6,485,706.
- the agent can be administered in an enteric-coated drug formulation as described in WO 02/49621.
- the agents can be administered intranasaly using the formulation described in U.S. 5,179,079. Formulations suitable for parenteral injection are described in WO 00/62759. The agents can be administered using the casein formulation described in U.S. 20030206939 and WO 00/06108. The agents can be administered using the particulate formulations described in U.S. 20020034536.
- the agents can be administered by pulmonary route utilizing several techniques including but not limited to intratracheal instillation (delivery of solution into the lungs by syringe), intratracheal delivery of liposomes, insufflation (administration of powder formulation by syringe or any other similar device into the lungs) and aerosol inhalation.
- Aerosols e.g., jet or ultrasonic nebulizers, metered-dose inhalers (MDIs), and dry-Powder inhalers (DPIs)
- MDIs metered-dose inhalers
- DPIs dry-Powder inhalers
- Aerosol formulations are stable dispersions or suspensions of solid material and liquid droplets in a gaseous medium and can be placed into pressurized acceptable propellants, such as hydrofluoroalkanes (HFAs, i.e. HFA-134a and HFA-227, or a mixture thereof), dichlorodifluoromethane (or other chlorofluorocarbon propellants such as a mixture of Propellants 11, 12, and/or 114), propane, nitrogen, and the like.
- HFAs hydrofluoroalkanes
- HFA-134a and HFA-227 or a mixture thereof
- dichlorodifluoromethane or other chlorofluorocarbon propellants such as a mixture of Propellants 11, 12, and/or 114
- propane nitrogen, and the like.
- Pulmonary formulations may include permeation enhancers such as fatty acids, and saccharides, chelating agents, enzyme inhibitors (e.g., protease inhibitors), adjuvants (e.g., glycocholate, surfactin, span 85, and nafamostat), preservatives (e.g., benzalkonium chloride or chlorobutanol), and ethanol (normally up to 5% but possibly up to 20%, by weight). Ethanol is commonly included in aerosol compositions as it can improve the function of the metering valve and in some cases also improve the stability of the dispersion. Pulmonary formulations may also include surfactants which include but are not limited to bile salts and those described in U.S.
- the surfactants described in U.S. 6,524,557 e.g., a C 8 -Ci 6 fatty acid salt, a bile salt, a phospholipid, or alkyl saccharide are advantageous in that some of them also reportedly enhance absorption of the compound in the formulation.
- dry powder formulations comprising a therapeutically effective amount of active compound blended with an appropriate carrier and adapted for use in connection with a dry-Powder inhaler.
- Absorption enhancers which can be added to dry powder formulations of the present invention include those described in U.S. 6,632,456.
- WO 02/080884 describes new methods for the surface modification of powders. Aerosol formulations may include U.S.
- Pulmonary formulations containing stable glassy state powder are described in U.S. 20020141945 and U.S. 6,309,671.
- Other aerosol formulations are described in EP 1338272A1 WO 90/09781, U. S. 5,348,730, U.S. 6,436,367, WO 91/04011, and U.S. 6,294,153 and U.S. 6,290,987 describes a liposomal based formulation that can be administered via aerosol or other means.
- Powder formulations for inhalation are described in U.S. 20030053960 and WO 01/60341.
- the agents can be administered intranasally as described in U.S. 20010038824.
- Solutions of medicament in buffered saline and similar vehicles are commonly employed to generate an aerosol in a nebulizer.
- Simple nebulizers operate on Bernoulli's principle and employ a stream of air or oxygen to generate the spray particles.
- More complex nebulizers employ ultrasound to create the spray particles. Both types are well known in the art and are described in standard textbooks of pharmacy such as Sprowls' American Pharmacy and Remington's The Science and Practice of Pharmacy.
- Other devices for generating aerosols employ compressed gases, usually hydrofluorocarbons and chlorofluorocarbons, which are mixed with the medicament and any necessary excipients in a pressurized container, these devices are likewise described in standard textbooks such as Sprowls and Remington.
- the agent can be incorporated into a liposome to improve half-life.
- the agent can also be conjugated to polyethylene glycol (PEG) chains.
- PEG polyethylene glycol
- Methods for pegylation and additional formulations containing PEG-conjugates i.e. PEG-based hydrogels, PEG modified liposomes
- the agent can be administered via a nanocochleate or cochleate delivery vehicle (BioDelivery Sciences International).
- the agents can be delivered transmucosally (i.e. across a mucosal surface such as the vagina, eye or nose) using formulations such as that described in U.S. 5,204,108.
- the agents can be formulated in microcapsules as described in WO 88/01165.
- the agent can be administered intra-orally using the formulations described in U.S. 20020055496, WO 00/47203, and U.S. 6,495,120.
- the agent can be delivered using nanoemulsion formulations described in WO 01/91728A2.
- compounds of formula I or formula II may be prepared by the methods illustrated in the general reaction schemes as, for example, described below, or by modifications thereof, using readily available starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants that are in themselves known, but are not mentioned here.
- Tables 1 and 2 above list compounds representative of embodiments of the invention. Processes for obtaining compounds of formula I or formula II are presented below. Other compounds of formula I or formula II may be prepared in analogous fashion to those whose synthesis is exemplified herein. The procedures below illustrate such methods.
- the substituent at C8 can be introduced either before formation of the bicyclic core (S2) by Suzuki/Stille reaction allowing C-C bond formatting chemistries.
- the intermediate S3 could be reacted by Buchwald or Cu mediated chemistries to for ether/amine linked C 8 substituent (S7).
- the substituent at the C-6 position can be introduced by a wide variety of approaches.
- Y is an alkyl, ester, nitrile
- S6/S7 containing alcohol alkyl halide (W)
- W alkyl halide
- the carbonate or -CH2-Br (W, S6/S7) upon reaction via organometallic coupling protocols (e.g.
- the alcohol can be converted to a primary or secondary amine.
- the W as acid or amine thus allows formation of amide, reverse amide, sulfonamide from acylation /sulfonation chemistries or diverse amine via reductive amine chemistry approaches.
- the substituents containing additional functions groups allow subsequent elaboration by standard chemistries outlines above depending upon the functional groups introduced at C6. These strategies allow incorporation of acyclic, heterocyclic or heteroaryl derived substituents at the C6 / C8 position of the imidazo[l,2-a]pyridine/ imidazo[l,2-a]pyrazine core.
- pyrozolo[l,5-a]pyridine S14
- S12 2,4-substituted pyridine
- S13 N-amination of 2,4-disubstituted pyridine (S12) by O-2-mesitylenesulfonyl hydroxyamine provides intermediate (S13).
- Subsequent 1,3-dipolar cycloaddition with methyl propiolate furnish the pyrozolo[l,5-a]pyridine (S 14), which can subsequently be transformed into the decarboxylated product (S 15) under acidic conditions.
- Formation of the key intermediate pyrazolo[l,5-a]pyrimidine (S21) can be obtained from the pyrazole starting material (S 18). Reaction of pyrazole (S 18) with methyl chloroformate and subsequent bromination with NBS give intermediate bromomethyl pyrazole (S20). Nucleophilic substitution of tosylmethyl isocyanide (TosMIC) on the bromomethyl pyrazole (S20) followed by intramolecular transfer of the methoxycarbonyl group followed by cyclization and 1 ,2-elimination of p-toluenesulfinic acid to afford the pyrazolo[l,5-a] pyrimidine intermediate (S21) analogous to Mendiola, J.
- TosMIC tosylmethyl isocyanide
- substitution at C-6 position can be obtained via the ester group at C-6 position by similar approaches described above for Gl analogs.
- the introduction of the substitutions at C-8 position to form a C-C bond can be accomplished by metal assisted cross coupling reactions.
- the key intermediate pyrazolo[l,5-a]pyrimidine (S26) can be also obtained from S25.
- the intermediate S25 in turn can be obtained from S18 via bromination and subsequent conversion to the ketone S24. Reaction of S25 with an orthoformate would then provide S26.
- the final substituent can be introduced as part of formation of S24; in such case cyclization of S25 to S26 directly would yield the desired analogs. [0090] Scheme 5.
- Formation of the key intermediate pyrazolo[l,5-a]pyrimidine can be obtained via cyclization reaction of the pyrazole starting material (S27) with acetoacetic acid ethyl ester (or ⁇ -keto esters).
- S27 pyrazole starting material
- acetoacetic acid ethyl ester or ⁇ -keto esters
- a large number of starting materials of the general structure S27 are commercial available or can be prepared by published procedures.
- the -OH group in S28 can convert to chloride or bromide (S29) which can form C-C link substitutions in S30 via organometallic coupling protocols (e.g. Suzuki, Stille reaction).
- compounds of the formula G6-b can be prepared from the intermediate 2,3-disubstituted-5,6-dihydro-pyrazolo[l,5-d][l,2,4]triazine-4,7-dione (S27). Cyclization of S25 with coupling reagents (such as CDI, triphosgene etc) afford S27, which can subsequently N-alkylation with Hetl/Arl/Rl-halide at N-5 position to provide (S28). The substitutions at C-7 position in compounds G6-b can be obtained by displacement of halogen (Cl or F) of S29 with hydroxyl, amine or thiol containing heterocyclic/aryls.
- coupling reagents such as CDI, triphosgene etc
- Stepl 6-Amino-5-(3-chloro-phenyl)-nicotinic acid methyl ester (2).
- methyl 6-amino-5-bromonicotinate Ig, 4.33 mmole
- 40 ml toluene 10 ml ethanol
- 20 ml water 1.37g, 13 mmole sodium carbonate
- 3-chlorophenyl boronic acid 740mg, 4.73 mmole
- the solution was degassed for 10 min. under argon, then the palladium tetrakis (500mg, 10%) was added. Reaction mixture was heated at 100 0 C for 6 hours.
- Step 2 8-(3-Chloro-phenyl)-imidazo[l,2-a]pyridine-6-carboxylic acid methyl ester (3).
- Step 3 [8-(3-Chloro-phenyl)-imidazo[l,2-a]pyridin-6-yl]-methanol (4).
- anhydrous THF was added at 0 0 C LiBH4 (2M in THF, 2 ml). Reaction mixture was stirred at RT for 3 days. Mixture was quenched with saturated solution of NH4C1, then extracted several times with ethylacetate.
- Step 4 Carbonic acid 8-(3-chloro-phenyl)-imidazo[l,2-a]pyridin-6-ylmethyl ester (5).
- pyridine 80 ul, 0.96 mmole
- the mixture was cooled to 0 0 C and methylchloro formate was added slowly (65uL, 0.81 mmole). Reaction mixture was stirred at room temperature for 3 days.
- Step 5 4-[8-(3-Chloro-phenyl)-imidazo[l,2-a]pyridin-6-ylmethyl]-phenylamine (D- 01).
- the reaction was diluted with ethyl acetate (10 mL), washed with saturated ammonium chloride (10 mL), the aqueous wash back extracted with ethyl acetate (2 x 10 mL), and the organic extracts were combined. The organic solution was washed with brine (15 mL) and the solvent removed under vacuum. The crude material was purified by silica gel thin layer preparatory chromatography eluting with 7.5 % acetone in dichloromethanes to give D-04 PR231 (15.1 mg, 18% yield) as a yellow gum.
- 6-ylmethyl]-phenyl ⁇ -urea D-05: A reaction mixture of compound 14 (60 mg crude, 0.2 mmol), 4-ureidophenylboronic acid pinacol ester (52 mg, 0.2 mmol), tetrakis(triphenylphosphine)palladium (46 mg, 0.04 mmol), K3PO4 (84 mg, 0.4 mmole) in DME (6 mL), ethanol (1.5 mL) and water (1.5 ml) was stirred at 65 0 C for 2 hours and then cooled to room temperature.
- Methods of the invention parallel the compositions and formulations.
- the methods comprise administering to a patient in need of treatment a therapeutically effective amount of a compound according to the invention.
- the present invention also provides a method for inhibiting phosphodiesterase 4.
- In-vitro assay for PDE4 enzymes The in-vitro activity of PDE4 enzymes and the in-vitro potency of therapeutic agents described in the present invention was measured using a real-time, enzyme-coupled spectrophotometric assay. By using three different coupling enzymes, the product of the PDE4 reaction is coupled to the oxidation of the reduced form ⁇ -nicotinamide adenine dinucleotide (NADH), which dissipation can be monitored spectrophotmetrically at 340 nM.
- NADH ⁇ -nicotinamide adenine dinucleotide
- Buffer A containing 50 mM Tris, pH 8.0, 16 mM MgCl 2 and 80 mM KCl is prepared and stored at room temperature.
- Buffer B containing 50 mM Tris, pH 8.0 is prepared and stored at toom temperature.
- Stock solutions of the following reagents are prepared in Buffer B and stored at -20 0 C: Adenosine-5 '-triphosphate (ATP), cyclic adenosine-5 '-monophosphate (cAMP), phosphoenolpyruvate (PEP) and NADH.
- ATP Adenosine-5 '-triphosphate
- cAMP cyclic adenosine-5 '-monophosphate
- PEP phosphoenolpyruvate
- An assay mix is prepared by mixing Buffer A, trichloroethylphosphine (TCEP), ATP, PEP, NADH, myokinase (MK), pyruvate kinase (PK), lactate dehydroganese (LDH) and PDE4 to a final volume of 20 mL, which is enough for a single 96-well assay plate.
- Assay mix 180 ⁇ L
- test article (10 ⁇ L ) in 1 : 1 DMSO/H 2 O mixture is pre-incubated at room temperature for 10 min. The enzymatic reaction is initiated by addition of c AMP (10 ⁇ L).
- Final concentration of all components in the assay (200 ⁇ L/well) are as follows: 10 mM MgCl 2 , 50 mM KCl, 5 mM TCEP, 2.5% DMSO, 0.4 mM NADH, 1 mM PEP, 0.04 mM ATP, 5 units MK, 1 unit PK, 1 unit LDH and appropriate amount of PDE4.
- Reaction progress curves are monitored in a plate reader capable of measuring light absorbance at 340 nM. A decrease in light absorbance at 340 nm is due to oxidation of NADH.
- Positive controls containing no test article and negative controls containing no test article and no cAMP are included on every assay plate. Reaction rates are determined from the slopes of the linear portions of the progress curves. All data is percent normalized with respect to controls and presented as percent inhibition.
- A-E are based on IC 50 in the assay described above.
- the activity of PDE4 inhibitors decribed in the present invention was also measured using in an ex- vivo assay measuring leukotriene E4 (LTE4) in human whole blood after Sephadex stimulation.
- LTE4 leukotriene E4
- the anti- inflammatory activity of therapeutic agents of the present invention is demonstrated by the inhibition of eosinophil activation as measured by sephadex bead stimulated LTE4 production in whole human blood.
- 356 ⁇ l of heparinized human whole blood (Vacutainer tube #6480) is added to wells of a 96 well plate.
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to substituted imidazopyridines, pyrazolotriazinones, triazolopyridines, pyrazolopyridines and pyrazolopyrimidines that are useful for treating stroke, myocardial infarct, and cardiovascular inflammatory conditions, to pharmaceutical compositions comprising these compounds, and to methods for the treatment of stroke, myocardial infarct, and cardiovascular inflammatory conditions in a mammal. The compounds have general formula I (I) or II (II) in which Cy1 and Cy2 are carbocycles or heterocycles.
Description
SUBSTITUTED AZA-BRIDGED BICYCLICS FOR CARDIOVASCULAR AND CNS
DISEASE
Cross-Reference to Related Applications
[0001] This application claims the priority of US provisional application 61/116,569, filed
November 20, 2008, the entire contents of which are incorporated herein by reference.
Field of the Invention
[0002] The invention relates to substituted imidazopyridines, pyrazolotriazinones, triazolopyridines, pyrazolopyridines and pyrazolopyrimidines that are useful for treating stroke, myocardial infarct, and cardiovascular inflammatory conditions, to pharmaceutical compositions comprising these compounds, and to methods for the treatment of stroke, myocardial infarct, and cardiovascular inflammatory conditions in a mammal.
Background of the Invention
[0003] PDE4 is the major cAMP-metabolizing enzyme found in inflammatory and immune cells. PDE4 inhibitors have proven potential as anti-inflammatory drugs, especially in inflammatory pulmonary diseases such as asthma, COPD and rhinitis. They suppress the release of cytokines and other inflammatory signals and inhibit the production of reactive oxygen species. A large number of PDE4 inhibitors have been developed for a variety of clinical indications (Torphy and Page. 2000. TIPS 21, 157-159; Burnouf and Pruniaux. 2002. Curr. Pharm. Design 8, 1255-1296; Lipworth. 2005. Lancet 365, 167-175). To quote from a recent article in the British Journal of Pharmacology, "PDE4 inhibitors have been in development as a novel anti- inflammatory therapy since the 1980s with asthma and chronic obstructive pulmonary disease (COPD) being primary indications. Despite initial optimism, none have yet reached the market. In most cases, the development of PDE4 inhibitors of various structural classes, including cilomilast, filaminast, lirimilast, piclamilast, tofimilast has been discontinued due to lack of efficacy. A primary problem is the low therapeutic ratio of these compounds, which severely limits the dose that can be given. Indeed, for many of these compounds it is likely that the maximum tolerated dose is
either sub-therapeutic or at the very bottom of the efficacy dose-response curve. Therefore, the challenge is to overcome this limitation." [Giembycz, Brit.J.Pharmacol. 155, 288-290 (2008)]. Many of the PDE4 inhibitors of the prior art have not reached the market because of the adverse side effect of emesis (Giembycz 2005. Curr. Opin. Pharm. 5, 238-244). Analysis of all known PDE4 inhibitors suggests that they are competitive with cAMP and bind within the active site (Houslay et al. 2005. DDT 10, 1503-1519); this may explain their narrow therapeutic ratio. The compounds of the present invention are non-competitive inhibitors of cAMP while being gene- specific inhibitors (PDE4D), and, based on the target rationale and in vitro potency, a person of skill in the art would expect the compounds to be useful as anti- inflammatory agents for the treatment, amelioration or prevention of inflammatory diseases and of complications arising therefrom.
Description of the Invention
[0004] There is provided, in accordance with an embodiment of the invention, a compound of formula I or formula II:
P is chosen from nitrogen and carbon;
Q is chosen from nitrogen and carbon, with the provisos that one of P or Q must be nitrogen, but P and Q cannot both be nitrogen;
R1 is selected from hydrogen, (Ci-C6) alkyl, haloalkyl, -CONHR5, lower alkoxy, alkylamino, dialkylamino, amino, -NHCOOR2 and -OCONH2;
W is nitrogen or CR2;
R2 is selected from hydrogen, (Ci-C6) alkyl, haloalkyl and optionally substituted heterocyclyl;
Y is CR3 or nitrogen;
R3 is selected from hydrogen, fluoro, hydroxyl and -OR10;
R10 is selected from (Ci-C6) alkyl optionally substituted with fluoro;
X is selected from CR4, nitrogen and N+ O";
R4 is selected from hydrogen, (Ci-C6) alkyl, halogen, amino, alkoxy and hydroxyl;
R5 is selected from hydrogen and (Ci-C6) alkyl;
R8 and R9 are independently selected from hydrogen, (Ci-C6) alkyl, (Ci-C6) hydroxyalkyl, (Cs-C6) carbocyclyl and a 3- to 6-membered heterocyclyl; or R8 and R9 together form a 4-6 membered ring which optionally contains a heteroatom selected from -O-, -NR5 and S(O)0-2; or R8 and R9 together form an oxo group;
Z is selected from -O-, -S(O)0-2, -NH-, -CH2- and a direct bond;
Cy1 is selected from optionally substituted (Cs-C6) carbocyclyl and optionally substituted heterocyclyl;
Cy2 is selected from optionally substituted aryl and optionally substituted heteroaryl; and
M is chosen from -CH2-, -CH2CH2-, -O-, -S(O)0-2, -OCH2, -CH2O, -CONH, -CONHCH2, -NHCO and -NHSO2.
[0005] There is also provided, in accordance with embodiments of the invention, a pharmaceutical composition comprising a compound as described herein, and a pharmaceutically acceptable carrier, excipient or diluent therefore.
[0006] In a third aspect, the invention relates to methods for the treatment or prophylaxis of a disease or condition mediated by phosphodiesterase-4. The methods comprise administering to a mammal a therapeutically effective amount of a compound having the general formula of formula I or II above. The disease or condition may be related to allergic, acute or chronic inflammation. The disease may be, for example, atherosclerosis, thrombosis, stroke, acute coronary syndrome, stable angina, peripheral vascular disease, critical leg ischemia, intermittent claudication, abdominal aortic aneurysm or myocardial infarction.
[0007] Selective PDE4 inhibitors of the invention are useful in improving cognition and thus useful for treating learning disorders, memory loss and other cognitive dysfunctions. Selective PDE4 inhibitors of the invention are also useful for treating asthma and Chronic Obstructive Pulmonary Disease (COPD). Compounds of the invention, which inhibit tumor growth and metastases, also find utility in the treatment and prevention of cancer, including esophageal cancer, brain cancer, pancreatic cancer, and colon cancer.
[0008] Selective PDE4 inhibitors of the invention are also thought to be useful for treating or preventing schizophrenia or Huntington's disease, bone loss, depression, anxiety, bladder inflammation, bladder pain and bladder overactivity.
[0009] These and other embodiments of the present invention will become apparent in conjunction with the description and claims that follow.
Detailed Description of the Invention
[0010] The invention relates to compounds of formula I or formula II
[0011] In accordance with some embodiments of the invention, P is nitrogen and Q is carbon. In accordance with other embodiments, Y is CR3. In further embodiments, X is CR4. In other embodiments, X is nitrogen. In still other embodiments, W is CR2. In yet other embodiments, W is nitrogen.
[0012] In accordance with some embodiments of the invention, P is carbon and Q is nitrogen. In accordance with other embodiments, W is CR2. In further embodiments, X is CR4. In other embodiments, X is nitrogen. In still other embodiments, Y is CR . In yet other embodiments, Y is nitrogen.
[0013] In accordance with some embodiments of the invention, in compounds of formula II, P is carbon and Q is nitrogen. In further embodiments, W can be nitrogen. In still other embodiments, W is CR2. Examples of "cores" include imidazolopyridines, triazolopyridines, pyrazolotriazinones and imidazolopyrazines:
[0014] In accordance with some embodiments, R2 is selected from hydrogen and (Ci-C6) alkyl, and in some embodiments, R2 is hydrogen. In further embodiments, X is CR4. In other embodiments, X is nitrogen. In further embodiments, R1 is selected from hydrogen and (Ci-C6) alkyl. In some embodiments, R1 is methyl. In other embodiments Z is a direct bond. In yet other embodiments, Z is selected from -O- and -S(O)0-2. In further embodiments, Z is -CH2-. In still other embodiments, Cy l is selected from optionally substituted aryl and heteroaryl. In further embodiments, Cy2 is selected from optionally substituted aryl and heteroaryl. In yet other embodiments, Cy1 and Cy2 are both optionally substituted phenyl. In accordance with other embodiments, R8 and R9 are each independently selected from hydrogen and (Ci-C6) alkyl. In further embodiments, R8 and R9 together form an oxo group. In still other embodiments, R8 and R9 together form a 4-6 membered ring, and this ring may optionally contain a heteroatom. In one embodiment, this heteroatom may be oxygen. In another embodiment, the heteroatom may be NR5. In still other embodiments, the heteroatom may be -S-, -S(O)- or -S(O)2-.
[0015] In accordance with some embodiments of the invention, Z is a direct bond. In other embodiments, M is -CH2-. In still other embodiments, M is -CONH-. In yet other embodiments, Cy1 is selected from optionally substituted aryl and an optionally substituted 5- or 6-membered ring nitrogen heterocycle. In accordance with some embodiments, Cy1 is selected from optionally substituted phenyl and an optionally substituted 5- or 6-membered ring nitrogen heterocycle. In still other embodiments, Cy1 is selected from optionally substituted phenyl, pyridinyl, morpholin-4-yl, piperazin-1-yl, piperidiny-1-yl, imidazol-1-yl, pyrazol-1-yl, and pyrazol-5-yl. In further embodiments, Cy2 is selected from optionally substituted phenyl and an optionally substituted 5- or 6-membered ring nitrogen heterocycle. Yet other embodiments include compounds in which Cy2 is selected from phenyl, 3-chlorophenyl, 3-nitrophenyl, 3-
bromophenyl, 3-acetylphenyl, 3-trichloromethylphenyl and 3-methylthiophenyl. In some embodiments, Cy2 is selected from phenyl and 3-chlorophenyl.
[0016] Yet other embodiments include compounds in which Cy1 is selected from phenyl and pyridinyl, each of which is optionally substituted with a substituent chosen from (1) hydrogen, halogen, halo alky 1, alkyl, acyl, alkoxyalkyl, hydroxyalkyl, hydroxyalkoxy, carbonyl, phenyl, heteroaryl, benzenesulfonyl, hydroxy, alkoxy, haloalkoxy, oxaalkyl, carboxy, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxycarbonylamino, carboxyalkyl, carboxyalkoxy, carboxy alky It hio, alkoxycarbonylaminoalkyl, carboxy alky lcarbonylamino, carboxamido, aminocarbonyloxy, alkylaminocarbonyl, dialkylaminocarbonyl, amino carbonylalkyl, cyano, acetoxy, nitro, amino, alkylamino, dialkylamino, aminoalkyl, (alkyl)(aryl)aminoalkyl, alkylamino alkyl, dialkylaminoalkyl, dialkylaminoalkoxy, alkyl(hydroxyalkyl)amino, heterocyclylalkoxy, mercapto, alkylthio, alkylsulfonyl, alkylsulfonylamino, alkylsulfinyl, alkylsulfonyl, arylthio, arylsulfonyl, arylsulfonylamino, arylsulfinyl, arylsulfonyl, acylaminoalkyl, acylaminoalkoxy, acylamino, amidino, aryl, benzyl, heterocyclyl, heterocyclylalkyl, phenoxy, benzyloxy, heteroaryloxy, heterocyclylamino, hydroxyimino, alkoxyimino, oxaalkyl, aminosulfonyl, trityl, amidino, guanidino, ureido, -NHC(=O)NHalkyl, -NHC(=O)NH-heterocyclyl, -alkyl-NHC(=O)N(alkyl)2, heterocyclylalkylcarbonylamino, benzyloxyphenyl, benzyloxy, the residues of amino acids, amino acid amides, protected residues of aminoacids, protected residues of amino acid amides, N-methylated amino acids and N-methylated amino acid amides and (2) phenyl and monocyclic heterocycle substituted with any of the foregoing.
[0017] In accordance with some embodiments of the invention, Cy1 is selected from phenyl and pyridinyl, each of which is optionally substituted with a substituent chosen from -CH3, -CH2CF3, -CF3, -CHO, -COOH, -CN, halogen, -OH, , -OEt, -C(K))NH2, -C(K))NHEt, -C(K))NMe2 -COOCH3, -COOEt, -CH2NHC(K))NH2, -CH(CH3)NHC(K))NH2, -CH2NHC(K))H, -CH2NHC(K))CH3, -CH2C(K))NH2, -CH2COOH, -CH2COOEt, -CH2NHC(K))OEt, -CH2NHC(K))O-C6H5, -CH2NHC(O)C(O)NH2, -CH2NHC(O)NHEt, -C(CH3)2OH, -CH2NHC(O)N(CHs)2, -CH2NHC(O)NHCH3, -CH2NH2, -CH(CH3)NH2, -C(CH3)2NH2, -CH2OH, -CH2CH2OH, -CH2NHSO2CH3, -CH2OC(O)NHEt, -OCH3, -OC(O)NH2, -OCH2CH2N(CH3)2, -OCH2CH2OCH3, -OCH(CH3)COOH, -SCH2COOH, -NHC(O)NH2,
-NHC(=O)NHEt, -NHCH3, -NHEt, -NH(tBoc), -NHCH2COOH, -N(CH3)CH2COOH, -NHC(=O)NHCH2CH2C1, -NHSO2NH2, -NHEt, -N(CH3)2, -NH2, , -NH(CH3)C(=O)NH2, - NHSO2CH3, -N(SO2CH3)2, -NHC(=0)0CH3, -NHC(=O)OtBu, -NHC(=O)CH3, -SO2NH2, -NHC(=O)CH2CH2COOH, -NHC(=0)NHCH2C00H, -CH2NHCHO, -NHC(=O)NHCH2COOEt, -NHC(=O)NH(CH2)3COOEt, -NHC(=O)NH(CH2)2COOEt, -N(CH3)CH2CH2OH, -NHC(=O)OEt, -N(Et)C(=O)OEt, -NHC(=O)NH(CH2)2COOH, -NHC(=O)CH2N(CH3)2, -NHC(=O)NH(CH2)3COOH, -NHC(=O)CH2NH2, -NHC(=O)CH2CH2NH2,
, and . In some embodiments, Cy1 is selected from phenyl and pyridinyl, each of which is substituted with a monocyclic heterocycle, and the monocyclic heterocycle is optionally substituted with a substituent chosen from the foregoing list. An example of the embodiment in which Cy1 is a pyridinyl substituted with a monocyclic heterocycle substituted with a carboxylic acid is found in example D-25 below:
. Exemplary carboxyalkoxy and carboxyalkylthio are lactic acid and thioglycollic acid respectively. Exemplary amino acids are glycine, alanine and proline.
[0018] In accordance with some embodiments of the invention, W is CR and R is selected from
H3C
hydrogen, methyl, -∞JΛW and
. In other embodiments, R > 2 is
J is selected from O, S, S(O), SO2, NH and NCH3 and L is C or N. In some of these embodiments, R2 is hydrogen.
[0019] In accordance with some embodiments of the invention, R4 is hydrogen. In other embodiments, R3 is hydrogen.
[0020] In some embodiments of the invention, R1 is selected from hydrogen and (Ci-C6) alkyl. In some of these compounds, R1 is methyl. In other embodiments, X is CH. In yet other embodiments, X is CF. Still other embodiments include compounds in which Cy l is selected from optionally substituted phenyl, pyridinyl, morpholin-4-yl, piperazin-1-yl, piperidiny-1-yl, imidazol-1-yl, pyrazol-1-yl, and pyrazol-5-yl. In other embodiments of the invention, Cy1 is phenyl optionally substituted with a substituent selected from amino, urea, alkylurea, -
NHCO2(C i-C6)alkyl, azeditine acid, azeditine amide,
and Jn further embodiments, Cy2 is optionally substituted phenyl. In yet other embodiments, Z is a direct bond. In some embodiments, M is -CH2-.
[0021] In accordance with some embodiments of the invention, R1 is selected from hydrogen and (Ci-C6) alkyl; X is CH; Cy 1 is selected from optionally substituted phenyl, pyridinyl, morpholin- 4-yl, piperazin-1-yl, piperidiny-1-yl, imidazol-1-yl, pyrazol-1-yl, and pyrazol-5-yl; Cy2 is optionally substituted phenyl; Z is a direct bond; and M is -CH2-.
[0022] In accordance with some embodiments of the invention, the compounds are of formula (A)
Cy1 is selected from optionally substituted (Cs-C6) carbocyclyl and optionally substituted heterocyclyl;
Cy2 is selected from optionally substituted aryl and optionally substituted heteroaryl;
R1 is selected from hydrogen, (Ci-C6) alkyl, haloalkyl, -CONHR5, lower alkoxy, alkylamino, dialkylamino, amino, -NHCOOR2 and -OCONH2;
R2 is selected from hydrogen, (Ci-C6) alkyl, haloalkyl and optionally substituted heterocyclyl;
R3 is selected from hydrogen, fluoro, hydroxyl and -OR10;
R10 is selected from (Ci-C6) alkyl optionally substituted with fluoro;
R4 is selected from hydrogen, (Ci-C6) alkyl, halogen, amino, alkoxy and hydroxyl; and
M is chosen from -CH2-, -CH2CH2-, -O-, -S(O)0-2, -OCH2, -CH2O, -CONH, -CONHCH2, -
NHCO and -NHSO2.
[0023] In some embodiments, Cy l is selected from optionally substituted phenyl, pyridinyl, morpholinyl, piperazinyl, piperidinyl, imidazolyl, pyrazolyl, oxazolidinyl, pyrrolidinyl, thiazolyl and benzo[c][l,2,5]oxadiazolyl.
[0024] In further embodiments of the invention, the compounds are of formula (A) wherein
Cy1 is selected from optionally substituted aryl and an optionally substituted 5- or 6-membered ring nitrogen heterocycle;
Cy2 is selected from optionally substituted phenyl and an optionally substituted 5- or 6- membered ring nitrogen heterocycle;
R1 is selected from hydrogen and (Ci-C6) alkyl;
R2 is selected from hydrogen, methyl,
and wherein J is selected from O, S(0)o-2, NH and NCH3 and L is selected from C and N; R3 is hydrogen; R4 is hydrogen; and M is -CH2-.
[0025] In yet other embodiments of the invention, the compounds are of formula (A) wherein Cy1 is selected from phenyl and pyridinyl, each of which is optionally substituted with a substituent chosen from halogen, haloalkyl, alkyl, acyl, alkoxyalkyl, hydroxyalkyl, carbonyl, phenyl, heteroaryl, benzenesulfonyl, hydroxy, alkoxy, haloalkoxy, oxaalkyl, carboxy, alkoxycarbonyl, alkoxycarbonylamino, alkoxycarbonylaminoalkyl, carboxy alky lcarbonylamino, carboxamido, aminocarbonyloxy, alkylaminocarbonyl, dialkylaminocarbonyl, aminocarbonylalkyl, cyano, acetoxy, nitro, amino, alkylamino, dialkylamino, aminoalkyl, (alkyl)(aryl)aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, dialkylaminoalkoxy, alkyl(hydroxyalkyl)amino, heterocyclylalkoxy, mercapto, alkylthio, alkylsulfonyl, alkylsulfonylamino, alkylsulfϊnyl, alkylsulfonyl, arylthio, arylsulfonyl, arylsulfonylamino, arylsulfinyl, arylsulfonyl, acylaminoalkyl, acylaminoalkoxy, acylamino, amidino, aryl, benzyl, heterocyclyl, heterocyclylalkyl, phenoxy, benzyloxy, heteroaryloxy, heterocyclylamino, hydroxyimino, alkoxyimino, oxaalkyl, amino sulfonyl, trityl, amidino, guanidino, ureido, -NHC(=O)NHalkyl, -NHC(=O)NH-heterocyclyl, -alkyl-NHC(=O)N(alkyl)2, heterocyclylalkylcarbonylamino, benzyloxyphenyl, benzyloxy, azetidine acid, azedtidine amide, the residues of amino acids, amino acid amides, protected residues of aminoacids, protected residues of amino acid amides, N-methylated amino acids and N-methylated amino acid amides.
[0026] In still other embodiments, Cy1 is selected from phenyl and pyridinyl, each of which is optionally substituted with a substituent chosen from -CH3, -CH2CF3, -CF3, -CHO, -COOH, -CN, halogen, -OH, , -OEt, -C(K))NH2, -C(K))NHEt, -C(O)NMe2 -COOCH3, -COOEt,
-CH2NHC(=O)NH2, -CH(CH3)NHC(=O)NH2, -CH2NHC(=O)H, -CH2NHC(=O)CH3, -CH2C(=O)NH2, -CH2COOH, -CH2COOEt, -CH2NHC(=O)OEt, -CH2NHC(=O)O-C6H5, -CH2NHC(=O)C(=O)NH2, -CH2NHC(=O)NHEt, -C(CH3)2OH, -CH2NHC(=O)N(CH3)2, -CH2NHC(=O)NHCH3, -CH2NH2, -CH(CH3)NH2, -C(CH3)2NH2, -CH2OH, -CH2CH2OH, -CH2NHSO2CH3, -CH20C(=0)NHEt, -OCH3, -0C(=0)NH2, -OCH2CH2N(CH3)2, -OCH2CH2OCH3, -OCH(CH3)COOH, -SCH2COOH, -NHC(=0)NH2, -NHC(=0)NHEt, -NHCH3, -NHEt, -NH(tBoc), -NHCH2COOH, -N(CH3)CH2COOH, -NHC(=O)NHCH2CH2C1, -NHSO2NH2, -NHEt, -N(CH3)2, -NH2, , -NH(CH3)C(=O)NH2, -NHSO2CH3, -N(SO2CH3)2, -NHC(=0)0CH3, -NHC(=O)OtBu, -NHC(=O)CH3, -SO2NH2, -NHC(=O)CH2CH2COOH, -NHC(=0)NHCH2C00H, -CH2NHCHO, -NHC(=O)NHCH2COOEt, -NHC(=O)NH(CH2)3COOEt, -NHC(=O)NH(CH2)2COOEt, -N(CH3)CH2CH2OH, -NHC(=O)OEt, -N(Et)C(=O)OEt, -NHC(=O)NH(CH2)2COOH, -NHC(=O)CH2N(CH3)2, -NHC(=O)NH(CH2)3COOH, -NHC(=O)CH2NH2, -NHC(=O)CH2CH2NH2,
[0027] In further embodiments of the invention, Cy2 is selected from phenyl and 3-chlorophenyl.
[0028] In some embodiments of the invention, the compound is selected from the following (Table 1):
[0029] Table 1.
[0030] In other embodiments of the invention, the compound is represented by the following (Table 2):
[0031] Table 2.
[0032] All of the compounds falling within the foregoing parent genus I and its subgenera are useful as PDE4 inhibitors. It may be found upon examination that species and genera not presently excluded are not patentable to the inventors in this application because of prior art. In this case, the exclusion of species and genera in applicants' claims are to be considered artifacts of patent prosecution and not reflective of the inventors' concept or description of their invention. The invention, in a composition aspect, is all active compounds of formula I and formula II except those that are in the public's possession.
[0033] PDE4 inhibitors have been shown to be effective therapeutic agents in clinical studies. For example, administration of cilomilast and roflumilast (PDE4 inhibitors) to patients suffering from asthma and COPD showed initially excellent results, although the effect of cilomilast disappeared on long-term trial [Lipworth, Lancet 365. 167-175 (2005)]. L- 454,560, a selective PDE4 inhibitor has been shown to improve learning in a rat model in vivo [Huang et al. Biochemical Pharmacology 73, 1971-1981 (2007)]. This suggests that selective PDE4 inhibitors will be useful in treating learning disorders, memory loss (e.g. Alzheimer's disease) and other cognitive dysfunctions. Selective PDE4 inhibitors (e.g. rolipram) are also useful for treating bone loss [Yao et al., J.Musculoskelet.Neuronal Interact. 7, 119-130 (2007)]. Additionally, a PDE4 inhibitor, YM976, was shown to ameliorate the effects of experimentally- induced interstitial cystitis in rats, resulting in a decrease in the frequency of urination and an increase in the volume of urine at each time of urination [Kitta et al., BJU Int. 102. 1472-1476 (2008)]. Another PDE4 inhibitor, IC485, was shown to be equally efficacious as tolteradine tartrate, a marketed drug for treating overactive bladder, in a rodent model of obstructive bladder [Kaiho et al. BJU Int. 101, 615-20 (2008)]. These findings suggest that PDE4 inhibitors will be useful in treating symptoms of bladder inflammation, such as overactivity and pain.
[0034] Furthermore, the compounds, compositions and methods of the present invention are useful in treating cancer. Phosphodiesterase activity has been shown to be associated with hematological malignancies [Lerner et al., BiochemJ. 393, 21-41 (2006); Ogawa et al, Blood 99, 3390-3397 (2002)].
[0035] Throughout this specification the terms and substituents retain their definitions.
[0036] Alkyl is intended to include linear, branched, or cyclic hydrocarbon structures and combinations thereof. A combination would be, for example, cyclopropylmethyl. When not otherwise restricted, the term refers to alkyl of 20 or fewer carbons. Lower alkyl refers to alkyl groups of 1, 2, 3, 4, 5 and 6 carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, s-and t-butyl and the like. Preferred alkyl and alkylene groups are those of Ci0 or below (e.g. Ci, C2, C3, C4, C5, C6, C7, C8, C9, Ci0); most preferred are lower alkyl. Cycloalkyl is a subset of alkyl and includes cyclic hydrocarbon groups of 3, 4, 5, 6, 7, and 8 carbon atoms. Examples of cycloalkyl groups include c-propyl, c-butyl, c-pentyl, norbornyl, adamantyl and the like.
[0037] C1 to C20 Hydrocarbon (e.g. C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20) includes alkyl, cycloalkyl, alkenyl, alkynyl, aryl and combinations thereof. Examples include benzyl, phenethyl, cyclohexylmethyl, camphoryl and naphthylethyl. The term "phenylene" refers to ortho, meta or para residues of the formulae:
Hydrocarbon refers to any substituent comprised of hydrogen and carbon as the only elemental constituents.
[0038] Unless otherwise specified, the term "carbocycle" (or "carbocyclyl") is intended to include ring systems in which the ring atoms are all carbon but of any oxidation state. Thus (C3-C10) carbocycle refers to such systems as cyclopropane, benzene and cyclohexene; (C8-
Ci2) carbopolycycle refers to such systems as norbornane, decalin, indane and naphthalene. Carbocycle, not otherwise limited, refers to monocycles, bicycles and polycycles.
[0039] Alkoxy or alkoxyl refers to groups of 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms of a straight, branched, cyclic configuration and combinations thereof attached to the parent structure through an oxygen. Examples include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy and the like. Lower-alkoxy refers to groups containing one to four carbons. For the purposes of the present patent application alkoxy also includes methylenedioxy and ethylenedioxy in which each oxygen atom is bonded to the atom, chain or ring from which the methylenedioxy or ethylenedioxy group is pendant so as to form a ring. Thus, for example, phenyl substituted by alkoxy may be, for example,
Oxaalkyl refers to alkyl residues in which one or more carbons (and their associated hydrogens) have been replaced by oxygen. Examples include methoxypropoxy, 3,6,9- trioxadecyl and the like. The term oxaalkyl is intended as it is understood in the art [see Naming and Indexing of Chemical Substances for Chemical Abstracts, published by the American Chemical Society, 1196, but without the restriction of Tfl27(a)], i.e. it refers to compounds in which the oxygen is bonded via a single bond to its adjacent atoms (forming ether bonds). It does not refer to doubly bonded oxygen, as would be found in carbonyl groups. Similarly, thiaalkyl and azaalkyl refer to alkyl residues in which one or more carbons have been replaced by sulfur or nitrogen, respectively. Examples include ethylaminoethyl and methylthiopropyl.
[0040] Acyl refers to formyl and to groups of 1, 2, 3, 4, 5, 6, 7 and 8 carbon atoms of a straight, branched or cyclic configuration, saturated, unsaturated and aromatic and combinations thereof, attached to the parent structure through a carbonyl functionality. One or more carbons in the acyl residue may be replaced by nitrogen, oxygen or sulfur as long as the point of attachment to the parent remains at the carbonyl. Examples include acetyl, propionyl, isobutyryl, ϊ-butoxycarbonyl, benzoyl, benzyloxycarbonyl and the like. Lower- acyl refers to groups containing one to four carbons. The double bonded oxygen, when referred to as a substituent itself, is called "oxo".
[0041] Aryl and heteroaryl refer to aromatic or heteroaromatic rings, respectively, as substituents. Aryl and heteroaryl mean (i) a phenyl group (or benzene) or a monocyclic 5- or 6-membered heteroaromatic ring containing 1-4 heteroatoms selected from O, N, or S; (ii) a bicyclic 9- or 10-membered aromatic or heteroaromatic ring system containing 0-4 heteroatoms selected from O, N, or S; or (iii) a tricyclic 13- or 14-membered aromatic or heteroaromatic ring system containing 0-5 heteroatoms selected from O, N, or S. Aromatic 6, 7, 8, 9, 10, 11, 12, 13 and 14-membered carbocyclic rings include, e.g., benzene, naphthalene, indane, tetralin, and fluorene and the 5, 6, 7, 8, 9 and 10-membered aromatic heterocyclic rings include, e.g., imidazole, pyridine, indole, thiophene, benzopyranone, thiazole, furan, benzimidazole, quinoline, isoquinoline, quinoxaline, pyrimidine, pyrazine, tetrazole and pyrazole. As used herein aryl refers to residues in which one or more rings are aromatic, but not all need be.
[0042] Arylalkyl refers to a substituent in which an aryl residue is attached to the parent structure through alkyl. Examples are benzyl, phenethyl and the like. This is in contradistinction to alkylaryl, in which an aryl residue is attached to the parent structure through alkyl (e.g. a p-tolyl residue). Heteroarylalkyl refers to a substituent in which a heteroaryl residue is attached to the parent structure through alkyl. Examples include, e.g., pyridinylmethyl, pyrimidinylethyl and the like. Heterocyclylalkyl refers to a substituent in which a heterocyclyl residue is attached to the parent structure through alkyl. Examples include morpholinoethyl and pyrrolidinylmethyl.
[0043] The term "heterocycle" (or "heterocyclyl") means a monocyclic, bicyclic or tricyclic residue with 1 to 13 carbon atoms and 1 to 4 heteroatoms chosen from the group consisting of nitrogen, oxygen and sulfur. The nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized. Unless otherwise specified, a heterocycle may be non-aromatic or aromatic. The heterocycle may be fused to an aromatic hydrocarbon radical. Suitable examples include pyrrolyl, pyridinyl, pyrazolyl, triazolyl, pyrimidinyl, pyridazinyl, oxazolyl, thiazolyl, imidazolyl, indolyl, thiophenyl, furanyl, tetrazolyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolindinyl, 1,3-dioxolanyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3- triazolyl, 1,3,4-thiadiazolyl, 2H-pyranyl, 4H-pyranyl, piperidinyl, 1,4-dithianyl, thiomorpholinyl, pyrazinyl, piperazinyl, 1,3,5-triazinyl, 1,2,5-trithianyl, benzo(b)thiophenyl,
benzimidazolyl, quinolinyl, and the like. A nitrogen heterocycle is a heterocycle containing at least one nitrogen in the ring; it may contain additional nitrogens, as well as other heteroatoms. Examples include piperidine, piperazine, morpholine, pyrrolidine and thiomorpholine. It is to be noted that heteroaryl is a subset of heterocycle in which the heterocycle is aromatic; examples include pyridine, pyrrole and thiazole. Examples of heterocyclyl residues additionally include piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2- oxo-pyrrolidinyl, 2-oxoazepinyl, azepinyl, 4-piperidinyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, benzimidazolyl, thiadiazolyl, benzopyranyl, benzothiazolyl, tetrahydrofuryl, tetrahydropyranyl, thienyl, benzothienyl, thiamorpholinyl, thiamorpholinylsulfoxide, thiamorpholinylsulfone, oxadiazolyl, triazolyl and tetrahydroquinolinyl. For the purpose of the present disclosure, heteroaryl includes the corresponding oxo compounds, e.g. pyridinone, imidazolone, pyridazinone, pyrimidinone etc.
[0044] An oxygen heterocycle is a heterocycle containing at least one oxygen in the ring; it may contain additional oxygens, as well as other heteroatoms. A sulphur heterocycle is a heterocycle containing at least one sulphur in the ring; it may contain additional sulphurs, as well as other heteroatoms. A nitrogen heterocycle is a heterocycle containing at least one nitrogen in the ring; it may contain additional nitrogens, as well as other heteroatoms.
[0045] As used herein, the term "optionally substituted" may be used interchangeably with "unsubstituted or substituted". Substituted alkyl, aryl, cycloalkyl, heterocyclyl, etc. refer to alkyl, aryl, cycloalkyl, or heterocyclyl wherein up to three H atoms in each residue are replaced with a specified radical. For example, substituted alkyl, aryl, cycloalkyl, heterocyclyl etc. refer to alkyl, aryl, cycloalkyl, or heterocyclyl wherein up to three H atoms in each residue are replaced with halogen, alkyl, haloalkyl, haloalkoxy, hydroxy, loweralkoxy (which for the purpose of the present disclosure includes methylene dioxy and ethylene dioxy), oxaalkyl, carboxy, carboalkoxy (also referred to as alkoxycarbonyl[-C(=O)O-alkyl]), carboxamido (i.e. [-C(=O)NH2]), alkylaminocarbonyl (i.e. [-C(=O)NH-alkyl]), alkylaminocarbonylamino (i.e. [-NHC(=O)NH-alkyl]),alkoxycarbonylamino (i.e. [-NHC(=O)O-alkyl]), acyl, alkoxyalkyl, benzenesulfonyl, cyano, carbonyl, nitro, amino, hydroxyalkyl, alkylamino, dialkylamino, aminoalkyl, (alkyl)(aryl)aminoalkyl, alkylaminoalkyl (including cycloalkylaminoalkyl), dialkylaminoalkyl, dialkylaminoalkoxy, heterocyclylalkoxy, mercapto, alkylthio, alkylsulfinyl, alkylsulfonyl, acylamino,
diacylamino, acylaminoalkyl, acylaminoalkoxy, amidino, alkoxycarbonylamino, acetoxy, sulfoxide, sulfone, sulfonylamino, aryl, phenyl, heterocyclyl, hydroxyimino, alkoxyimino, aminosulfonyl, trityl, amidino, guanidino, ureido (i.e. [-NHC(=O)NH2]), benzyloxyphenyl, benzyl, heteroaryl, heterocyclylalkyl, phenoxy, benzyloxy, or heteroaryloxy. Haloakyl refers to an alkyl group in which one or more hydrogens are replaced by halogen, for example, trifluoromethyl, trifluoromethoxy, trichloroethyl, and difluoromethyl. "Oxo" is also included among the substituents referred to in "optionally substituted"; it will be appreciated by persons of skill in the art that, because oxo is a divalent radical, there are circumstances in which it will not be appropriate as a substituent (e.g. on phenyl). In one embodiment, 1, 2 or 3 hydrogen atoms are replaced with a specified radical. Additional substituents that are considered within the scope of the term are the are the residues of amino acids, amino acid amides, protected residues of aminoacids and their amides, and N-methylated (mono- or di-, as appropriate) amino acids and amino acid amides.
[0046] The term "a residue of an amino acid, amino acid amide", etc. refers to an amino acid etc. minus the functional groups that are considered part of the bond to the parent structure. For example, in Fragment A illustrated below:
after one subtracts the hydrogen that connects (BOC)glycinamide to the phenyl ring, the structure of A that remains is:
This is not sensu stricto a protected amino acid amide, since it lacks the hydrogen on the C-terminal amide. This and similar structures that lack atoms at the points of attachment (e.g. the OH of COOH or the H OfNH2) are referred to herein as "residues" of their respective parents.
[0047] The term "halogen" means fluorine, chlorine, bromine or iodine.
[0048] The terms "haloalkyl" and "haloalkoxy" mean alkyl or alkoxy, respectively, substituted with one or more halogen atoms. The terms "alkylcarbonyl" and "alkoxycarbonyl" mean -C(=O)alkyl or -C(O)alkoxy, respectively.
[0049] Substituents Rn are generally defined when introduced and retain that definition throughout the specification and in all independent claims.
[0050] In the characterization of some of the substituents, it is recited that certain substituents may combine to form rings. Unless stated otherwise, it is intended that such rings may exhibit various degrees of unsaturation (from fully saturated to fully unsaturated), may include heteroatoms and may be substituted with lower alkyl or alkoxy.
[0051] The term "prodrug" refers to a compound that is made more active in vivo. Commonly the conversion of prodrug to drug occurs by enzymatic processes in the liver or blood of the mammal. Many of the compounds of the invention may be chemically modified without absorption into the systemic circulation, and in those cases, activation in vivo may come about by chemical action (as in the acid-catalyzed cleavage in the stomach) or through the intermediacy of enzymes and microflora in the gastrointestinal GI tract.
[0052] It will be recognized that the compounds of this invention can exist in radiolabeled form, i.e., the compounds may contain one or more atoms containing an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Radioisotopes of hydrogen, carbon, phosphorous, fluorine, iodine and chlorine include 3H, 14C, 35S, 18F, 32P, 33P, 125I, and 36Cl, respectively. Compounds that contain those radioisotopes and/or other radioisotopes of other atoms are within the scope of this invention. Radiolabeled compounds described herein and prodrugs thereof can generally be prepared by methods well known to those skilled in the art. Conveniently, such radiolabeled compounds can be prepared by carrying out the procedures disclosed in the Examples and Schemes by substituting a readily available radiolabeled reagent for a non-radio labeled reagent.
[0053] PDE4 inhibitors have been shown to be effective therapeutic agents in clinical studies. For example, administration of cilomilast and roflumilast (PDE4 inhibitors) to patients suffering from asthma and COPD showed initially excellent results, although the effect of cilomilast disappeared on long-term trial [Lipworth, Lancet 365, 167-175 (2005)].
L-454,560, a selective PDE4 inhibitor has been shown to improve learning in a rat model in vivo [Huang et al. Biochemical Pharmacology 73. 1971-1981 (2007)]. This suggests that selective PDE4 inhibitors will be useful in treating learning disorders, memory loss (e.g. Alzheimer's disease) and other cognitive dysfunctions. Rolipram, a selective PDE4 inhibitor has been shown to improve the outcome in two separate studies in mice in vivo in models accepted by persons of skill in the art as predictive of utility in schizophrenia [Kanes et al., Neuroscience 144. 239-246 (2007); Davis and Gould, Behav.Neurosci. 119. 595-602 (2005)]. Rolipram has also been shown to exhibit a neuroprotective effect in a rat model of Huntington's disease [DeMarch et al. Neurobiol.Dis. 25, 266-273 (2007)]. Selective PDE4 inhibitors (e.g. rolipram) are also useful for treating bone loss [Yao et al., J.Musculoskelet.Neuronal Interact. 7. 119-130 (2007)].
[0054] In addition to the foregoing studies demonstrating utility in in vivo models, a number of authors have suggested connections between PDE4 inhibition and putative utilities as antidepressants [Houslay et al., Drug Discov Today 10, 1503-1519 (2005); Polesskaya et al., BioLPsychiatr. 61, 56-64 (2007); anon. Current Opin.Invetig. Drugs 5. 34-39 (2004)] and as anxiolytics [Zhang et al., Neuropsychopharmacology Aug 15, 2007 Epub; Cherry et al., Biochim.Biophys.Acta 1518. 27-35 (2001)]. Other possible utilities may include Pick's disease and epilepsy.
[0055] Furthermore, the compounds, compositions and methods of the present invention are useful in treating cancer. Phosphodiesterase activity has been shown to be associated with hematological malignancies [Lerner et al., BiochemJ. 393. 21-41 (2006); Ogawa et al., Blood 99. 3390-3397 (2002)]. The compounds may also be administered to overcome cognitive impairment induced by one or more of the following agents, alcohol, amphetamine, antipsychotic medication, anti-retroviral therapy, MDMA ( 3,4-methylenedioxy-N- methylamphetamine, cannabis, cocaine, delta-9 tetrahydrocannabinol, dexamphetamine, haloperidol, heroin and other opiates, ketamine and metamphetamine.
[0056] Furthermore, the compounds, compositions and methods of the present invention, particularly when radiolabeled as described above or labeled by methods well-known in the art with florescent and spin labels, may be employed as imaging agents and in other ways for diagnosis and/or treatment. Moreover, immobilization of compounds of the invention on
solid support could be of utility for affinity purification and modification of compounds of the invention with chemically active groups may be used for protein labeling.
[0057] For many of the utilities outlined above, it may be advantageous to administer compounds of the general formula I or formula II together with cholinesterase inhibitors (e.g. tacrine, huperzine, donepezil); NMDA antagonists (e.g. lanicemine, remacemide, neramexane, memantine); calpain inhibitors (e.g. CEP-3122); antioxidants (e.g. vitamin E, coenzyme QlO) and agents that have shown clinical efficacy but whose mechanism is unclear (e.g. dimebon). Compounds of formula I or formula II may also be administered together with one or more of the following agents to improve cognition: amisulpride, atomoxetine, bromocryptine, buspirone, caffeine, chlorpromazine, clonidine, clozapine, diazepam, flumazenil, fluoxetine, galantamine, guanfacine, methylphenidate, idazoxan, modafinil, olanzapine, paroxetine, pergolide, phenserine, quetiapine, risperidone, rivastigmine, SGS742 and sulpiride.
[0058] The terms "methods of treating or preventing" mean amelioration, prevention or relief from the symptoms and/or effects associated with lipid disorders. The term "preventing" as used herein refers to administering a medicament beforehand to forestall or obtund an acute episode or, in the case of a chronic condition to diminish the likelihood or seriousness of the condition. The person of ordinary skill in the medical art (to which the present method claims are directed) recognizes that the term "prevent" is not an absolute term. In the medical art it is understood to refer to the prophylactic administration of a drug to substantially diminish the likelihood or seriousness of a condition, and this is the sense intended in applicants' claims. As used herein, reference to "treatment" of a patient is intended to include prophylaxis.
[0059] The term "mammal" is used in its dictionary sense. The term "mammal" includes, for example, mice, hamsters, rats, cows, sheep, pigs, goats, and horses, monkeys, dogs (e.g., Canis familiaris), cats, rabbits, guinea pigs, and primates, including humans.
[0060] The cognitive impairment to be treated may arise from one or more of the following disorders, which may not in themselves be necessarily associated with PDE4 abnormality: acute pain, AD/HD - Attention deficit hyperactivity disorder, AIDS dementia complex, alcoholism, amphetamine addiction, amygdalo-hippocampectomy, anorexia nervosa, anterior
parietal damage, antisocial behavior, antisocial personality disorder, anxiety, autism, basal ganglia lesions, bipolar disorder, borderline personality disorder, camptocormia, capgras syndrome, carcinoid syndrome, carotid endarterectomy surgery, chronic drug misuse, chronic fatigue syndrome, chronic occupational solvent encephalopathy, chronic pain, brain ischemia, coronary artery bypass surgery, critical illness requiring intensive care, dementia Alzheimer- type (DAT), dementia Lewy Body type, dementia of frontal type, dementia caused by ischemia, dental pain, developmental dyslexia, diabetes, dorsolateral frontal cortical compression, Down's Syndrome, drug abuse, dysexecutive syndrome, fibromyalgia, frontal lobe damage, frontal lobe excision, frontal variant frontotemporal dementia, gluten ataxia, hallucinosis, head injury, hearing loss, heart disease, heart failure, heavy social drinking, hepatic encephalopathy, heroin addiction, herpes encephalitis, hippocampal atrophy, HIV/AIDS, Huntington's disease, hydrocephalus, hypercortisolemia, hyperostosis frontalis interna, hypertension, idiopathic pain, insomnia, Korsakoff syndrome, late paraphrenia, lead exposure, left ventricular systolic dysfunction, orbitofrontal cortex lesion, liver failure, long term health effects of diving, Machado-Joseph disease, mad hatter's disease, manic depression, melancholia, mercury poisoning, mild cognitive impairment (MCI), mild cognitive impairment (MCI) of aging, motor neuron disease, multiple sclerosis, multiple system atrophy, narcolepsy, neuronal migration disorders, normal pressure hydrocephalus, obsessive compulsive disorder, organophosphate pesticide exposure, panic disorder, paraphrenia, Parkinson's disease, periventricular brain insult, personality disorder, gasoline sniffing, phenylketonuria, post-concussion syndrome, premature birth needing intensive care, premenstrual dysphoric disorder, progressive supranuclear palsy, psychopathy, psychosis, questionable dementia, renal cancer, Roifman syndrome, schizoaffective disorder, schizophrenia, seasonal affective disorder, self harm, semantic dementia, specific language impairment, social withdrawal in schizophrenia, solvent encephalopathy, spina bifida, Steele- Richardson-Olzsewski syndrome, stiff person syndrome, striatocapsular infarct, subarachnoid hemorrhage, substance abuse, tardive dyskinesia, temporal lobe excision, temporal lobe lesion, tinnitus, Tourette's syndrome, transient cerebral ischemia, traumatic brain injury, trichotillomania, tuberous sclerosis, and white matter lesions.
[0061] Compounds described herein may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms. Each chiral center may be defined, in terms of absolute stereochemistry, as (R)- or (S)-. The present invention is meant to include all such possible isomers, as well as mixtures thereof, including
racemic and optically pure forms. Optically active (R)- and (S)-, (-)- and (+)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included.
[0062] The graphic representations of racemic, ambiscalemic and scalemic or enantiomerically pure compounds used herein are taken from Maehr J. Chem. Ed. 62, 114- 120 (1985): solid and broken wedges are used to denote the absolute configuration of a chiral element; wavy lines and single thin lines indicate disavowal of any stereochemical implication which the bond it represents could generate; solid and broken bold lines are geometric descriptors indicating the relative configuration shown but denoting racemic character; and wedge outlines and dotted or broken lines denote enantiomerically pure compounds of indeterminate absolute configuration.
[0063] As used herein, and as would be understood by the person of skill in the art, the recitation of "a compound" is intended to include salts, solvates and inclusion complexes of that compound as well as any stereoisomeric form, or a mixture of any such forms of that compound in any ratio. Thus, in accordance with some embodiments of the invention, a compound as described herein, including in the contexts of pharmaceutical compositions, methods of treatment, and compounds per se, is provided as the salt form. In accordance with some embodiments of the invention, the salt is a hydrochloride salt.
[0064] The term "solvate" refers to a compound in the solid state, wherein molecules of a suitable solvent are incorporated in the crystal lattice. A suitable solvent for therapeutic administration is physiologically tolerable at the dosage administered. Examples of suitable solvents for therapeutic administration are ethanol and water. When water is the solvent, the solvate is referred to as a hydrate. Inclusion complexes are described in Remington: The Science and Practice of Pharmacy 19th Ed. (1995) volume 1, page 176-177. The most commonly employed inclusion complexes are those with cyclodextrins, and all cyclodextrin complexes, natural and synthetic, with or without added additives and polymer(s), such as described in US Patents 5,324,718 and 5,472,954, are specifically encompassed within the claims.
[0065] The term "pharmaceutically acceptable salt" refers to salts prepared from pharmaceutically acceptable non-toxic acids or bases including inorganic acids and bases and organic acids and bases. When the compounds of the present invention are basic, salts may be prepared from pharmaceutically acceptable non-toxic acids including inorganic and organic acids. Suitable pharmaceutically acceptable acid addition salts for the compounds of the present invention include acetic, benzenesulfonic (besylate), benzoic, camphorsulfonic, carbonic, citric, ethanedisulfonic, ethanesulfonic, ethylenediaminetetraacetic, fumaric, glucoheptonic, gluconic, glutamic, hydrobromic, hydrochloric, hydroiodic, hydroxynaphthoic, isethionic, lactic, lactobionic, laurylsulfonic, maleic, malic, mandelic, methanesulfonic, mucic, naphthylenesulfonic, nitric, pamoic, pantothenic, phosphoric, polygalacturonic, salicylic, stearic, succinic, sulfuric, tannic, tartaric acid, teoclatic, p- toluenesulfonic, and the like. When the compounds contain an acidic side chain, suitable pharmaceutically acceptable base addition salts for the compounds of the present invention include, but are not limited to, metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from lysine, arginine, N,N'- dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine.
[0066] The term "enantiomeric excess" is well known in the art and is defined for a resolution of ab into a + b as
_ J cone, of a - cone, of b \ eea 100 yconc. of a + cone, of b
[0067] The term "enantiomeric excess" is related to the older term "optical purity" in that both are measures of the same phenomenon. The value of ee will be a number from 0 to 100, zero being racemic and 100 being pure, single enantiomer. A compound which in the past might have been called 98% optically pure is now more precisely described as 96% ee; in other words, a 90% ee reflects the presence of 95% of one enantiomer and 5% of the other in the material in question.
[0068] The configuration of any carbon-carbon double bond appearing herein is selected for convenience only and is not intended to designate a particular configuration; thus a carbon-
carbon double bond depicted arbitrarily herein as E may be Z, E, or a mixture of the two in any proportion.
[0069] Terminology related to "protecting", "deprotecting" and "protected" functionalities occurs throughout this application. Such terminology is well understood by persons of skill in the art and is used in the context of processes which involve sequential treatment with a series of reagents. In that context, a protecting group refers to a group which is used to mask a functionality during a process step in which it would otherwise react, but in which reaction is undesirable. The protecting group prevents reaction at that step, but may be subsequently removed to expose the original functionality. The removal or "deprotection" occurs after the completion of the reaction or reactions in which the functionality would interfere. Thus, when a sequence of reagents is specified, as it is in the processes of the invention, the person of ordinary skill can readily envision those groups that would be suitable as "protecting groups". Suitable groups for that purpose are discussed in standard textbooks in the field of chemistry, such as Protective Groups in Organic Synthesis by T.W.Greene [John Wiley & Sons, New York, 1991], which is incorporated herein by reference. Particular attention is drawn to the chapters entitled "Protection for the Hydroxyl Group, Including 1,2- and 1,3- Diols" (pages 10-86).
[0070] The abbreviations Me, Et, Ph, Tf, Ts and Ms represent methyl, ethyl, phenyl, trifluoromethanesulfonyl, toluenesulfonyl and methanesulfonyl respectively. A comprehensive list of abbreviations utilized by organic chemists (i.e. persons of ordinary skill in the art) appears in the first issue of each volume of the Journal of Organic Chemistry. The list, which is typically presented in a table entitled "Standard List of Abbreviations" is incorporated herein by reference.
[0071] While it may be possible for compounds of formula I and formula II to be administered as the raw chemical, it will often be preferable to present them as part of a pharmaceutical composition. In accordance with an embodiment of the present invention there is provided a pharmaceutical composition comprising a compound of formula I or formula II or a pharmaceutically acceptable salt or solvate thereof, together with one or more pharmaceutically carriers thereof and optionally one or more other therapeutic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Furthermore, when
reference is made in an independent claim to a compound or a pharmaceutically acceptable salt thereof, it will be understood that claims which depend from that independent claim which refer to such a compound also include pharmaceutically acceptable salts of the compound, even if explicit reference is not made to the salts in the dependent claim.
[0072] The formulations include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous and intraarticular), rectal and topical (including dermal, buccal, sublingual and intraocular) administration. The most suitable route may depend upon the condition and disorder of the recipient. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association a compound of formula I or formula II or a pharmaceutically acceptable salt or solvate thereof ("active ingredient") with the carrier, which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
[0073] Formulations suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.
[0074] A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free- flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide sustained, delayed or controlled release of the active ingredient therein. The pharmaceutical compositions may include a "pharmaceutically acceptable inert carrier", and this expression is intended to include one or more inert excipients, which include starches, polyols, granulating agents, microcrystalline cellulose, diluents, lubricants, binders, disintegrating agents, and the like. If desired, tablet dosages of
the disclosed compositions may be coated by standard aqueous or nonaqueous techniques, "Pharmaceutically acceptable carrier" also encompasses controlled release means.
[0075] Pharmaceutical compositions may also optionally include other therapeutic ingredients, anti-caking agents, preservatives, sweetening agents, colorants, flavors, desiccants, plasticizers, dyes, and the like. Any such optional ingredient must be compatible with the compound of formula I or formula II to insure the stability of the formulation. The composition may contain other additives as needed, including for example lactose, glucose, fructose, galactose, trehalose, sucrose, maltose, raffinose, maltitol, melezitose, stachyose, lactitol, palatinite, starch, xylitol, mannitol, myoinositol, and the like, and hydrates thereof, and amino acids, for example alanine, glycine and betaine, and peptides and proteins, for example albumen.
[0076] Examples of excipients for use as the pharmaceutically acceptable carriers and the pharmaceutically acceptable inert carriers and the aforementioned additional ingredients include, but are not limited to binders, fillers, disintegrants, lubricants, anti-microbial agents, and coating agents.
[0077] The dose range for adult humans is generally from 0.005 mg to 10 g/day orally. Tablets or other forms of presentation provided in discrete units may conveniently contain an amount of compound of formula I or formula II which is effective at such dosage or as a multiple of the same, for instance, units containing 5 mg to 500 mg, usually around 10 mg to 200 mg. The precise amount of compound administered to a patient will be the responsibility of the attendant physician. However, the dose employed will depend on a number of factors, including the age and sex of the patient, the precise disorder being treated, and its severity.
[0078] A dosage unit (e.g. an oral dosage unit) can include from, for example, 1 to 30 mg, 1 to 40 mg, 1 to 100 mg, 1 to 300 mg, 1 to 500 mg, 2 to 500 mg, 3 to 100 mg, 5 to 20 mg, 5 to 100 mg (e.g. 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg) of a compound described herein.
[0079] For additional information about pharmaceutical compositions and their formulation, see, for example, Remington: The Science and Practice of Pharmacy, 20th Edition, 2000. The agents can be administered, e.g., by intravenous injection, intramuscular injection, subcutaneous injection, intraperitoneal injection, topical, sublingual, intraarticular (in the joints), intradermal, buccal, ophthalmic (including intraocular), intranasaly (including using a cannula), or by other routes. The agents can be administered orally, e.g., as a tablet or cachet containing a predetermined amount of the active ingredient, gel, pellet, paste, syrup, bolus, electuary, slurry, capsule, powder, granules, as a solution or a suspension in an aqueous liquid or a non-aqueous liquid, as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion, via a micellar formulation (see, e.g. WO 97/11682) via a liposomal formulation (see, e.g., EP 736299,WO 99/59550 and WO 97/13500), via formulations described in WO 03/094886 or in some other form. The agents can also be administered transdermally (i.e. via reservoir-type or matrix-type patches, microneedles, thermal poration, hypodermic needles, iontophoresis, electroporation, ultrasound or other forms of sonophoresis, jet injection, or a combination of any of the preceding methods (Prausnitz et al. 2004, Nature Reviews Drug Discovery 3: 115)). The agents can be administered locally, for example, at the site of injury to an injured blood vessel. The agents can be coated on a stent. The agents can be administered using high-velocity transdermal particle injection techniques using the hydrogel particle formulation described in U.S. 20020061336. Additional particle formulations are described in WO 00/45792, WO 00/53160, and WO 02/19989. An example of a transdermal formulation containing plaster and the absorption promoter dimethylisosorbide can be found in WO 89/04179. WO 96/11705 provides formulations suitable for transdermal administration. The agents can be administered in the form a suppository or by other vaginal or rectal means. The agents can be administered in a transmembrane formulation as described in WO 90/07923. The agents can be administered non-invasively via the dehydrated particles described in U.S. 6,485,706. The agent can be administered in an enteric-coated drug formulation as described in WO 02/49621. The agents can be administered intranasaly using the formulation described in U.S. 5,179,079. Formulations suitable for parenteral injection are described in WO 00/62759. The agents can be administered using the casein formulation described in U.S. 20030206939 and WO 00/06108. The agents can be administered using the particulate formulations described in U.S. 20020034536.
[0080] The agents, alone or in combination with other suitable components, can be administered by pulmonary route utilizing several techniques including but not limited to intratracheal instillation (delivery of solution into the lungs by syringe), intratracheal delivery of liposomes, insufflation (administration of powder formulation by syringe or any other similar device into the lungs) and aerosol inhalation. Aerosols (e.g., jet or ultrasonic nebulizers, metered-dose inhalers (MDIs), and dry-Powder inhalers (DPIs)) can also be used in intranasal applications. Aerosol formulations are stable dispersions or suspensions of solid material and liquid droplets in a gaseous medium and can be placed into pressurized acceptable propellants, such as hydrofluoroalkanes (HFAs, i.e. HFA-134a and HFA-227, or a mixture thereof), dichlorodifluoromethane (or other chlorofluorocarbon propellants such as a mixture of Propellants 11, 12, and/or 114), propane, nitrogen, and the like. Pulmonary formulations may include permeation enhancers such as fatty acids, and saccharides, chelating agents, enzyme inhibitors (e.g., protease inhibitors), adjuvants (e.g., glycocholate, surfactin, span 85, and nafamostat), preservatives (e.g., benzalkonium chloride or chlorobutanol), and ethanol (normally up to 5% but possibly up to 20%, by weight). Ethanol is commonly included in aerosol compositions as it can improve the function of the metering valve and in some cases also improve the stability of the dispersion. Pulmonary formulations may also include surfactants which include but are not limited to bile salts and those described in U.S. 6,524,557 and references therein. The surfactants described in U.S. 6,524,557, e.g., a C8-Ci6 fatty acid salt, a bile salt, a phospholipid, or alkyl saccharide are advantageous in that some of them also reportedly enhance absorption of the compound in the formulation. Also suitable in the invention are dry powder formulations comprising a therapeutically effective amount of active compound blended with an appropriate carrier and adapted for use in connection with a dry-Powder inhaler. Absorption enhancers which can be added to dry powder formulations of the present invention include those described in U.S. 6,632,456. WO 02/080884 describes new methods for the surface modification of powders. Aerosol formulations may include U.S. 5,230,884, U.S. 5,292,499, WO 017/8694, WO 01/78696, U.S. 2003019437, U. S. 20030165436, and WO 96/40089 (which includes vegetable oil). Sustained release formulations suitable for inhalation are described in U.S. 20010036481A1, 20030232019A1, and U.S. 20040018243A1 as well as in WO 01/13891, WO 02/067902, WO 03/072080, and WO 03/079885. Pulmonary formulations containing microparticles are described in WO 03/015750, U.S. 20030008013, and WO 00/00176. Pulmonary formulations containing stable glassy state powder are described in U.S. 20020141945 and U.S. 6,309,671. Other aerosol formulations are described in EP
1338272A1 WO 90/09781, U. S. 5,348,730, U.S. 6,436,367, WO 91/04011, and U.S. 6,294,153 and U.S. 6,290,987 describes a liposomal based formulation that can be administered via aerosol or other means. Powder formulations for inhalation are described in U.S. 20030053960 and WO 01/60341. The agents can be administered intranasally as described in U.S. 20010038824.
[0081] Solutions of medicament in buffered saline and similar vehicles are commonly employed to generate an aerosol in a nebulizer. Simple nebulizers operate on Bernoulli's principle and employ a stream of air or oxygen to generate the spray particles. More complex nebulizers employ ultrasound to create the spray particles. Both types are well known in the art and are described in standard textbooks of pharmacy such as Sprowls' American Pharmacy and Remington's The Science and Practice of Pharmacy. Other devices for generating aerosols employ compressed gases, usually hydrofluorocarbons and chlorofluorocarbons, which are mixed with the medicament and any necessary excipients in a pressurized container, these devices are likewise described in standard textbooks such as Sprowls and Remington.
[0082] The agent can be incorporated into a liposome to improve half-life. The agent can also be conjugated to polyethylene glycol (PEG) chains. Methods for pegylation and additional formulations containing PEG-conjugates (i.e. PEG-based hydrogels, PEG modified liposomes) can be found in Harris and Chess, Nature Reviews Drug Discovery 2:214-221 and the references therein. The agent can be administered via a nanocochleate or cochleate delivery vehicle (BioDelivery Sciences International). The agents can be delivered transmucosally (i.e. across a mucosal surface such as the vagina, eye or nose) using formulations such as that described in U.S. 5,204,108. The agents can be formulated in microcapsules as described in WO 88/01165. The agent can be administered intra-orally using the formulations described in U.S. 20020055496, WO 00/47203, and U.S. 6,495,120. The agent can be delivered using nanoemulsion formulations described in WO 01/91728A2.
[0083] In general, compounds of formula I or formula II may be prepared by the methods illustrated in the general reaction schemes as, for example, described below, or by modifications thereof, using readily available starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants that are in themselves known, but are not mentioned here.
[0084] Tables 1 and 2 above list compounds representative of embodiments of the invention. Processes for obtaining compounds of formula I or formula II are presented below. Other compounds of formula I or formula II may be prepared in analogous fashion to those whose synthesis is exemplified herein. The procedures below illustrate such methods. Furthermore, although the syntheses depicted herein may result in the preparation of enantiomers having a particular stereochemistry, included within the scope of the present invention are compounds of formula I and formula II in any stereoisomeric form, and preparation of compounds of formula I and formula II in stereoisomeric forms other than those depicted herein would be obvious to one of ordinary skill in the chemical arts based on the procedures presented herein.
[0085] General Synthetic Methods
3 3 RI R2
1 8 L 1 8ArZHeI
Cy2
General formula I => QJ Q2 QJ Q4 Q^ General formula Il => Qg
[0086] Scheme 1.
S2 S 4 S6
Compounds of the Formula Gl can be prepared by reaction of the 2-aminopryridies or 2- aminopyrazine with an α-haloketone (or α-halo aldehyde) to provide the imidazo[l,2- a]pyridine (X=CH or CF)/imidazo[l,2-a]pyrazine (X=N) (S4/S5). The substituent at C8 can be introduced either before formation of the bicyclic core (S2) by Suzuki/Stille reaction allowing C-C bond formatting chemistries. Alternatively, the intermediate S3 could be reacted by Buchwald or Cu mediated chemistries to for ether/amine linked C 8 substituent (S7). The substituent at the C-6 position can be introduced by a wide variety of approaches. When Y is an alkyl, ester, nitrile, following standard function group inter-conversion intermediates S6/S7 containing alcohol, alkyl halide (W) could be generated. The subsequent chemistries employed depends on the 1 -carbon functionality (Y = CH3, CHO, COOR', CN etc.) present as C6. For example, the function group alcohol may be coveted to a carbonate (W= CH-OCO2R'). The carbonate or -CH2-Br (W, S6/S7) upon reaction via organometallic coupling protocols (e.g. Suzuki, Stille reaction) allows C-C liked substituents or displacement of a halogen or tosylate (W) with a cyclic or heterocyclic -NH2, -OH, or -SH containing reagents allow formation of a C-N, C-O, or C-S bond linked substituent at C6. Alternatively, addition of a Grignard or organolithium reagent to Y=ester, allows formation of the ketone/secondary alcohol linked substituents (M = CO, C(OH)H or C(OH)R). S6/S7 intermediates (W= CH2Br or CH20H) could be derivatized to produce ether / amine linked C6 substituents. The alcohol can be converted to a primary or secondary amine. The W as acid or amine thus allows formation of amide, reverse amide, sulfonamide from acylation /sulfonation chemistries or diverse amine via reductive amine chemistry approaches. The substituents containing additional functions groups allow subsequent elaboration by standard chemistries outlines above depending upon the functional groups introduced at C6. These
strategies allow incorporation of acyclic, heterocyclic or heteroaryl derived substituents at the C6 / C8 position of the imidazo[l,2-a]pyridine/ imidazo[l,2-a]pyrazine core.
[0087] Scheme 2.
Formation of the [l,2,4]triazolo[l,5-a]pyridine (SlO, X=CH,CF)/ [l,2,4]triazolo[l,5- ajpyrazine (SlO, X=N) can be obtained from the 2-aminopryridies (S8, X=CH, CF) or 2- aminopyrazine (S8, X=N) starting material via reaction with dimethylformamide dimethyl acetal (R2= H) or dimethyl acetamide dimethyl acetal (R2= CH3) to provide intermediate S9, which following the ring closing reaction with dehydrating reagents (such as: TFAA, PPA, Ts-Cl or Ms-Cl) can provide the key triazolo-pyridine/pyrazine cores (SlO). Subsequent elaboration at C6/C8, analogous to approaches described above for Gl would provide analogs represented by G2.
[0088] Scheme 3.
V KJ H2N V H*C00CH3 <VY H2SO4 <YY
SH S15
Formation of pyrozolo[l,5-a]pyridine (S14) can be obtained from 2,4-substituted pyridine (S12) via S13. N-amination of 2,4-disubstituted pyridine (S12) by O-2-mesitylenesulfonyl hydroxyamine provides intermediate (S13). Subsequent 1,3-dipolar cycloaddition with methyl propiolate furnish the pyrozolo[l,5-a]pyridine (S 14), which can subsequently be transformed into the decarboxylated product (S 15) under acidic conditions. The 3 -ester in pyrozolo[l,5-a]pyridine (S 14) could also be converted to other group (S 16) by standard functional group transformations. Subsequent elaboration at C6/C8 in pyrozolo[l,5-
a]pyridine (S 15 or S 16), analogous to approaches described above for Gl would provide analogs represented by G3.
S17 S18 S19 S20 S21
G4 a
R3
\ R3
R3 R3
R2 — ( ~^ » ^/^^CH2Ra
" R2- N NH -*" R2-
N N H R2^ I I K^^N NH O N NH NH2
S26 G4 b
Formation of the key intermediate pyrazolo[l,5-a]pyrimidine (S21) can be obtained from the pyrazole starting material (S 18). Reaction of pyrazole (S 18) with methyl chloroformate and subsequent bromination with NBS give intermediate bromomethyl pyrazole (S20). Nucleophilic substitution of tosylmethyl isocyanide (TosMIC) on the bromomethyl pyrazole (S20) followed by intramolecular transfer of the methoxycarbonyl group followed by cyclization and 1 ,2-elimination of p-toluenesulfinic acid to afford the pyrazolo[l,5-a] pyrimidine intermediate (S21) analogous to Mendiola, J. et.al. JOC 2004, 69, 4974-83. The substitution at C-6 position can be obtained via the ester group at C-6 position by similar approaches described above for Gl analogs. The introduction of the substitutions at C-8 position to form a C-C bond can be accomplished by metal assisted cross coupling reactions.
The key intermediate pyrazolo[l,5-a]pyrimidine (S26) can be also obtained from S25. The intermediate S25 in turn can be obtained from S18 via bromination and subsequent conversion to the ketone S24. Reaction of S25 with an orthoformate would then provide S26. When Ra =h (for S26) elaboration to final product can be achieved as described above. Alternatively, the final substituent can be introduced as part of formation of S24; in such case cyclization of S25 to S26 directly would yield the desired analogs.
[0090] Scheme 5.
S30 G5 (Z = bone ieteroatom
Formation of the key intermediate pyrazolo[l,5-a]pyrimidine (S28) can be obtained via cyclization reaction of the pyrazole starting material (S27) with acetoacetic acid ethyl ester (or β-keto esters). A large number of starting materials of the general structure S27 are commercial available or can be prepared by published procedures. The -OH group in S28 can convert to chloride or bromide (S29) which can form C-C link substitutions in S30 via organometallic coupling protocols (e.g. Suzuki, Stille reaction). The introduction of C-6 substitution in G5 can be obtained via the methyl (R' =H) at C-6 position by similar approaches described above for Gl analogs.
[0091] Scheme 6.
Compounds of the Formula G6-a, can be obtained from the intermediate 5H-pyrazolo[l,5- d][l,2,4]triazin-4-one (S26). By coupling of 2-ester pyrazole (S24) with hydrazine give an intermediate S25, which can be subsequently cyclized to key intermediate S26. Pyrazole starting material, S24, with varying R2/R3 groups are either commercial available or can be prepared by literature procedures. The introduction of substitutions at N-5 position (G6-a) can be obtained via N-alkylation with Ari/Heti-CH2-halide (-Br or Cl).
[0092] Alternatively, compounds of the formula G6-b, can be prepared from the intermediate 2,3-disubstituted-5,6-dihydro-pyrazolo[l,5-d][l,2,4]triazine-4,7-dione (S27). Cyclization of S25 with coupling reagents (such as CDI, triphosgene etc) afford S27, which can subsequently N-alkylation with Hetl/Arl/Rl-halide at N-5 position to provide (S28). The substitutions at C-7 position in compounds G6-b can be obtained by displacement of halogen (Cl or F) of S29 with hydroxyl, amine or thiol containing heterocyclic/aryls.
Examples
[0093] Example 1. D-Ol
[0094] Stepl. 6-Amino-5-(3-chloro-phenyl)-nicotinic acid methyl ester (2). To a 100 ml INRBF were added methyl 6-amino-5-bromonicotinate (Ig, 4.33 mmole), 40 ml toluene, 10 ml ethanol, 20 ml water, 1.37g, 13 mmole sodium carbonate and 3-chlorophenyl boronic acid (740mg, 4.73 mmole). The solution was degassed for 10 min. under argon, then the palladium tetrakis (500mg, 10%) was added. Reaction mixture was heated at 1000C for 6 hours. TLC (20%EA/hexane) shows no SM. The reaction mixture was concentrated down to half, diluted with 20 ml water and extracted 3x 80 ml ethylacetate. Combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to give about 1.5 g crude. Trituration with 5% methanol in ether gave 700 mg solid (2). Mother liquor was concentrated to a solid and trituration was repeated to get a second crop of 230 mg (2). IH- NMR confirmed the structure.
[0095] Step 2. 8-(3-Chloro-phenyl)-imidazo[l,2-a]pyridine-6-carboxylic acid methyl ester (3). A 50 ml INRB flask equipped with condenser and Dean Stark trap was loaded with 6- Amino-5-(3-chloro-phenyl)-nicotinic acid methyl ester (680 mg, 2.6 mmole) 20 ml, toluene and 1.2 g chloroacetaldehyde (50% solution in water). The mixture was heated to reflux and water was colected in the trap. After 4 hrs, TLC (EA/ hexane= 1;1) shows a new spot, Rf closer to starting material. Mixture was concentrated down, diluted with 10 ml water, neutralized to pH= 7 using saturated aq. Solution of NaHCO3 and extracted 3X 50 ml methylene chloride. Combined organic layers were washed with brine, dried over Na2SO4,
filtered and concentrated to afford 500 mg product as brown solid (3), pure by IH-NMR. This material was used for the next step.
[0096] Step 3. [8-(3-Chloro-phenyl)-imidazo[l,2-a]pyridin-6-yl]-methanol (4). To a solution of 8-(3-Chloro-phenyl)-imidazo[l,2-a]pyridine-6-carboxylic acid methyl ester 3 (200 mg, 0.698 mmole) in 10 ml anhydrous THF was added at 00C LiBH4 (2M in THF, 2 ml). Reaction mixture was stirred at RT for 3 days. Mixture was quenched with saturated solution of NH4C1, then extracted several times with ethylacetate. Combined organic layers were washed with water, brine, dried over Na2SO4, filtered, concentrated to afford 230 mg crude. This was purified by a preparative silicagel plate (1.5 mm) using 5%MeOH/ CH2C12 to afford 150 mg product (4), pure by IH-NMR.
[0097] Step 4. Carbonic acid 8-(3-chloro-phenyl)-imidazo[l,2-a]pyridin-6-ylmethyl ester (5). To a solution of [8-(3-Chloro-phenyl)-imidazo[l,2-a]pyridin-6-yl]-methanol (4) (100 mg, 0.387 mmole) in 2 ml anhydrous THF was added pyridine (80 ul, 0.96 mmole). The mixture was cooled to 00C and methylchloro formate was added slowly (65uL, 0.81 mmole). Reaction mixture was stirred at room temperature for 3 days. Water was added and the aqueous portion was extracted with ethyl acetate(2 x 10 ml), the organic portions were combined, washed with brine, dried over Na2SO4 and concentrated. The crude material was purified by silicagel preparative TLC plate 50%ethylacetate/ hexane as the eluent to give 80 mg of product (5) in 65 % yield.
[0098] Step 5. 4-[8-(3-Chloro-phenyl)-imidazo[l,2-a]pyridin-6-ylmethyl]-phenylamine (D- 01). A reaction mixture of compound 5 (80 mg, 0.25 mmol), 2-aminopyridine-5-boronic acid pinacol ester 5 (62 mg, 0.27 mmol), l,5-bis(diphenylphosphino) pentane (33 mg, 0.075 mmole), allylpalladium chloride dimer (14 mg, 0.0375 mmol), K2CO3 (104 mg, 0.75 mmole) in DMF (2 ml)) was stirred at 85 0C for 8 hours and then cooled to room temperature. Water was added and the aqueous portion was extracted with ethyl acetate(2 x 10 ml), the organic portions were combined, washed with brine, dried over Na2SO4 and concentrated. The crude material was purified by silicagel preparative TLC plate 60%ethylacetate/ hexane as the eluent to give 22 mg of product D-Ol in 28 % yield.
[0099] IH-NMR, MS, LCMS.
[00100] Example 2. D-02
[00101] Synthesis of 8-(3-Chloro-phenyl)-2-methyl-imidazo[l,2-a]pyridine-6- carboxylic acid methyl ester and 8-(3-Chloro-phenyl)-2-methyl-imidazo[l,2-a]pyridine-6- carboxylic acid ethyl ester (6 and 7): In a microwave vial, was place 2 (990 mg, 3.76 mmole), chloroacetone (1.74 g, 19 mmole) and ethanol (15 ml). The reaction mixture was stirred at 160 oC for 3 hrs on a microwave synthesizer and then cooled to room temperature. After removal of solvent under vacuum, the residue was dissolved in water and the pH was adjusted to 8-9 by addition of NaHCO3 aq. The aqueous portion was extracted with ethyl acetate (3 x 50 ml), the organic portions were combined, washed with sat. NaHCO3 aq., brine, dried over Na2SO4 and concentrated. The crude material was purified by column chromatography utilizing EtOAc/hexanes as the eluent to give 1.18 g of a mixture of 6 and 7 (-1.8: 1.5) in 53% yield. 1H-NMR (400 MHz, CDCl3).
[00102] Synthesis of [8-(3-Chloro-phenyl)-2-methyl-imidazo[l,2-a]pyridin-6-yl]- methanol (8): To a mixture of compound 6 and 7 (-1.8: 1.5) (1.18 g, 2.2 mmol) in THF (anhydrous, 60 ml), was added DIBAL-H (IM in hexane, 24 ml) dropwise at -78 oC under N2. The reaction mixture was stirred at -78 oC to r.t. and r.t. for 3 hrs. The reaction mixture was diluted with ice/water, adjusted pH to acidic and then stirred at r.t for about 20 min. After pH adjusted to 8-9 by addition of NaOH aq (6N), the aqueous portion was extracted with ethyl acetate (3x 100 ml). Organic layer was washed with sat. NaHCO3 aq., brine, and dried over Na2SO4. After removal of solvent, the solid was washed with ether to give 800 mg of product 8 in 75 % yield. 1H-NMR (400 MHz, DMSO-d6)
[00103] Synthesis of 6-Bromomethyl-8-(3-chloro-phenyl)-2-methyl-imidazo[l,2- a]pyridine (9): To a mixture of compound 8 (27 mg, 0.1 mmol) in DCM (2 ml) was added PBr3 (14 mg, 0.05 mmole) at -10 oC under N2. The reaction mixture was stirred at -10 oC to r.t. and r.t for 1 hr. The reaction mixture was diluted with DCM (4 ml) and washed with diluted NaHCO3 aq., water, brine, and dried over Na2SO4. After removal of solvent, crude product 9 obtained. Crude 9 directly used in next step without further purification.
[00104] Synthesis of {4-[8-(3-Chloro-phenyl)-2-methyl-imidazo[l,2-a]pyridin-6- ylmethyl] -phenyl} -urea (D-02): A reaction mixture of compound 9 (~0.1 mmol), A- ureidophenylboronic acid pinacol ester (26 mg, 0.1 mmol), tetrakis(triphenylphosphine)palladium (23 mg, 0.02 mmol), K3PO4 (42 mg, 0.2 mmole) in DME (4 ml), ethanol (1 ml) and water (1 ml) was stirred at 65 0C for 2 hours and then cooled to room temperature. Water (5 ml) was added and the aqueous portion was extracted with ethyl acetate(2 x 10 mL), the organic portions were combined, washed with brine, dried over Na2SO4 and concentrated. The crude material was purified by column chromatography utilizing MeOH/DCM as the eluent to give 4 mg of D-02 in 10% yield for two step. 1H-NMR (400 MHz, Acetone-d6): 2.37 (3H, s), 3.97 (2H, s), 5.35 (2H, br), 7.20 (2H, d, J=8 Hz), 7.36 - 7.48 (5H, m), 7.64 (IH, m), 7.97 (IH, br), 8.07 (IH, m), 8.23 (IH, m), 8.33 (IH, m). MS(ESI+): 391.5 (M+l). LC-MS: 90 %.
[00105] Example 3. D-03
10 D-03
[00106] Synthesis of 4-[8-(3-Chloro-phenyl)-6-methoxycarbonyloxymethyl-2-methyl- imidazo[l,2-a]pyridin-3-yl]-4H-pyridine-l-carboxylic acid methyl ester (10): To a mixture of compound 8 (480 mg, 1.76 mmol) and pyridine (362 mg, 4.6 mmole) in THF (15 ml), was added methyl chloroformate (376 mg, 3.96 mmole) dropwise at -10 oC under N2. The reaction mixture was stirred at r.t over night. The reaction mixture was diluted with water, pH adjusted to 8-9 by addition of NaHCO3 aq and then extracted with ethyl acetate (2x 5 ml).
The organic portions were combined, washed with brine, dried over Na2SO4 and concentrated. The crude material was purified by column chromatography utilizing ethyl acetate/hexane as the eluent to give 520 mg of 10 in 63% yield. 1H-NMR (400 MHz, CDCl3)
[00107] Synthesis of {(Z)-3-[6-(6-Amino-pyridin-3-ylmethyl)-8-(3-chloro-phenyl)-2- methyl-imidazo[l,2-a]pyridin-3-yl]-but-l-enyl}-vinyl-carbamic acid methyl ester (D-03): A reaction mixture of compound 10 (100 mg, 0.3 mmol), 2-aminopyridine-5-boronic acid pinacol ester (73 mg, 0.33 mmol), l,5-bis(diphenylphosphino) pentane (44 mg, 0.1 mmole), allylpalladium chloride dimer (14 mg, 0.045 mmol), K2CO3 (124 mg, 0.9 mmole) in DMF (2 ml)) was stirred at 90 0C for 2 hours and then cooled to room temperature. Water was added and the aqueous portion was extracted with ethyl acetate(3 x 10 ml), the organic portions were combined, washed with brine, dried over Na2SO4 and concentrated. The crude material was purified by column chromatography utilizing MeOH/DCM as the eluent to give 20 mg of D-03 in 14 % yield. 1H-NMR (400 MHz, DMSO-d6): 2.32 (3H, s), 3.76 (2H, s), 3.84 (3H, s), 4.90 (3H, br), 5.72 (2H, s), 6.36 (IH, d, J = 8 Hz), 6.94 (2H, br), 7.27 (IH, dd, J = 8 and 2.4 Hz), 7.36 (IH, d, J=I.6 Hz), 7.45 (IH, m), 7.50 (IH, dd, J = 8 and 8 Hz), 7.86 (IH, d, J=2.4 Hz), 7.99 (IH, m), 8.18 (IH, m), 8.21 (IH, s). MS(ESI+): 486.6 (M+ 1). LC-MS: 99 %.
[00108] Example 4. D-04.
5 D-04
[00109] Synthesis of S-CS-Chloro-pheny^-ό-Cό-fluoro-pyridin-S-ylmethyl)- imidazo[l,2-a]pyridine (D-04): A suspension of 5 (80 mg, 0.253 mmol), 2-fluoro-5- pyridine boronic acid (35.7 mg, 0.253 mmol), and solid potassium carbonate (104 mg, 0.759 mmol) was degassed with a nitrogen stream for 20 min. To the suspension was added palladium allyl chloride dimer (13.9 mg, 0.0380 mmol) and bis(diphenylphosphino)pentane (33.4 mg, 0.0759 mmol) and the reaction was stirred at 100 0C under nitrogen overnight. The reaction was diluted with ethyl acetate (10 mL), washed with saturated ammonium chloride (10 mL), the aqueous wash back extracted with ethyl acetate (2 x 10 mL), and the organic extracts were combined. The organic solution was washed with brine (15 mL) and the solvent
removed under vacuum. The crude material was purified by silica gel thin layer preparatory chromatography eluting with 7.5 % acetone in dichloromethanes to give D-04 PR231 (15.1 mg, 18% yield) as a yellow gum. IH NMR (400 MHz CDC13) d: 8.163 (d, J = 2.40 Hz, IH), 7.934-7.865 (m, 3H), 7.689-7.610 (m, 3H), 7.429-7.357 (m, 2H), 7.066 (d, J = 1.60 Hz, IH), 6.166 (dd, J = 608.40 Hz, 602.80 Hz, IH), 4.008 (s, 3H). LCMS = 96.7%. MS(APCI+) = 338.1 (M+l).
[00110] Example 5. D-05
12 13
[00111] Synthesis of 8-(3-Chloro-phenyl)-2,3-dimethyl-imidazo[l,2-a]pyridine-6- carboxylic acid methyl ester and 8-(3-Chloro-phenyl)-2,3-dimethyl-imidazo[l,2- a]pyridine-6-carboxylic acid ethyl ester (11 and 12): In a microwave vial, was place 2 (1052 mg, 4 mmole), 3-bromo-2-butanone (2820 mg, 18.6 mmole) and ethanol (15 ml). The reaction mixture was stirred at 160 oC for 2 hrs on a microwave synthesizer and then cooled to room temperature. After removal of solvent under vacuum, the residue was dissolved in water and the pH was adjusted to 8-9 by addition of NaHCO3 aq. The aqueous portion was extracted with ethyl acetate (3 x 50 mL), the organic portions were combined, washed with sat. NaHCO3 aq., brine, dried over Na2SO4 and concentrated. The crude material was purified by column chromatography utilizing EtOAc/hexanes as the eluent to gave 600 mg of a mixture of 11 and 12 (-1:6) in 46% yield. 1H-NMR (400 MHz, CDCl3)
[00112] Synthesis of [8-(3-Chloro-phenyl)-2,3-dimethyl-imidazo[l,2-a]pyridin-6- yl]-methanol (13): To a mixture of compound 11 and 12 (~6: 1) (600 mg, 1.8 mmol) in
THF (anhydrous, 30 ml), was added DIBAL-H (IM in Toluene, 12 ml) dropwise at -78 oC under N2. The reaction mixture was stirred at -78 oC to r.t. and r.t over night. The reaction mixture was diluted with ice/water, adjusted pH to acidic and then stirred at r.t for about 20 min. After pH adjusted to 8-9 by addition of NaOH aq (6N), the aqueous portion was extracted with ethyl acetate (3x100 ml). Organic layer was washed with sat. NaHCO3 aq., brine, and dried over Na2SO4. After removal of solvent, the solid was washed with ether to give 428 mg of product 13. Yield: 82 %. 1H-NMR (400 MHz, DMOS-d6)
[00113] Synthesis of 6-Bromomethyl-8-(3-chloro-phenyl)-2,3-dimethyl- imidazo[l,2-a]pyridine (14): To a mixture of compound 13 (57 mg, 0.2 mmol) in DCM (4 ml) and DMF (0.2 ml), was added PBr3 (57 mg, 0.2 mmole) at -10 oC under N2. The reaction mixture was stirred at -10 oC to r.t. and r.t for 1 hr. The reaction mixture was diluted with DCM (4 ml) and washed with diluted NaHCO3 aq., water, brine, and dried over Na2SO4. After removal of solvent, 60 mg of crude product 14 obtained. Crude 14 directly used in next step without further purification.
[00114] Synthesis of {4-[8-(3-Chloro-phenyl)-2,3-dimethyl-imidazo[l,2-a]pyridin-
6-ylmethyl]-phenyl}-urea (D-05): A reaction mixture of compound 14 (60 mg crude, 0.2 mmol), 4-ureidophenylboronic acid pinacol ester (52 mg, 0.2 mmol), tetrakis(triphenylphosphine)palladium (46 mg, 0.04 mmol), K3PO4 (84 mg, 0.4 mmole) in DME (6 mL), ethanol (1.5 mL) and water (1.5 ml) was stirred at 65 0C for 2 hours and then cooled to room temperature. Water (10 mL) was added and the aqueous portion was extracted with ethyl acetate(2 x 15 mL), the organic portions were combined, washed with brine (75 mL), dried over Na2SO4 and concentrated. The crude material was purified by column chromatography utilizing MeOH/DCM as the eluent to gave 6 mg of D-05 as a solid in 7% yield for two step. 1H-NMR (400 MHz, Acetone-d6): 2.36 (3H, s), 2.45 (3H, s), 4.01 (2H, s), 5.35 (2H, br), 7.21 (2H, d, J= 8 Hz), 7.34 (IH, d, J = 2 Hz), 7.38 (IH, m), 7.42 (2H, d, J = 8 Hz), 7.45 (IH, dd, J = 8 and 8 Hz), 7.95 (IH, br), 8.04 (IH, m), 8.06 (IH, m), 8.34 (IH, m). MS(APCI+): 405.1 (M+ 1). LC-MS: 99 %.
13
14 D-06
[00116] Synthesis of 6-Bromomethyl-8-(3-chloro-phenyl)-2,3-dimethyl- imidazo[l,2-a]pyridine (14): To a mixture of compound 13 (57 mg, 0.2 mmol) in DCM (4 ml) and DMF (0.2 ml), was added PBr3 (57 mg, 0.2 mmole) at -10 oC under N2. The reaction mixture was stirred at - 10 oC to r.t. and r.t for 1 hr. The reaction mixture was diluted with DCM (4 ml) and washed with diluted NaHCCβ aq., water, brine, and dried over Na2SO4. After removal of solvent, crude product 14 obtained. Crude 14 directly used in next step without further purification.
[00117] Synthesis of l-[8-(3-Chloro-phenyl)-2,3-dimethyl-imidazo[l,2-a]pyridin-6- ylmethyl]-pyrrolidin-2-one (D-06): To a mixture of NaH (60 % in oil, 16 mg, 0.4 mmole) in DMF (2 ml), was added 2-pyrrolidone (34 mg, 0.4 mmole) at -10 oC. After reaction mixture stirring at r.t. for 10 min, compound 14 (crude, 0.2 mmol) dissolved in DMF (3 ml) was added at -10 oC under N2. The reaction mixture was stirred at -10 oC to r.t. and r.t over night. After removal of solvent under vacuum, the reaction mixture was diluted with water and extracted with ethyl acetate (3 x 10 ml), the organic portions were combined, washed with brine (75 mL), dried over Na2SO4 and concentrated. The crude material was purified by column chromatography utilizing ethyl acetate/hexane as the eluent gave 50 mg of D-06 as an oil in 70% yield for two step. To a solution of D-06 (50 mg) in DCM (4 ml), was added HCl in Et2O (2N, 0.2 ml), after removal of solvent, solid was washed with ether to give 37 mg of D-06 HCl salt as solid. 1H-NMR (400 MHz, CD3OD): 2.07 (2H, m), 2.45 (2H, t, J=8 Hz), 2.50 (3H, s), 2.60 (3H, s), 3.48 (2H, m), 4.67 (2H, s), 7.58 - 7.64 (3H, m), 7.74 (IH, m), 7.78 (IH, m), 8.58 (IH, m). MS(APCI+): 354 (M+ 1). LC-MS: 98 %.
[00118] Example 7. D-07
[00119] Synthesis of Carbonic acid 8-(3-chloro-phenyl)-2,3-dimethyl-imidazo[l,2- a]pyridin-6-ylmethyl ester methyl ester (15): To a mixture of compound 13 (57 mg, 0.2 mmol) and pyridine (79 mg, 1 mmole) in THF (2 ml), was added methyl chloroformate (76 mg, 0.8 mmole) dropwise at r.t. under N2. The reaction mixture was stirred at r.t over night. The reaction mixture was diluted with water, pH adjusted to 8-9 by addition of NaHCO3 aq and then extracted with ethyl acetate (2x 5 ml). The organic portions were combined, washed with brine, dried over Na2SO4. After removal of solvent, 60 mg of crude product 15 obtained. Crude 15 directly used in next step without further purification.
[00120] Synthesis of 5-[8-(3-Chloro-phenyl)-2,3-dimethyl-imidazo[l,2-a]pyridin-6- ylmethyl]-pyridin-2-ylamine (D-07): A reaction mixture of compound 15 (crude, 0.15 mmol), 2-aminopyridine-5-boronic acid pinacol ester (33 mg, 0.15 mmol), 1,5- bis(diphenylphosphino) pentane (20 mg, 0.045 mmole), allylpalladium chloride dimer (7 mg, 0.023 mmol), K2CO3 (62 mg, 0.45 mmole) in DMF (1 ml)) was stirred at 90 0C for 2 hours and then cooled to room temperature. Water was added and the aqueous portion was extracted with ethyl acetate(3 x 15 ml), the organic portions were combined, washed with brine, dried over Na2SO4 and concentrated. The crude material was purified by column chromatography utilizing MeOH/DCM as the eluent to give 18 mg of D-07 in 33 % yield for two step. 1H-NMR (400 MHz, Acetone-d6): 2.36 (3H, s), 2.45 (3H, s), 3.92 (2H, s), 5.22 (2H, br), 6.48 (IH, d, J = 8), 7.34 - 7.42 (3H, m), 7.46, (IH, dd, J = 8 and 8 Hz), 7.99, IH, d, J = 1.6 Hz), 8.05 (IH, s), 8.08 (IH, m), 8.35 (IH, m). MS(APCI+): 363.1 (M+l). LC-MS: 99 %.
[00121] Example 8. D-08
[00122] Synthesis of S-CS-Chloro-pheny^-ό-Cό-fluoro-pyridin-S-ylmethyl)^^- dimethyl-imidazo[l,2-a]pyridine (D-08): A reaction mixture of compound 15 (crude, 0.15 mmol), 2-fluoro-5-pyridine-boronic acid (21 mg, 0.15 mmol), l,5-bis(diphenylphosphino) pentane (20 mg, 0.045 mmole), allylpalladium chloride dimer (7 mg, 0.023 mmol), K2CO3 (62 mg, 0.45 mmole) in DMF (1 ml)) was stirred at 90 0C for 2 hours and then cooled to room temperature. Water was added and the aqueous portion was extracted with ethyl acetate(4 x 10 ml), the organic portions were combined, washed with brine, dried over Na2SO4 and concentrated. The crude material was purified by column chromatography utilizing ethyl acetate/hexane as the eluent to give 28 mg of D-08 in 51 % yield. To a solution of D-08 (28 mg) in Et20 (4 ml), was added HCl in Et20 (2N, 0.1 ml), solid was washed with ether to give 26 mg of D-08 HCl salt as solid. 1H-NMR (400 MHz, DMSO- d6): 2.44 (3H, s), 2.55 (3H, s), 4.19 (2H, s), 7.15 (IH, dd, J = 8 and 3Hz), 7.60 - 7.68 (3H, m), 7.76 (IH, m), 7.92 (IH, m), 8.01 (IH, m), 8.31 (IH, m), 8.79 (IH, s). MS(APCI+): 366.1 (M+l). LC-MS: 98 %.
[00123] Example 9. D-09
[00124] Synthesis of 4-[8-(3-Chloro-phenyl)-2,3-dimethyl-imidazo[l,2-a]pyridin-6- ylmethylj-phenylamine (D-09): A reaction mixture of compound 15 (crude, 0.15 mmol), A- aminophenyl boronic acid pinacol ester (33 mg, 0.15 mmol), l,5-bis(diphenylphosphino)
pentane (20 mg, 0.045 mmole), allylpalladium chloride dimer (7 mg, 0.023 mmol), K2CO3 (62 mg, 0.45 mmole) in DMF (1 ml)) was stirred at 90 0C for 2 hours and then cooled to room temperature. Water was added and the aqueous portion was extracted with ethyl acetate(4 x 10 ml), the organic portions were combined, washed with brine, dried over Na2SO4 and concentrated. The crude material was purified by column chromatography utilizing ethyl acetate/hexane as the eluent to give D-09. To a solution of D-09 in DCM (3 ml), was added HCl in Et20 (2N, 0.1 ml), solid was washed with ether to give 19 mg of D-09 HCl salt as solid. 1H-NMR (400 MHz, DMSO- d6): 2.44 (3H, s), 2.55 (3H, s), 4.13 (2H, s), 7.11 (2H, m), 7.40 (2H, m), 7.60 - 7.68 (3H, m), 7.74 (IH, m), 7.83 (IH, m), 8.75 (IH, m). MS(APCI+): 362.1 (M+l). LC-MS: 96 %.
[00125] Example 10. D-10
D-07 D-10
[00126] Synthesis of l-{5-[8-(3-Chloro-phenyl)-2,3-dimethyl-imidazo[l,2- a]pyridin-6-ylmethyl]-pyridin-2-yl}-3-ethyl-urea (D-10): To a mixture of compound D-07 (7 mg, 0.02 mmol) in pyridine (1 ml), was added ethyl isocyanate (20 mg, 0.25 mmole). The reaction mixture was stirred at r.t. for 5 days and concentrated. The crude material was purified by column chromatography utilizing MeOH/DCM as the eluent to give 6 mg of D-10 in 69 % yield. 1H-NMR (400 MHz, CD3OD): 1.18 (3H, t, J= 7.2 Hz), 2.51 (3H, s), 2.61 (3H, s), 3.20 (2H, q, J =7.2 Hz), 4.30 (2H, s), 7.28 (IH, d, J= 8Hz), 7.60 (3H, m), 7.71 (IH, m), 7.80 (IH, m), 8.22 (IH, m), 8.25 (IH, m), 8.66 (IH, s). MS(APCI+): 434.1 (M+l). LC-MS: 97 %.
[00127] Example 11. D-Il
[00128] Synthesis of Carbonic acid 8-(3-chloro-phenyl)-2-methyl-imidazo[l,2- a]pyridin-6-ylmethyl ester methyl ester (16): To a mixture of compound 8 (136 mg, 0.5 mmol) in THF (10 ml), was added NaH (60 % in oil, 50 mg, 1.25 mmole) at -10 oC and stirred at r.t. for 20 min. Methyl chloro formate (105 mg, 1.1 mmole) was added dropwise at - 20 oC under N2. The reaction mixture was stirred at r.t over night. The reaction mixture was diluted with water and extracted with ethyl acetate (2x 20 ml). The organic portions were combined, washed with brine, dried over Na2SO4. After removal of solvent, 180 mg of crude product 16 obtained. Crude 16 directly used in next step without further purification. 1H-NMR (400 MHz, CDC13)
[00129] Synthesis of 4-[8-(3-Chloro-phenyl)-2-methyl-imidazo[l,2-a]pyridin-6- ylmethylj-phenylamine (D-Il): A reaction mixture of compound 16 (70 mg crude, 0.25 mmol), 4-aminophenyl boronic acid pinacol ester (55 mg, 0.25 mmol), 1,5- bis(diphenylphosphino) pentane (33 mg, 0.075 mmole), allylpalladium chloride dimer (14 mg, 0.038 mmol), K2CO3 (104 mg, 0.75 mmole) in DMF (2 ml)) was stirred at 90 0C for 2 hours and then cooled to room temperature. Water was added and the aqueous portion was extracted with ethyl acetate(4 x 10 ml), the organic portions were combined, washed with brine, dried over Na2SO4 and concentrated. The crude material was purified by column chromatography utilizing ethyl acetate/hexane as the eluent to give 11 mg of D-Il in 13 % yield for two steps. To a solution of D-Il (11 mg) in ether (3 ml), was added HCl in Et2O (2N, 0.1 ml), solid was washed with ether to give 11 mg of D-Il HCl salt as solid. 1H-NMR (400 MHz, DMSO-d6): 2.45 (3H, s), 4.11 (2H, s), 6.85 (IH, m), 7.18 (3H, m), 7.38 (2H, d, J = 8Hz), 7.64 (3H, m), 7.78 (IH, s), 7.86 (IH, s), 8.14 (IH, s), 8.77 (IH, s), 9.70-10.0 (2H, br). MS(APCI+): 348.1 (M+l) LC-MS: 95 %.
[00130] Example 12. D- 12
[00131] Example 13. D-13
[00132] Synthesis of 5-[8-(3-Chloro-phenyl)-2-methyl-imidazo[l,2-a]pyridin-6- ylmethyl]-pyridin-2-ylamine (D-12): A reaction mixture of compound 16 (70 mg crude, 0.25 mmol), 2-aminopyridine-5-boronic acid pinacol este (55 mg, 0.25 mmol), 1,5- bis(diphenylphosphino) pentane (33 mg, 0.075 mmole), allylpalladium chloride dimer (14 mg, 0.038 mmol), K2CO3 (104 mg, 0.75 mmole) in DMF (2 ml)) was stirred at 90 0C for 2 hours and then cooled to room temperature. Water was added and the aqueous portion was extracted with ethyl acetate(4 x 10 ml), the organic portions were combined, washed with brine, dried over Na2SO4 and concentrated. The crude material was purified by column chromatography utilizing MeOH/DCM as the eluent to give 35 mg of D-12 in 40 % yield for two step. To a solution of D-12 (35 mg) in DCM (3 ml), was added HCl in Et20 (2N, 0.1 ml), solid was washed with ether to give 35 mg of D-12 HCl salt as solid. 1H-NMR (400 MHz, DMSO-d6): 2.46 (3H, s), 4.02 (2H, s), 6.98 (IH, d, J=8 Hz), 7.60 - 7.70 (3H, m), 7.82 (IH, br), 7.87 (IH, br), 7.90 (IH, m), 7.96 (IH, m), 8.04 (IH, br), 8.11 (IH, br), 8.75 (IH, br). MS(APCI+): 349.1 (M+ 1). LC-MS: 99 %.
[00133] Synthesis of l-{5-[8-(3-Chloro-phenyl)-2-methyl-imidazo[l,2-a]pyridin-6- ylmethyl]-pyridin-2-yl}-3-ethyl-urea (D-13): To a mixture of compound D-12 (30 mg, 0.08 mmol) in pyridine (1 ml), was added ethyl isocyanate (57 mg, 0.8 mmole). The reaction mixture was stirred at r.t. for 5 days and concentrated. The crude material was purified by column chromatography utilizing MeOH/DCM as the eluent to give 25 mg of D-13 in 75 % yield. To a solution of D-13 (25 mg) in DCM (3 ml), was added HCl in Et20 (2N, 0.1 ml), solid was washed with ether to give 25 mg of D-13 HCl salt as solid. 1H-NMR (400 MHz, DMSO-d6): 1.09 (3H, m), 2.46 (3H, s), 3.18 (2H, m), 4.10 (2H, s), 7.37 (IH, d, J= 8 Hz),
7.65 (3H, m), 7.78 (IH, br), 7.80 - 7.88 (2H, br), 7.90 (IH, m), 8.14 (IH, m), 8.23 (IH, m), 8.77 (IH, s), 9.8 - 10.4 (IH, br). MS(APCI+): 420.1 (M+l). LC-MS: 99 %.
[00134] Example 14. D- 14
[00135] Example 15. D- 15
2-bromopropanal (17) was prepared according to reference (Aleem Gangjee, et al. J. Medi. Chem. 2005, 48, 7215-7222).
[00136] Synthesis of 8-(3-Chloro-phenyl)-3-methyl-imidazo[l,2-a]pyridine-6- carboxylic acid methyl ester and 8-(3-Chloro-phenyl)-3-methyl-imidazo[l,2-a]pyridine- 6-carboxylic acid ethyl ester (18 and 19): In a microwave vial, was place 2 (570 mg, 2.1 mmole), 2-bromopropanal (17) (1.3 g, 10 mmole) and ethanol (10 ml). The reaction mixture was stirred at 150 oC for 2 hrs on a microwave synthesizer and then cooled to room temperature. After removal of solvent under vacuum, the residue was dissolved in water and the pH was adjusted to 8-9 by addition of NaHCO3 aq. The aqueous portion was extracted with ethyl acetate (3 x 30 ml), the organic portions were combined, washed with sat. NaHCO3 aq., brine, dried over Na2SO4 and concentrated. The crude material was purified by column chromatography utilizing EtOAc/hexanes as the eluent to give 400 mg of a mixture of 18 and 19 (-1 :2) in 63% yield. 1H-NMR (400 MHz, CDCl3)
[00137] Synthesis of [8-(3-Chloro-phenyl)-3-methyl-imidazo[l,2-a]pyridin-6-yl]- methanol (20): To a mixture of compound 18 and 19 (-1 :2) (700 mg, 2.2 mmol) in THF (anhydrous, 30 ml), was added DIBAL-H (IM in Toluene, 14 ml) dropwise at -78 oC under N2. The reaction mixture was stirred at -78 oC to r.t. and r.t. for 3 hrs. The reaction mixture was diluted with ice/water, adjusted pH to acidic and then stirred at r.t for about 20 min. After pH adjusted to 8-9 by addition of NaOH aq (6N), the aqueous portion was extracted with ethyl acetate (4x 80 ml). Organic layer was washed with sat. NaHCO3 aq., brine, and dried over Na2SO4. After removal of solvent, the residue was purified by column chromatography utilizing MeOH/DCM as the eluent to give 145 mg of product 20 in 24 % yield. 1H-NMR (400 MHz, CDCl3)
[00138] Synthesis of Carbonic acid 8-(3-chloro-phenyl)-3-methyl-imidazo[l,2- a]pyridin-6-ylmethyl ester methyl ester (21): To a mixture of compound 20 (110 mg, 0.4 mmol) in THF (8 ml), was added NaH (60 % in oil, 40 mg, 1 mmole) at -10 oC and stirred at r.t. for 20 min. Methyl chloroformate (86 mg, 0.9 mmole) was added dropwise at -20 oC under N2. The reaction mixture was stirred at r.t over night. The reaction mixture was diluted with water and extracted with ethyl acetate (3x 8 ml). The organic portions were combined, washed with brine, dried over Na2SO4. After removal of solvent, 130 mg of crude product 21 obtained. Crude 21 directly used in next step without further purification.
[00139] Synthesis of 5-[8-(3-Chloro-phenyl)-3-methyl-imidazo[l,2-a]pyridin-6- ylmethyl]-pyridin-2-ylamine (D-14): A reaction mixture of compound 21 (65 mg crude, 0.2 mmol), 2-aminopyridine-5-boronic acid pinacol ester (44 mg, 0.2 mmol), 1,5- bis(diphenylphosphino) pentane (26 mg, 0.06 mmole), allylpalladium chloride dimer (11 mg, 0.03 mmol), K2CO3 (83 mg, 0.6 mmole) in DMF (2 ml)) was stirred at 90 0C for 2 hours and then cooled to room temperature. Water was added and the aqueous portion was extracted with ethyl acetate(2 x 30 ml), the organic portions were combined, washed with brine, dried over Na2SO4 and concentrated. The crude material was purified by column chromatography utilizing MeOH/DCM as the eluent to give 32 mg of D-14 in 45 % yield for two steps. To a solution of D-14 (16 mg) in DCM (3 ml), was added HCl in Et2O (2N, 0.1 ml), solid was washed with ether to give 17 mg of D-14 HCl salt as solid. 1H-NMR (400 MHz, CD3OD): 2.70 (3H, s), 4.16 (2H, s), 7.01 (IH, d, J= 8 Hz), 7.58 - 7.64 (3H, m), 7.71 (IH, m), 7.83 (IH, m), 7.86 (IH, m), 7.88 (IH, m), 7.94 (IH, m), 8.71 (IH, s). MS(APCI+): 349.1 (M+ 1). LC- MS: 99 %.
[00140] Synthesis of l-{5-[8-(3-Chloro-phenyl)-3-methyl-imidazo[l,2-a]pyridin-6- ylmethyl]-pyridin-2-yl}-3-ethyl-urea (D-15): To a mixture of compound D-14 (16 mg, 0.046 mmol) in pyridine (1 ml), was added ethyl isocyanate (36 mg, 0.5 mmole). The reaction mixture was stirred at r.t. for 2 days and concentrated. The crude material was purified by column chromatography utilizing MeOH/DCM as the eluent to give 16 mg of D- 15 in 83 % yield. To a solution of D-15 (16 mg) in DCM (3 ml), was added HCl in Et20 (2N, 0.1 ml), solid was washed with ether to give 16 mg of D-15 HCl salt as solid. 1H-NMR (400 MHz, CD3OD): 1.18 (3H, t, J= 7.2 Hz), 2.70 (3H, s), 3.13 (2H, q, J=7.2 Hz), 4.32 (2H, s), 7.28 (IH, d, J = 8Hz), 7.58 - 7.64 (3H, m), 7.72 (IH, m), 7.84 (IH, m), 7.88 (IH, m), 8.23 - 8.25 (2H, m), 8.74 (IH, m). MS(APCI+): 420.1 (M+l). LC-MS: 97 %.
[00141] Example 16. D- 16
[00142] Example 17. D- 17
[00143] Synthesis of 4-[8-(3-Chloro-phenyl)-3-methyl-imidazo[l,2-a]pyridin-6- ylmethylj-phenylamine (D-16): A reaction mixture of compound 21 (65 mg crude, 0.2 mmol), 4-aminophenyl boronic acid pinacol ester (44 mg, 0.2 mmol), 1,5- bis(diphenylphosphino) pentane (26 mg, 0.06 mmole), allylpalladium chloride dimer (11 mg, 0.03 mmol), K2CO3 (83 mg, 0.6 mmole) in DMF (2 ml)) was stirred at 90 0C for 2 hours and then cooled to room temperature. Water was added and the aqueous portion was extracted with ethyl acetate(3 x 30 ml), the organic portions were combined, washed with brine, dried over Na2SO4 and concentrated. The crude material was purified by column chromatography utilizing MeOH/DCM as the eluent to give 21 mg of D-16 in 30 % yield. To a solution of D- 16 (14 mg) in DCM (3 ml), was added HCl in Et20 (2N, 0.1 ml), solid was washed with ether to give 14 mg of D-16 HCl salt as solid. 1H-NMR (400 MHz, CD3OD): 2.68 (3H, s),
4.31 (2H, s), 7.37 (2H, d, J=7.2 Hz), 7.54 - 7.60 (5H, m), 7.67 (IH, m), 7.78 (IH, m), 7.81 (IH, m), 8.69 (IH, s). MS(APCI+): 348.1 (M+ 1). LC-MS: 99 %.
[00144] Synthesis of l-{4-[8-(3-Chloro-phenyl)-3-methyl-imidazo[l,2-a]pyridin-6- ylmethyl]-phenyl}-3-ethyl-urea (D-17): To a mixture of compound D-16 (12 mg, 0.034 mmol) in pyridine (1 ml), was added ethyl isocyanate (36 mg, 0.5 mmole). The reaction mixture was stirred at r.t. for 2 days and concentrated. The crude material was purified by column chromatography utilizing ethyl acetate/hexane as the eluent to give 12 mg of D-17 in 84 % yield. To a solution of D-17 (12 mg) in DCM (3 ml), was added HCl in Et20 (2N, 0.1 ml), solid was washed with ether to give 12 mg of D-17 HCl salt as solid. 1H-NMR (400 MHz, CD3OD): 1.13 (3H, t, J=7.2 Hz), 2.66 (3H, s), 3.20 (2H, q, J=7.2 Hz), 4.16 (2H, s), 7.24 (2H, d, J=8 Hz), 7.33 (2H, d, J= 8 Hz), 7.50 - 7.60 (3H, m), 7.68 (IH, m), 7.77 (2H, m), 8.55 (IH, m). MS(APCI+): 419.1 (M+ 1). LC-MS: 98 %.
[00145] Example 18. D- 18
[00146] Example 19. D- 19
[00147] Example 20. D-20
MeMgBr
THF
[00148] Synthesis of 5-[8-(3-Chloro-phenyl)-2-methyl-imidazo[l,2-a]pyridin-6- ylmethyl]-pyridine-2-carboxylic acid methyl ester (D-18): A reaction mixture of compound 16 (200 mg crude, 0.55 mmol), 2-(methylcarboxy) pyridine-5-boronic acid
pinacol este (145 mg, 0.55 mmol), l,5-bis(diphenylphosphino) pentane (73 mg, 0.165 mmole), allylpalladium chloride dimer (30 mg, 0.082 mmol), K2CO3 (228 mg, 1.65 mmole) in DMF (3 ml)) was stirred at 90 0C for 2 hours and then cooled to room temperature. Water was added and the aqueous portion was extracted with ethyl acetate (3 x 8 ml), the organic portions were combined, washed with brine, dried over Na2SO4 and concentrated. The crude material was purified by column chromatography utilizing MeOH/DCM as the eluent to give 72 mg of D-18 in 33 % yield for two step. To a solution of D-18 (11 mg) in DCM (3 ml), was added HCl in Et20 (2N, 0.1 ml), solid was washed with ether to give 11 mg of D-18 HCl salt as solid. 1H-NMR (400 MHz, CD3OD): 2.52 (3H, s), 4.01 (2H, s), 4.39 (2H, s), 7.57 - 7.63 (3H, m), 7.72 (IH, m), 7.84 (IH, m), 8.00 (IH, m), 8.20 (IH, m), 8.26 (IH, d, J=8 Hz), 8.69, IH, m), 8.78 (IH, m). MS(APCI+): 392.0 (M+ 1). LC-MS: 98 %.
[00149] Synthesis of 2-{5-[8-(3-Chloro-phenyl)-2-methyl-imidazo[l,2-a]pyridin-6- ylmethyl]-pyridin-2-yl}-propan-2-ol (D-19) and l-{5-[8-(3-Chloro-phenyl)-2-methyl- imidazo[l,2-a]pyridin-6-ylmethyl]-pyridin-2-yl}-ethanone (D-20): To a mixture of compound D-18 (60 mg, 0.15 mmol) in THF (3 ml), was added MeMgBr (3 M in ether, 0.26 ml, 0.78 mmole) dropwise at -10 oC. The reaction mixture was stirred at r.t. over night. Water was added and the aqueous portion was extracted with ethyl acetate (4 x 10 ml), the organic portions were combined, washed with brine, dried over Na2SO4 and concentrated. The crude material was purified by column chromatography utilizing MeOH/DCM as the eluent to give 22 mg of D-19 in 37 % yield and 9 mg of D-20 in 16 % yield. To a solution of D-19 (22 mg) in DCM (3 ml), was added HCl in Et2O (2N, 0.1 ml), solid was washed with ether to give 22 mg of D-19 HCl salt as solid. For D-19 HCl salt: 1H-NMR (400 MHz, DMSO-d6): 1.52 (6H, s), 2.46 (3H, s), 4.27 (2H, s), 7.65 (3H, m), 7.79 (IH, br), 7.94 (IH, br), 7.98 (IH, br), 8.14-8.20 (2H, m), 8.70 (IH, m), 8.88 (IH, br). MS(APCI+): 392.1 (M+l). LC-MS: 94 %.
[00150] To a solution of D-20 (9 mg) in DCM (3 ml), was added HCl in Et2O (2N, 0.1 ml), solid was washed with ether to give 9 mg of D-20 HCl salt as solid. For D-20 HCl salt:
1H-NMR (400 MHz, DMSO-d6): 2.46 (3H, s), 2.61 (3H, s), 4.27 (2H, s), 7.65 (3H, m), 7.78 (IH, br), 7.90 - 7.98 (3H, m), 8.14 (IH, m), 8.77 (IH, m), 8.84 (IH, br). MS(APCI+): 376.1 (M+l). LC-MS: 84 %.
[00151] Example 21. D-21
D-12 D-21
[00152] Synthesis of N-{5-[8-(3-Chloro-phenyl)-2-methyl-imidazo[l,2-a]pyridin-6- ylmethyl]-pyridin-2-yl}-2-dimethylamino-acetamide (D-21): To a mixture of compound D-12 (20 mg, 0.057 mmol) and dimethylamino acetyl chloride hydrochloride (23 mg, 0.14 mmole) in DCM (2 ml), was added diisopropylethylamine (37 mg, 0.3 mmole). The reaction mixture was stirred at 40 oC for 3 days and diluted with DCM (5 ml) and sat. NaHCO3 aq. The aqueous portion was extracted with DCM (3 x 10 ml), the organic portions were combined, washed with brine, dried over Na2SO4 and concentrated. The crude material was purified by column chromatography utilizing MeOH/DCM as the eluent to give 13 mg of D- 21 in 53 % yield. To a solution of D-21 (13 mg) in DCM (3 ml), was added HCl in Et20 (2N, 0.1 ml), solid was washed with ether to give 13 mg of D-21 HCl salt as solid. 1H-NMR (400 MHz, DMSO-d6): 2.47 (3H, s), 2.85 (3H, s), 2.87 (3H, s), 4.14 (2H, s), 4.18 (2H, br), 7.65 (3H, m), 7.78 (IH, br), 7.84 (IH, dd, J= 8 and 2.4 Hz), 7.90 (IH, br), 8.00 (IH, br), 8.16 (IH, br), 8.40 (IH, d, J=2.4 Hz), 8.82 (IH, br, 10.0 (IH, br), 11.15 (IH, s), 14.0 (IH, br). MS(APCI+): 434.1 (M+l). LC-MS: 99 %.
[00153] Example 22. D-22
[00154] Example 23. D-23
D-12 D-22 D-23
[00155] Synthesis of (D-22): To a mixture of compound D-12 (40 mg, 0.115 mmol) and diisopropylethylamine (74 mg, 0.57 mmole) in DCM (3 ml), was added ethyl
chloroformate (31 mg, 0.29 mmole). The reaction mixture was stirred at r.t. over night and diluted with DCM (5 ml) and sat. NaHCO3 aq. The aqueous portion was extracted with DCM (2 x 8 ml), the organic portions were combined, washed with brine, dried over Na2SO4 and concentrated. The crude material was purified by column chromatography utilizing MeOH/DCM as the eluent to give 49 mg of D-22 in 87 % yield. To a solution of D-22 (40 mg) in ether (8 ml), was added HCl in Et20 (2N, 0.15 ml), solid was washed with ether to give 50 mg of D-22 HCl salt as solid. 1H-NMR (400 MHz, DMSO-d6): 1.11 (6H, m), 2.46 (3H, s), 4.14 (4H, q, J=7.2 Hz), 4.20 (2H, s), 7.43 (IH, d, J=8 Hz), 7.64 (3H, m), 7.77 (IH, br), 7.89 (IH, dd, J=8 and 2.4 Hz), 7.95 (IH, s), 8.17 (IH, s), 8.50 (IH, d, J=2.4 Hz), 8.90 (IH, s), 14.0 (IH, br). MS(APCI+): 493.1 (M+ 1). LC-MS: 99 %.
[00156] Synthesis of {5-[8-(3-Chloro-phenyl)-2-methyl-imidazo[l,2-a]pyridin-6- ylmethyl]-pyridin-2-yl}-carbamic acid ethyl ester (D-23): A reaction mixture of compound D-22 (20 mg, 0.04 mmol) in EtOH (3 ml) and NaOH aq. (2N, 1 ml) was stirred at r.t. for 4 hrs and diluted with water (5 ml). The aqueous portion was extracted with ethyl acetate (2 x 10 ml), the organic portions were combined, washed with brine, dried over Na2SO4 and concentrated. The crude material was purified by column chromatography utilizing MeOH/DCM as the eluent to give 16 mg of D-23 in 95 % yield. To a solution of D- 23 (16 mg) in ether (5 ml), was added HCl in Et20 (2N, 0.1 ml), solid was washed with ether to give 17 mg of D-23 HCl salt as solid. 1H-NMR (400 MHz, DMSO-d6): 1.23 (3 H, t, J=7.2 Hz), 2.46 (3H, s), 4.10 (2H, s), 4.14 (2H, q, J=7.2 Hz), 7.65 (3H, m), 7.78 (3H, m), 7.91 (IH, m), 8.14 (IH, s), 8.30 (IH, br), 8.78 (IH, s), 10.25 (IH, br). MS(APCI+): 421.1 (M+l). LC- MS: 99 %.
[00157] Example 24. D-24
[00158] Example 25. D-25
OH
[00159] Synthesis of S-CS-Chloro-pheny^-ό-Cό-fluoro-pyridin-S-ylmethyl)-!- methyl-imidazo[l,2-a]pyridine (D-24): A reaction mixture of compound 16 (220 mg crude, 0.55 mmol), 2-fluoro-5-pyridine boronic acid (78 mg, 0.55 mmol), 1,5- bis(diphenylphosphino) pentane (73 mg, 0.165 mmole), allylpalladium chloride dimer (30 mg, 0.082 mmol), K2CO3 (228 mg, 1.65 mmole) in DMF (3 ml)) was stirred at 90 0C for 2 hours and then cooled to room temperature. Water was added and the aqueous portion was extracted with ethyl acetate (5 x 8 ml), the organic portions were combined, washed with brine, dried over Na2SO4 and concentrated. The crude material was purified by column chromatography utilizing MeOH/DCM as the eluent to give 120 mg of D-24 in 62 % yield. To a solution of D-24 (70 mg) in DCM (3 ml), was added HCl in Et20 (2N, 0.2 ml), solid was washed with ether to give 70 mg of D-24 HCl salt as solid. 1H-NMR (400 MHz, DMSO- d6): 2.46 93H, s), 4.17 (2H, s), 7.17 (IH, dd, J= 8 and 2.4 Hz), 7.64 (3H, m), 7.78 (IH, br), 7.93 (IH, d, J=1.6 Hz), 7.98 (IH, m), 8.14 (IH, s), 8.28 (IH, d, J = 2.8 Hz), 8.80 (IH, s). MS(APCI+): 352.0 (M+l). LC-MS: 99 %.
[00160] Synthesis of ({5-[8-(3-Chloro-phenyl)-2-methyl-imidazo[l,2-a]pyridin-6- ylmethyl]-pyridin-2-yl}-methyl-amino)-acetic acid (D-25): A mixture of compound D-24 (50 mg, 0.13 mmol), sacosine (23 mg, 0.26 mmole) and DBU (120 mg, 0.78 mmole) was stirred at 150 oC for 1 hr. and cooled to r.t.,. A sat. NH4C1 aq. was added and the aqueous portion was extracted with DCM (5 x 10 ml), the organic portions were combined, washed with brine, dried over Na2SO4 and concentrated. The crude material was purified by column chromatography utilizing MeOH/DCM as the eluent to give 38 mg of D-25 in 70 % yield. To a solution of D-25 (38 mg) in DCM (3 ml), was added HCl in Et2O (2N, 0.15 ml), solid was washed with ether to give 38 mg of D-25 HCl salt as solid. 1H-NMR (400 MHz, DMSO-d6): 2.46 (3H, s), 3.17 (3H, s), 4.08 (2H, s), 4.46 (2H, s), 4.40 - 4.70 (2H, br), 7.10 (IH, br), 7.65 (3H, m), 7.78 (IH, br), 7.94 (2H, m), 8.11 (IH, m), 8.16 (IH, br), 8.83 (IH, br). MS(APCI+): 421.1 (M+l). LC-MS: 99 %.
[00161] Example 26. D-26
D-24 D-26
[00162] Synthesis of l-{5-[8-(3-Chloro-phenyl)-2-methyl-imidazo[l,2-a]pyridin-6- ylmethyl]-pyridin-2-yl}-azetidine-2-carboxylic acid (D-26): A mixture of compound D-24 (65 mg, 0.17 mmol), D,L-Azetidine-2-carboxylic acid (34 mg, 0.34 mmole) and DBU (304 mg, 2 mmole) was stirred at 150 oC for 1 hr. and cooled to r.t.,. A saturated NH4C1 aq. was added and the aqueous portion was extracted with DCM (5 x 10 ml), the organic portions were combined, washed with brine, dried over Na2SO4 and concentrated. The crude material was purified by column chromatography utilizing MeOH/DCM as the eluent to give 35 mg of D-26 in 48 % yield. To a solution of D-26 (35 mg) in DCM (3 ml), was added HCl in Et20 (2N, 0.15 ml), solid was washed with ether to give 35 mg of D-26 HCl salt as solid. 1H- NMR (400 MHz, DMSO-d6): 2.40 (IH, m), 2.46 (3H, s), 2.77 (IH, m), 4.08 (2H, s), 4.12 (IH, m), 4.21 (IH, m), 5.10 (IH, m), 6.90 (IH, br), 7.65 (3H, m), 7.78 (IH, s), 7.94 (IH, s), 7.96 (IH, m), 8.11 (IH, m), 8.17 (IH, s), 8.85 (IH, s). MS(APCI+): 433.1 (M+l). LC-MS: 97 %.
[00163] Example 27. D-27
[00164] 5-Methyl-2H-pyrazole-3-carboxylic acid hydrazide (23): To a 20 mL vial with stir bar was added, Ethyl 3-methylpyrazole-5-carboxylate (1.56 g, 10.1 mmol), EtOH (4 mL), and hydrazine hydrate (2.46 mL, 50.6 mmol). The reaction was heated at 78 0C for 18
hours. The reaction was concentrated to afford 23 as a white solid (1.35 g, 95%), 23 was used as is in the next reaction.
[00165] 2-Methyl-7-phenyl-5H-pyrazolo[l,5-d] [l,2,4]triazin-4-one (24): Into a 50 mL round bottom flask equipped with a stir bar was added 23 (1.35 g, 9.63 mmol), DMF (25 mL), and phenyl orthoformate (2.48 mL, 14.5 mmol). The reaction was refluxed for 24 hours. The DMF was removed by blowing a stream of N2 into the hot flask. Ethyl acetate (5 mL) was added to the flask followed by H2O (5 mL). The flask was shaken and the aqueous portion discarded. This was repeated once more. The EA was concentrated. EtOH (2 mL) was added to the viscous oil, the flask was capped, and allowed to sit overnight at RT. The mixture was filtered to obtain the off- white solid that had formed overnight. The solid was washed with EtOH, collected, and dried under vacuum to give 0.37 g (17%) of off-white solid, 24. 1H-NMR (500 MHz, CDCl3) δ 13.35 (s, IH), 8.07 (dd, 2H, J= 7.5, 1.5 Hz), 7.66- 7.61 (m, 3H), 6.72 (s, IH), 2.34 (s, 3H).
[00166] 5-(4-Fluoro-benzyl)-2-methyl-7-phenyl-5H-pyrazolo[l,5-d] [l,2,4]triazin-
4-one, (D-27): To a 25 mL round bottom flask equipped with a stir bar was added 24 (50.6 mg) and dry THF (2 mL). The 24 remained insoluble so dry DMF (2 mL) was added to obatin a homogeneuos solution which was cooled to 0 0C and NaH (6.4 mg) was added. The reaction was stirred at 0 0C for 15 min. then RT for 15 min. The mixture was then cooled to 0 0C and 4-Fluorobenzyl bromide (0.028 ml, 0.22 mmole) was added. The reaction was allowed to slowly come to RT and stir for 16 hours. 5 drops Of H2O were added and the reaction concentrated. Purification by flash column chromatography (15 g SiO2, wet-pack with hexane) using 15% EA/Hexanes afforded 40.4 mg (54%) of D-27 as a off- white solid. 1H-NMR (500 MHz, CDCl3) δ 8.12 - 8.09 (m, 2H), 7.55 - 7.49 (m, 5H), 7.04 - 6.98 (m, 3H), 5.28 (s, 2H), 2.47 (s, 3H). 13C-NMR (125 MHz, CDCl3) δ 163.7, 161.8, 154.2, 153.3, 138.6, 135.5, 132.3, 131.1, 131.0, 129.8, 129.3, 128.5, 115.8, 115.6, 106.7, 52.8, 14.2; LC/MS = 96.6%, 335.6 (ESI+).
[00167] In similar fashion the following were synthesized:
[00168] Methods of the invention parallel the compositions and formulations. The methods comprise administering to a patient in need of treatment a therapeutically effective amount of a compound according to the invention. The present invention also provides a method for inhibiting phosphodiesterase 4.
[00169] In-vitro assay for PDE4 enzymes. The in-vitro activity of PDE4 enzymes and the in-vitro potency of therapeutic agents described in the present invention was measured using a real-time, enzyme-coupled spectrophotometric assay. By using three different coupling enzymes, the product of the PDE4 reaction is coupled to the oxidation of the reduced form β -nicotinamide adenine dinucleotide (NADH), which dissipation can be monitored spectrophotmetrically at 340 nM.
[00170] Assay description. Buffer A containing 50 mM Tris, pH 8.0, 16 mM MgCl2 and 80 mM KCl is prepared and stored at room temperature. Buffer B containing 50 mM Tris, pH 8.0 is prepared and stored at toom temperature. Stock solutions of the following reagents are prepared in Buffer B and stored at -200C: Adenosine-5 '-triphosphate (ATP), cyclic adenosine-5 '-monophosphate (cAMP), phosphoenolpyruvate (PEP) and NADH. An assay mix is prepared by mixing Buffer A, trichloroethylphosphine (TCEP), ATP, PEP, NADH, myokinase (MK), pyruvate kinase (PK), lactate dehydroganese (LDH) and PDE4 to a final volume of 20 mL, which is enough for a single 96-well assay plate. Assay mix (180 μL) and test article (10 μL ) in 1 : 1 DMSO/H2O mixture is pre-incubated at room temperature for 10 min. The enzymatic reaction is initiated by addition of c AMP (10 μL). Final
concentration of all components in the assay (200 μL/well) are as follows: 10 mM MgCl2, 50 mM KCl, 5 mM TCEP, 2.5% DMSO, 0.4 mM NADH, 1 mM PEP, 0.04 mM ATP, 5 units MK, 1 unit PK, 1 unit LDH and appropriate amount of PDE4. Reaction progress curves are monitored in a plate reader capable of measuring light absorbance at 340 nM. A decrease in light absorbance at 340 nm is due to oxidation of NADH. Positive controls containing no test article and negative controls containing no test article and no cAMP are included on every assay plate. Reaction rates are determined from the slopes of the linear portions of the progress curves. All data is percent normalized with respect to controls and presented as percent inhibition.
[00171] The results of testing of representative species are shown below. The values
A-E are based on IC50 in the assay described above.
[00172] Table 3.
[00174] It should be noted that compounds D-28 and D-49 are 50 to 70-fold selective for inhibiting the B isoform over the D isoform, whereas D-29, D-30 and D-31 are slightly (3 to 6-fold) more selective for the D isoform over the B.
[00175] The activity of PDE4 inhibitors decribed in the present invention was also measured using in an ex- vivo assay measuring leukotriene E4 (LTE4) in human whole blood after Sephadex stimulation. The anti- inflammatory activity of therapeutic agents of the present invention is demonstrated by the inhibition of eosinophil activation as measured by sephadex bead stimulated LTE4 production in whole human blood. For each sample, 356 μl of heparinized human whole blood (Vacutainer tube #6480) is added to wells of a 96 well plate. Then, 4 μl of a series of compound dilutions (in DMSO) are added in triplicates, suspension mixed and allowed to incubate at 370C for 15 min with gentle shaking. After that, blood samples are stimulated by adding 40 μL of Sephadex G-15 beads (Sigma-Aldrich, Sweden). The beads are predissolved in PBS (0.16 g/ mL PBS). After mixing, the suspension is incubated at 37 0C for 90 min. Then, 8 μL of 15% EDTA/PBS is added to each sample, mixed and plate centrifuged for 5 min at 115 x g at 210C and supernatants taken. In each plate, 10 positive controls and 10 negative controls are used, containing DMSO instead of
compound solution. The positive controls are stimulated with Sephadex as described for the samples, and in the negative controls (unstimulated), Sephadex solution is replaced by PBS. LTE4 levels in the resulting plasma samples are determined using a commercial enzyme- linked immunoassay (Cayman Chemical Company, Ann Arbor, MI) according to the manufacturer's instructions. Table 5 provides data for some representative examples:
[00176] Table 5.
[00177] Persons of skill in the art accept that positive results in PDE4 models are predictive of therapeutic utility as discussed above.
Claims
CLAIMS We claim: 1. A compound of formula I or formula II
P is chosen from nitrogen and carbon;
Q is chosen from nitrogen and carbon, with the provisos that one of P or Q must be nitrogen, but P and Q cannot both be nitrogen;
R1 is selected from hydrogen, (Ci-C6) alkyl, haloalkyl, -CONHR5, lower alkoxy, alkylamino, dialkylamino, amino, -NHCOOR2 and -OCONH2;
W is nitrogen or CR ;
R2 is selected from hydrogen, (Ci-C6) alkyl, haloalkyl and optionally substituted heterocyclyl;
Y is CR3 or nitrogen;
R3 is selected from hydrogen, fluoro, hydroxyl and -OR10;
R10 is selected from (Ci-C6) alkyl optionally substituted with fluoro;
X is selected from CR4, nitrogen and N+ O";
R4 is selected from hydrogen, (Ci-C6) alkyl, halogen, amino, alkoxy and hydroxyl;
R5 is selected from hydrogen and (Ci-C6) alkyl;
R8 and R9 are independently selected from hydrogen, (Ci-C6) alkyl, (Ci-C6) hydroxyalkyl, (C3-C6) carbocyclyl and a 3- to 6-membered heterocyclyl; or R8 and R9 together form a 4-6 membered ring which optionally contains a heteroatom selected from -O- , -NR5 and S(Oy2; or R8 and R9 together form an oxo group;
Z is selected from -0-, -S(0)o-2, -NH-, -CH2- and a direct bond;
Cy1 is selected from optionally substituted (C3-C6) carbocyclyl and optionally substituted heterocyclyl; Cy2 is selected from optionally substituted aryl and optionally substituted heteroaryl; and
M is chosen from -CH2-, -CH2CH2-, -O-, -S(O)0-2-, -OCH2-, -CH2O-, -CONH-, -CONHCH2-, -NHCO- and -NHSO2-, with the proviso that when M is -NH- or -CONH-, Q is not nitrogen; and with the proviso that 4'-[(7-phenylpyrazolo[l,5-a]pyrimidin-5-yl)methyl]-[l,r- Biphenyl]-2-carbonitrile, 7-[3-(acetylethylamino)phenyl]-3-cyanopyrazolo[ 1 ,5-a]pyrimidin- 5-yl-β-D-Glucopyranosiduronic acid and 7-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-5- (phenylmethyl)-[l,2,4]Triazolo[l,5-a]pyrimidine are excluded compounds.
2. A compound according to claim 1 wherein P is nitrogen;
Q is carbon; W is CR2;
Y is CR3; and
X is selected from CR4 and N.
3. A compound according to claim 1 wherein P is nitrogen;
Q is carbon; W is nitrogen;
Y is CR3; and
X is selected from CR4 and N.
4. A compound according to claim 1 wherein P is carbon;
Q is nitrogen; W is CR2;
Y is CR3;
X is selected from CR4 and N; and
Z is selected from -0-, -S(0)o-2, -CH2- and a direct bond.
5. A compound according to claim 1 wherein P is carbon;
Q is nitrogen;
W is CR2;
Y is nitrogen;
X is CR4; and
Z is selected from -O-, -S(0)o-2, -CH2- and a direct bond.
6. A compound according to claim 1 of formula II wherein P is carbon;
Q is nitrogen;
W is nitrogen or CR2; and
X is nitrogen.
7. A compound according to any of claims 1-6 wherein Z is a direct bond;
M is -CH2- or -CONH-;
Cy1 is selected from optionally substituted aryl and an optionally substituted 5- or 6- membered ring nitrogen heterocycle; and
Cy2 is selected from optionally substituted phenyl and an optionally substituted 5- or 6- membered ring nitrogen heterocycle.
8. A compound according to claim 7 wherein
Cy1 is selected from optionally substituted phenyl and an optionally substituted 5- or 6- membered ring nitrogen heterocycle; and
Cy2 is selected from phenyl, 3-chlorophenyl, 3-nitrophenyl, 3-bromophenyl, 3-acetylphenyl, 3-trichloromethylphenyl and 3-methylthiophenyl.
9. A compound according to claim 8 wherein
Cy1 is selected from optionally substituted phenyl, pyridinyl, morpholin-4-yl, piperazin-1-yl, piperidiny-1-yl, imidazol-1-yl, pyrazol-1-yl, and pyrazol-5-yl; and Cy2 is selected from phenyl and 3-chlorophenyl.
10. A compound according to claim 9 wherein Cy1 is selected from phenyl and pyridinyl, each of which is optionally substituted with a substituent chosen from halogen, haloalkyl, alkyl, acyl, alkoxyalkyl, hydroxyalkyl, carbonyl, phenyl, heteroaryl, benzenesulfonyl, hydroxy, alkoxy, haloalkoxy, oxaalkyl, carboxy, alkoxycarbonyl, alkoxycarbonylamino, alkoxycarbonylaminoalkyl, carboxyalkylcarbonylamino, carboxamido, aminocarbonyloxy, alkylaminocarbonyl, dialkylaminocarbonyl, aminocarbonylalkyl, cyano, acetoxy, nitro, amino, alkylamino, dialkylamino, aminoalkyl, (alkyl)(aryl)aminoalkyl, alkylamino alkyl, dialkylaminoalkyl, dialkylaminoalkoxy, alkyl(hydroxyalkyl)amino, heterocyclylalkoxy, mercapto, alkylthio, alkylsulfonyl, alkylsulfonylamino, alkylsulfinyl, alkylsulfonyl, arylthio, arylsulfonyl, arylsulfonylamino, arylsulfinyl, arylsulfonyl, acylaminoalkyl, acylaminoalkoxy, acylamino, amidino, aryl, benzyl, heterocyclyl, heterocyclylalkyl, phenoxy, benzyloxy, heteroaryloxy, heterocyclylamino, hydroxyimino, alkoxyimino, oxaalkyl, aminosulfonyl, trityl, amidino, guanidino, ureido, -NHC(=O)NHalkyl, -NHC(=O)NH-heterocyclyl, -alkyl-NHC(=O)N(alkyl)2, heterocyclylalkylcarbonylamino, benzyloxyphenyl, benzyloxy, azetidine acid, azedtidine amide, the residues of amino acids, amino acid amides, protected residues of aminoacids, protected residues of amino acid amides, N-methylated amino acids and N-methylated amino acid amides.
11. A compound according to claim 9 wherein Cy1 is selected from phenyl and pyridinyl, each of which is optionally substituted with a substituent chosen from -CH3, -CH2CF3, -CF3, -CHO, -COOH, -CN, halogen, -OH, , -OEt, -C(=0)NH2, -C(=O)NHEt, -C(=0)NMe2 -COOCH3, -COOEt, -CH2NHC(=O)NH2, -CH(CH3)NHC(=O)NH2, -CH2NHC(=0)H, -CH2NHC(=O)CH3, -CH2C(=O)NH2, -CH2COOH, -CH2COOEt, -CH2NHC(=O)OEt, -CH2NHCC=O)O-C6H5, -CH2NHC(=O)C(=O)NH2, -CH2NHC(=O)NHEt, -C(CH3)2OH, -CH2NHC(=O)N(CH3)2, -CH2NHC(=O)NHCH3, -CH2NH2, -CH(CH3)NH2, -C(CH3)2NH2, -CH2OH, -CH2CH2OH, -CH2NHSO2CH3, -CH2OC(=O)NHEt, -OCH3, -0C(=0)NH2, -OCH2CH2N(CH3)2, -OCH2CH2OCH3, -NHC(=0)NH2, -NHC(=O)NHEt, -NHCH3, -NHEt, -NH(tBoc), -NHCH2COOH, -N(CH3)CH2COOH, -NHC(=O)NHCH2CH2C1, -NHSO2NH2, -NHEt, -N(CH3)2, -NH2, , -NH(CH3)C(=O)NH2, -NHSO2CH3, -N(SO2CH3)2, -NHC(=O)OCH3, -NHC(=O)OtBu, -NHC(=O)CH3, -SO2NH2, -NHC(=O)CH2CH2COOH, -NHC(=O)NHCH2COOH, -CH2NHCHO, -NHC(=O)NHCH2COOEt, -NHC(=O)NH(CH2)3COOEt, -NHC(=O)NH(CH2)2COOEt, -N(CH3)CH2CH2OH, -NHC(O)OEt, -N(Et)C(O)OEt, -NHC(=O)NH(CH2)2COOH, -NHC(=O)CH2N(CH3)2, -NHC(=O)NH(CH2)3COOH, -NHC(=O)CH2NH2, -NHC(=O)CH2CH2NH2,
12. A compound according to any of claims 1, 2, 4, 5 or 6 wherein W is CR ; and
13. A compound according to claim 12 wherein R is hydrogen.
14. A compound according to any of claims 1-5 wherein R4 is hydrogen.
15. A compound according to any of claims 1-4 wherein R3 is hydrogen.
16. A compound according to any of claims 1-5 wherein R1 is selected from hydrogen and (Ci-Cβ) alkyl; X is selected from CH and CF;
Cy 1 is selected from optionally substituted phenyl, pyridinyl, morpholinyl, piperazinyl, piperidinyl, imidazolyl, pyrazolyl, oxazolidinyl, pyrrolidinyl, thiazolyl, benzo[c] [ 1 ,2,5]oxadiazolyl;
Cy2 is optionally substituted phenyl;
Z is a direct bond; and
M is -CH2- or -CONH-.
17. A compound according to claim 16 wherein R1 is methyl; and Cy 1 is phenyl optionally substituted with a substituent selected from amino, urea,
18. A compound according to claim 6 wherein R1 is selected from hydrogen and (Ci-C6) alkyl; R2 is selected from hydrogen and (Ci-C6) alkyl;
Cy 1 is selected from optionally substituted aryl and heteroaryl; and Cy2 is selected from optionally substituted aryl and heteroaryl.
19. A compound according to claim 18 wherein R1 is methyl;
R2 is hydrogen;
R8 and R9 together form an oxo group; Cy * is optionally substituted phenyl; and Cy2 is optionally substituted phenyl.
20. A compound according to claim 18 wherein R1 is methyl;
R2 is hydrogen;
R8 and R9 are each independently selected from hydrogen and (Ci-Cβ) alkyl;
Cy * is optionally substituted phenyl; and
Cy2 is optionally substituted phenyl.
21. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to any of claims 1-20.
22. A method for the treatment or prophylaxis of a disease or condition mediated by phosphodiesterase-4 comprising administering to a mammal a therapeutically effective amount of a compound according to any of claims 1-20.
23. A method according to claim 22 wherein said disease or condition is chosen from stroke, myocardial infarct, cardiovascular inflammatory conditions, atherosclerosis, thrombosis, acute coronary syndrome, stable angina, peripheral vascular disease, critical leg ischemia, intermittent claudication and abdominal aortic aneurysm.
24. A method according to claim 22 wherein said disease or condition is cancer.
25. A method according to claim 22 wherein said disease or condition is chosen from asthma and COPD.
26. A method for improving cognitive function comprising administering to a mammal a therapeutically effective amount of a compound according to any of claims 1-20.
27. A method according to claim 26 wherein said cognitive function is memory or cognition.
28. A method according to claim 26 for treating learning disorders.
29. A method for treating schizophrenia or Huntington's disease comprising administering to a mammal a therapeutically effective amount of a compound according to any of claims 1-20.
30. A method for treating or preventing bone loss comprising administering to a mammal a therapeutically effective amount of a compound according to any of claims 1-20.
31. A method for treating depression or anxiety comprising administering to a mammal a therapeutically effective amount of a compound according to any of claims 1-20.
32. A method for treating or preventing bladder inflammation, bladder pain or bladder overactivity comprising administering to a mammal a therapeutically effective amount of a compound according to any of claims 1-20.
33. A pharmaceutical composition comprising
(a) a pharmaceutically acceptable carrier;
(b) a compound according to any of claims 1-20; and
(c) a second agent chosen from cholinesterase inhibitors, NMDA antagonists, calpain inhibitors and antioxidants.
34. A pharmaceutical composition according to claim 33 wherein said second agent is chosen from tacrine, huperzine, donepezil, lanicemine, remacemide, neramexane, memantine, vitamin E and coenzyme QlO.
35. Use of a compound according to any of claims 1-20 for the treatment or prophylaxis of a disease or condition mediated by phosphodiesterase-4 comprising administering to a mammal a therapeutically effective amount of said compound.
36. Use according to claim 35 wherein said disease or condition is selected from stroke, myocardial infarct, cardiovascular inflammatory conditions, atherosclerosis, thrombosis, acute coronary syndrome, stable angina, peripheral vascular disease, critical leg ischemia, intermittent claudication and abdominal aortic aneurysm.
37. Use according to claim 35 wherein said disease or condition is cancer.
38. Use according to claim 35 wherein said disease or condition is chosen from asthma and COPD.
39. Use of a compound according to any of claims 1-20 for improving cognitive function comprising administering to a mammal a therapeutically effective amount of said compound.
40. Use according to claim 39 wherein said cognitive function is memory or cognition.
41. Use according to claim 39 for treating learning disorders.
42. Use of a compound according to any of claims 1-20 for treating schizophrenia or Huntington's disease comprising administering to a mammal a therapeutically effective amount of said compound.
43. Use of a compound according to any of claims 1-20 for treating or preventing bone loss comprising administering to a mammal a therapeutically effective amount of said compound.
44. Use of a compound according to any of claims 1-20 for treating depression or anxiety comprising administering to a mammal a therapeutically effective amount of said compound.
45. Use of a compound according to any of claims 1-20 for treating or preventing bladder inflammation, bladder pain or bladder overactivity comprising administering to a mammal a therapeutically effective amount of said compound.
46. A salt of a compound of any of claims 1-20 wherein said salt is pharmaceutically acceptable.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11656908P | 2008-11-20 | 2008-11-20 | |
US61/116,569 | 2008-11-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010059836A1 true WO2010059836A1 (en) | 2010-05-27 |
Family
ID=41503645
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/065162 WO2010059836A1 (en) | 2008-11-20 | 2009-11-19 | Substituted aza-bridged bicyclics for cardiovascular and cns disease |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2010059836A1 (en) |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2410857A1 (en) * | 2009-03-23 | 2012-02-01 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
US8716282B2 (en) | 2009-10-30 | 2014-05-06 | Janssen Pharmaceutica Nv | Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors |
US8791267B2 (en) | 2007-11-21 | 2014-07-29 | Decode Genetics Ehf | Biaryl PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders |
US20140303141A1 (en) * | 2011-09-19 | 2014-10-09 | Hoffmann-La Roche Inc. | Triazolopyridine compounds |
US8859543B2 (en) | 2010-03-09 | 2014-10-14 | Janssen Pharmaceutica Nv | Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases |
US8871754B2 (en) | 2012-11-19 | 2014-10-28 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
US8957078B2 (en) | 2013-03-15 | 2015-02-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8969360B2 (en) | 2013-03-15 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9040692B2 (en) | 2013-03-14 | 2015-05-26 | Dart Neuroscience (Cayman) Ltd. | Substituted pyridine and pyrazine compounds as PDE4 inhibitors |
US9120788B2 (en) | 2013-02-19 | 2015-09-01 | Pfizer Inc. | Azabenzimidazole compounds |
US9273058B2 (en) | 2013-11-14 | 2016-03-01 | Bristol-Myers Squibb Company | Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitors |
US9309250B2 (en) | 2011-06-22 | 2016-04-12 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors |
US9340546B2 (en) | 2012-12-07 | 2016-05-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9550784B2 (en) | 2012-07-09 | 2017-01-24 | Beerse Pharmaceutica NV | Inhibitors of phosphodiesterase 10 enzyme |
US9556169B2 (en) | 2012-11-19 | 2017-01-31 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
US9598421B2 (en) | 2014-08-06 | 2017-03-21 | Pfizer Inc. | Imidazopyridazine compounds |
US9663519B2 (en) | 2013-03-15 | 2017-05-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
US9670215B2 (en) | 2014-06-05 | 2017-06-06 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9669035B2 (en) | 2012-06-26 | 2017-06-06 | Janssen Pharmaceutica Nv | Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl-[1,2,4]triazolo-[4,3-A]]quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological of metabolic disorders |
US10131669B2 (en) | 2014-07-24 | 2018-11-20 | Pfizer Inc. | Pyrazolopyrimidine compounds |
US10160760B2 (en) | 2013-12-06 | 2018-12-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US10604523B2 (en) | 2011-06-27 | 2020-03-31 | Janssen Pharmaceutica Nv | 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives |
US11179394B2 (en) | 2014-06-17 | 2021-11-23 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of Chk1 and ATR inhibitors |
US11464774B2 (en) | 2015-09-30 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
US11718622B2 (en) | 2020-03-16 | 2023-08-08 | Exelixis Inc. | Heterocyclic adenosine receptor antagonists |
Citations (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988001165A1 (en) | 1986-08-11 | 1988-02-25 | Innovata Biomed Limited | Pharmaceutical formulations comprising microcapsules |
WO1989004179A1 (en) | 1987-11-03 | 1989-05-18 | Also Laboratori S.A.S. | Pharmaceutical formulations for transdermal administration |
WO1990007923A1 (en) | 1989-01-19 | 1990-07-26 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
WO1990009781A1 (en) | 1989-02-23 | 1990-09-07 | Rorer International (Holdings), Inc. | Therapeutic aerosol formulations |
WO1991004011A1 (en) | 1989-09-20 | 1991-04-04 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
US5179079A (en) | 1986-12-16 | 1993-01-12 | Novo Nordisk A/S | Nasal formulation and intranasal administration therewith |
US5204108A (en) | 1987-10-10 | 1993-04-20 | Danbiosyst Uk Ltd. | Transmucosal formulations of low molecular weight peptide drugs |
US5230884A (en) | 1990-09-11 | 1993-07-27 | University Of Wales College Of Cardiff | Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations |
US5292499A (en) | 1990-09-11 | 1994-03-08 | University Of Wales College Of Cardiff | Method of preparing medical aerosol formulations including drug dissolved in reverse micelles |
US5324718A (en) | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
US5472954A (en) | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
WO1996011705A1 (en) | 1994-10-13 | 1996-04-25 | Pharmaderm Research & Development Ltd. | Formulations comprising therapeutically-active proteins or polypeptides |
EP0736299A1 (en) | 1995-04-03 | 1996-10-09 | Cerbios-Pharma S.A. | Process for preparing a liposomal, water-dispersable, solid, dry, therapeutic formulation for oral administration |
WO1996040089A2 (en) | 1995-06-07 | 1996-12-19 | Abbott Laboratories | Aerosol drug formulations containing vegetable oils |
WO1997011682A2 (en) | 1995-09-26 | 1997-04-03 | University Of Pittsburgh | Emulsion and micellar formulations for the delivery of biologically active substances to cells |
WO1997013500A2 (en) | 1995-10-12 | 1997-04-17 | Supergen, Inc. | LIPOSOME FORMULATIONS OF 5β STEROIDS |
WO1999059550A1 (en) | 1998-05-20 | 1999-11-25 | The Liposome Company, Inc. | Novel particulate formulations |
WO2000000176A1 (en) | 1998-06-30 | 2000-01-06 | Quadrant Healthcare (Uk) Limited | Microparticle formulation for inhalation |
WO2000006108A1 (en) | 1998-07-29 | 2000-02-10 | Pacific Biolink Pty. Limited | Casein formulations for the delivery of bioactive constituents |
WO2000045792A1 (en) | 1999-02-03 | 2000-08-10 | Powderject Research Limited | Hydrogel particle formulations |
WO2000047203A1 (en) | 1999-02-12 | 2000-08-17 | Mqs, Inc. | Formulation and system for intra-oral delivery of pharmaceutical agents |
WO2000053160A1 (en) | 1999-03-08 | 2000-09-14 | Powderject Research Limited | Delivery of microparticle formulations using needleless syringe device for sustained-release of bioactive compounds |
WO2000062759A1 (en) | 1999-04-16 | 2000-10-26 | Novo Nordisk A/S | Dry, mouldable drug formulation |
WO2001013891A2 (en) | 1999-08-25 | 2001-03-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
WO2001060341A1 (en) | 2000-02-17 | 2001-08-23 | Rijksuniversiteit Groningen | Powder formulation |
US6290987B1 (en) | 1998-09-27 | 2001-09-18 | Generex Pharmaceuticals, Inc. | Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids |
US6294153B1 (en) | 1998-12-21 | 2001-09-25 | Generex Pharmaceuticals, Inc. | Aerosol pharmaceutical formulation for pulmonary and nasal delivery |
WO2001078696A2 (en) | 2000-04-17 | 2001-10-25 | Vectura Limited | Formulations for use in inhaler devices |
WO2001078694A2 (en) | 2000-04-17 | 2001-10-25 | Vectura Limited | Formulations for use in inhaler devices |
US6309671B1 (en) | 1995-04-14 | 2001-10-30 | Inhale Therapeutic Systems | Stable glassy state powder formulations |
US20010036481A1 (en) | 1999-08-25 | 2001-11-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
US20010038824A1 (en) | 2000-01-20 | 2001-11-08 | Ikuo Horii | Intranasal cyclic peptide formulations |
WO2001091728A2 (en) | 2000-06-02 | 2001-12-06 | The Regents Of The University Of Michigan | Nanoemulsion formulations |
WO2002019989A2 (en) | 2000-09-08 | 2002-03-14 | Powderject Research Limited | Alginate particle formulation |
WO2002049621A1 (en) | 2000-12-18 | 2002-06-27 | Licentia Oy | Enteric-coated drug formulations and their manufacture |
US6436367B1 (en) | 1998-12-21 | 2002-08-20 | Generex Pharmaceuticals Inc. | Aerosol formulations for buccal and pulmonary application |
WO2002080884A2 (en) | 2001-03-21 | 2002-10-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder inhaler formulations |
US6485706B1 (en) | 1999-06-04 | 2002-11-26 | Delrx Pharmaceutical Corp. | Formulations comprising dehydrated particles of pharma-ceutical agents and process for preparing the same |
US20030008013A1 (en) | 1998-06-30 | 2003-01-09 | Stuart Robinson | Formulation for inhalation |
US20030019437A1 (en) | 2001-07-26 | 2003-01-30 | John Fore | Ungulate game animal feed system and method |
US6524557B1 (en) | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
WO2003015750A1 (en) | 2001-08-16 | 2003-02-27 | Baxter International, Inc. | Propellant-based microparticle formulations |
EP1338272A1 (en) | 1998-12-21 | 2003-08-27 | Generex Pharmaceuticals Inc. | Aerosol formulations for buccal and pulmonary application comprising chenodeoxycholate or deoxycholate |
US20030165436A1 (en) | 2000-04-17 | 2003-09-04 | Staniforth John Nicholas | Formulations for use in inhaler devices |
WO2003072080A1 (en) | 2002-02-22 | 2003-09-04 | Advanced Inhalation Research, Inc. | Inhalable formulations for sustained release |
WO2003079885A2 (en) | 2002-03-20 | 2003-10-02 | Advanced Inhalation Research, Inc. | Inhalable sustained therapeutic formulations |
US6632456B1 (en) | 1993-06-24 | 2003-10-14 | Astrazeneca Ab | Compositions for inhalation |
WO2003094886A2 (en) | 2002-05-07 | 2003-11-20 | Ferring Bv | Desmopressin in an orodispersible dosage form |
US20050075342A1 (en) * | 2003-01-09 | 2005-04-07 | Fujisawa Pharmaceutical Co., Ltd. | Pyrrolopyridazine derivatives |
WO2008099902A1 (en) * | 2007-02-15 | 2008-08-21 | Ishihara Sangyo Kaisha, Ltd. | Pyridyl-triazolopyrimidine derivative or its salt, pesticide containing it and its production process |
-
2009
- 2009-11-19 WO PCT/US2009/065162 patent/WO2010059836A1/en active Application Filing
Patent Citations (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988001165A1 (en) | 1986-08-11 | 1988-02-25 | Innovata Biomed Limited | Pharmaceutical formulations comprising microcapsules |
US5179079A (en) | 1986-12-16 | 1993-01-12 | Novo Nordisk A/S | Nasal formulation and intranasal administration therewith |
US5204108A (en) | 1987-10-10 | 1993-04-20 | Danbiosyst Uk Ltd. | Transmucosal formulations of low molecular weight peptide drugs |
WO1989004179A1 (en) | 1987-11-03 | 1989-05-18 | Also Laboratori S.A.S. | Pharmaceutical formulations for transdermal administration |
WO1990007923A1 (en) | 1989-01-19 | 1990-07-26 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
WO1990009781A1 (en) | 1989-02-23 | 1990-09-07 | Rorer International (Holdings), Inc. | Therapeutic aerosol formulations |
WO1991004011A1 (en) | 1989-09-20 | 1991-04-04 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
US5348730A (en) | 1989-09-20 | 1994-09-20 | Minnesota Mining And Manufacturing Company | Method for preparing medicinal aerosol formulation containing coated medicament |
US5230884A (en) | 1990-09-11 | 1993-07-27 | University Of Wales College Of Cardiff | Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations |
US5292499A (en) | 1990-09-11 | 1994-03-08 | University Of Wales College Of Cardiff | Method of preparing medical aerosol formulations including drug dissolved in reverse micelles |
US5324718A (en) | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
US5472954A (en) | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
US6632456B1 (en) | 1993-06-24 | 2003-10-14 | Astrazeneca Ab | Compositions for inhalation |
WO1996011705A1 (en) | 1994-10-13 | 1996-04-25 | Pharmaderm Research & Development Ltd. | Formulations comprising therapeutically-active proteins or polypeptides |
US6524557B1 (en) | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
EP0736299A1 (en) | 1995-04-03 | 1996-10-09 | Cerbios-Pharma S.A. | Process for preparing a liposomal, water-dispersable, solid, dry, therapeutic formulation for oral administration |
US20020141945A1 (en) | 1995-04-14 | 2002-10-03 | Foster Linda C. | Stable glassy state powder formulations |
US6309671B1 (en) | 1995-04-14 | 2001-10-30 | Inhale Therapeutic Systems | Stable glassy state powder formulations |
WO1996040089A2 (en) | 1995-06-07 | 1996-12-19 | Abbott Laboratories | Aerosol drug formulations containing vegetable oils |
WO1997011682A2 (en) | 1995-09-26 | 1997-04-03 | University Of Pittsburgh | Emulsion and micellar formulations for the delivery of biologically active substances to cells |
WO1997013500A2 (en) | 1995-10-12 | 1997-04-17 | Supergen, Inc. | LIPOSOME FORMULATIONS OF 5β STEROIDS |
WO1999059550A1 (en) | 1998-05-20 | 1999-11-25 | The Liposome Company, Inc. | Novel particulate formulations |
US20020034536A1 (en) | 1998-05-20 | 2002-03-21 | Walter Perkins | Novel particulate formulations |
WO2000000176A1 (en) | 1998-06-30 | 2000-01-06 | Quadrant Healthcare (Uk) Limited | Microparticle formulation for inhalation |
US20030008013A1 (en) | 1998-06-30 | 2003-01-09 | Stuart Robinson | Formulation for inhalation |
US20030206939A1 (en) | 1998-07-29 | 2003-11-06 | Pacific Biolink Pty. Limited | Casein formulations for the delivery of bioactive constituents |
WO2000006108A1 (en) | 1998-07-29 | 2000-02-10 | Pacific Biolink Pty. Limited | Casein formulations for the delivery of bioactive constituents |
US6290987B1 (en) | 1998-09-27 | 2001-09-18 | Generex Pharmaceuticals, Inc. | Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids |
EP1338272A1 (en) | 1998-12-21 | 2003-08-27 | Generex Pharmaceuticals Inc. | Aerosol formulations for buccal and pulmonary application comprising chenodeoxycholate or deoxycholate |
US6294153B1 (en) | 1998-12-21 | 2001-09-25 | Generex Pharmaceuticals, Inc. | Aerosol pharmaceutical formulation for pulmonary and nasal delivery |
US6436367B1 (en) | 1998-12-21 | 2002-08-20 | Generex Pharmaceuticals Inc. | Aerosol formulations for buccal and pulmonary application |
WO2000045792A1 (en) | 1999-02-03 | 2000-08-10 | Powderject Research Limited | Hydrogel particle formulations |
US20020061336A1 (en) | 1999-02-03 | 2002-05-23 | O'connor Barbara Horsey | Hydrogel particle formulation |
US6495120B2 (en) | 1999-02-12 | 2002-12-17 | Mccoy Randall | Formulation and system for intra-oral delivery of pharmaceutical agents |
US20020055496A1 (en) | 1999-02-12 | 2002-05-09 | Mccoy Randall | Formulation and system for intra-oral delivery of pharmaceutical agents |
WO2000047203A1 (en) | 1999-02-12 | 2000-08-17 | Mqs, Inc. | Formulation and system for intra-oral delivery of pharmaceutical agents |
WO2000053160A1 (en) | 1999-03-08 | 2000-09-14 | Powderject Research Limited | Delivery of microparticle formulations using needleless syringe device for sustained-release of bioactive compounds |
WO2000062759A1 (en) | 1999-04-16 | 2000-10-26 | Novo Nordisk A/S | Dry, mouldable drug formulation |
US6485706B1 (en) | 1999-06-04 | 2002-11-26 | Delrx Pharmaceutical Corp. | Formulations comprising dehydrated particles of pharma-ceutical agents and process for preparing the same |
US20010036481A1 (en) | 1999-08-25 | 2001-11-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
US20040018243A1 (en) | 1999-08-25 | 2004-01-29 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
WO2001013891A2 (en) | 1999-08-25 | 2001-03-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
US20010038824A1 (en) | 2000-01-20 | 2001-11-08 | Ikuo Horii | Intranasal cyclic peptide formulations |
WO2001060341A1 (en) | 2000-02-17 | 2001-08-23 | Rijksuniversiteit Groningen | Powder formulation |
US20030053960A1 (en) | 2000-02-17 | 2003-03-20 | Rijksuniversiteit Groningen | Powder formulation |
US20030165436A1 (en) | 2000-04-17 | 2003-09-04 | Staniforth John Nicholas | Formulations for use in inhaler devices |
WO2001078696A2 (en) | 2000-04-17 | 2001-10-25 | Vectura Limited | Formulations for use in inhaler devices |
WO2001078694A2 (en) | 2000-04-17 | 2001-10-25 | Vectura Limited | Formulations for use in inhaler devices |
WO2001091728A2 (en) | 2000-06-02 | 2001-12-06 | The Regents Of The University Of Michigan | Nanoemulsion formulations |
WO2002019989A2 (en) | 2000-09-08 | 2002-03-14 | Powderject Research Limited | Alginate particle formulation |
WO2002049621A1 (en) | 2000-12-18 | 2002-06-27 | Licentia Oy | Enteric-coated drug formulations and their manufacture |
WO2002067902A2 (en) | 2001-02-23 | 2002-09-06 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
WO2002080884A2 (en) | 2001-03-21 | 2002-10-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder inhaler formulations |
US20030019437A1 (en) | 2001-07-26 | 2003-01-30 | John Fore | Ungulate game animal feed system and method |
WO2003015750A1 (en) | 2001-08-16 | 2003-02-27 | Baxter International, Inc. | Propellant-based microparticle formulations |
WO2003072080A1 (en) | 2002-02-22 | 2003-09-04 | Advanced Inhalation Research, Inc. | Inhalable formulations for sustained release |
US20030232019A1 (en) | 2002-02-22 | 2003-12-18 | Advanced Inhalation Research, Inc. | Inhalable formulations for sustained release |
WO2003079885A2 (en) | 2002-03-20 | 2003-10-02 | Advanced Inhalation Research, Inc. | Inhalable sustained therapeutic formulations |
WO2003094886A2 (en) | 2002-05-07 | 2003-11-20 | Ferring Bv | Desmopressin in an orodispersible dosage form |
US20050075342A1 (en) * | 2003-01-09 | 2005-04-07 | Fujisawa Pharmaceutical Co., Ltd. | Pyrrolopyridazine derivatives |
WO2008099902A1 (en) * | 2007-02-15 | 2008-08-21 | Ishihara Sangyo Kaisha, Ltd. | Pyridyl-triazolopyrimidine derivative or its salt, pesticide containing it and its production process |
Non-Patent Citations (32)
Title |
---|
"PDE4 inhibitors have been in development as a novel anti-inflammatory therapy since", BRITISH JOURNAL OF PHARMACOLOGY, 1980 |
ANON, CURRENT OPIN.INVETIG.DRUGS, vol. 5, 2004, pages 34 - 39 |
BURNOUF; PRUNIAUX, CURR. PHARM. DESIGN, vol. 8, 2002, pages 1255 - 1296 |
CHERRY ET AL., BIOCHIM.BIOPHYS.ACTA, vol. 1518, 2001, pages 27 - 35 |
DAVIS; GOULD, BEHAV.NEUROSCI., vol. 119, 2005, pages 595 - 602 |
DEMARCH ET AL., NEUROBIOL.DIS., vol. 25, 2007, pages 266 - 273 |
GIEMBYCZ, BRIT.J.PHARMACOL, vol. 155, 2008, pages 288 - 290 |
GIEMBYCZ, CURR. OPIN. PHARM., vol. 5, 2005, pages 238 - 244 |
HARRIS; CHESS, NATURE REVIEWS DRUG DISCOVERY, vol. 2, pages 214 - 221 |
HOUSLAY ET AL., DDT, vol. 10, 2005, pages 1503 - 1519 |
HOUSLAY ET AL., DRUG DISCOV TODAY, vol. 10, 2005, pages 1503 - 1519 |
HUANG ET AL., BIOCHEMICAL PHARMACOLOGY, vol. 73, 2007, pages 1971 - 1981 |
KAIHO ET AL., BJU INT., vol. 101, 2008, pages 615 - 20 |
KANES ET AL., NEUROSCIENCE, vol. 144, 2007, pages 239 - 246 |
KITTA ET AL., BJU INT., vol. 102, 2008, pages 1472 - 1476 |
LERNER ET AL., BIOCHEM.J., vol. 393, 2006, pages 21 - 41 |
LERNER ET AL., BIOCHEMJ., vol. 393, 2006, pages 21 - 41 |
LIPWORTH, LANCET, vol. 365, 2005, pages 167 - 175 |
MAEHR, J. CHEM. ED., vol. 62, 1985, pages 114 - 120 |
MENDIOLA, J., JOC, vol. 69, 2004, pages 4974 - 83 |
NAMING: "Indexing of Chemical Substances for Chemical Abstracts", vol. 1196, AMERICAN CHEMICAL SOCIETY, pages: 1127 |
OGAWA ET AL., BLOOD, vol. 99, 2002, pages 3390 - 3397 |
POLESSKAYA ET AL., BIOL.PSYCHIATR., vol. 61, 2007, pages 56 - 64 |
PRAUSNITZ ET AL., NATURE REVIEWS DRUG DISCOVERY, vol. 3, 2004, pages 115 |
PROTECTION FOR THE HYDROXYL GROUP, INCLUDING 1,2- AND 1,3-DIOLS, pages 10 - 86 |
REMINGTON: "The Science and Practice of Pharmacy", 2000 |
REMINGTON: "The Science and Practice of Pharmacy", vol. 1, 1995, pages: 176 - 177 |
SHIOTA ET AL.: "Regioselective Reactions of Organozinc reagents with 2,4-Dichloropyrazolo[1,5-a]pyrimidine", J. ORG. CHEM., vol. 64, no. 2, 1 August 1999 (1999-08-01), pages 453 - 457, XP002564166 * |
T.W.GREENE: "Organic Synthesis", 1991, JOHN WILEY & SONS |
TORPHY; PAGE, TIPS, vol. 21, 2000, pages 157 - 159 |
YAO ET AL., J.MUSCULOSKELET.NEURONAL INTERACT., vol. 7, 2007, pages 119 - 130 |
ZHANG ET AL., NEUROPSVCHOPHARMACOLOGY, 15 August 2007 (2007-08-15) |
Cited By (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8791267B2 (en) | 2007-11-21 | 2014-07-29 | Decode Genetics Ehf | Biaryl PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders |
EP2410857A1 (en) * | 2009-03-23 | 2012-02-01 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
US20120064181A1 (en) * | 2009-03-23 | 2012-03-15 | Burgey Christopher S | P2X3 Receptor Antagonists for Treatment of Pain |
EP2410857A4 (en) * | 2009-03-23 | 2012-10-31 | Merck Sharp & Dohme | P2x3, receptor antagonists for treatment of pain |
US9238647B2 (en) * | 2009-03-23 | 2016-01-19 | Merck Sharp & Dohme Corp. | P2X3 receptor antagonists for treatment of pain |
US8716282B2 (en) | 2009-10-30 | 2014-05-06 | Janssen Pharmaceutica Nv | Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors |
US8859543B2 (en) | 2010-03-09 | 2014-10-14 | Janssen Pharmaceutica Nv | Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases |
US9309250B2 (en) | 2011-06-22 | 2016-04-12 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors |
US10604523B2 (en) | 2011-06-27 | 2020-03-31 | Janssen Pharmaceutica Nv | 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives |
US20140303141A1 (en) * | 2011-09-19 | 2014-10-09 | Hoffmann-La Roche Inc. | Triazolopyridine compounds |
US8946427B2 (en) * | 2011-09-19 | 2015-02-03 | Hoffmann-La Roche Inc. | Triazolopyridine compounds |
US9669035B2 (en) | 2012-06-26 | 2017-06-06 | Janssen Pharmaceutica Nv | Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl-[1,2,4]triazolo-[4,3-A]]quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological of metabolic disorders |
US9550784B2 (en) | 2012-07-09 | 2017-01-24 | Beerse Pharmaceutica NV | Inhibitors of phosphodiesterase 10 enzyme |
US9556169B2 (en) | 2012-11-19 | 2017-01-31 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
US8871754B2 (en) | 2012-11-19 | 2014-10-28 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
US9926314B2 (en) | 2012-11-19 | 2018-03-27 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
US10787452B2 (en) | 2012-12-07 | 2020-09-29 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US11117900B2 (en) | 2012-12-07 | 2021-09-14 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9340546B2 (en) | 2012-12-07 | 2016-05-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US11370798B2 (en) | 2012-12-07 | 2022-06-28 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US10392391B2 (en) | 2012-12-07 | 2019-08-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9650381B2 (en) | 2012-12-07 | 2017-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9718827B2 (en) | 2012-12-07 | 2017-08-01 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9120788B2 (en) | 2013-02-19 | 2015-09-01 | Pfizer Inc. | Azabenzimidazole compounds |
US9815832B2 (en) | 2013-02-19 | 2017-11-14 | Pfizer Inc. | Azabenzimidazole compounds |
US9120770B2 (en) | 2013-03-14 | 2015-09-01 | Dart Neuroscience (Cayman) Ltd. | Substituted pyridine and pyrazine compounds as PDE4 inhibitors |
US9573937B2 (en) | 2013-03-14 | 2017-02-21 | Dart Neuroscience (Cayman) Ltd. | Substituted pyridine and pyrazine compounds as PDE4 inhibitors |
US11279691B2 (en) | 2013-03-14 | 2022-03-22 | Dart Neuroscience Llc | Substituted pyridine and pyrazine compounds as PDE4 inhibitors |
EP3345902A1 (en) | 2013-03-14 | 2018-07-11 | Dart NeuroScience (Cayman) Ltd | Substituted pyridine and pyrazine compounds as pde4 inhibitors |
US9040692B2 (en) | 2013-03-14 | 2015-05-26 | Dart Neuroscience (Cayman) Ltd. | Substituted pyridine and pyrazine compounds as PDE4 inhibitors |
US8957078B2 (en) | 2013-03-15 | 2015-02-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9663519B2 (en) | 2013-03-15 | 2017-05-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8969360B2 (en) | 2013-03-15 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9273058B2 (en) | 2013-11-14 | 2016-03-01 | Bristol-Myers Squibb Company | Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitors |
US10160760B2 (en) | 2013-12-06 | 2018-12-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US10815239B2 (en) | 2013-12-06 | 2020-10-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US11485739B2 (en) | 2013-12-06 | 2022-11-01 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9670215B2 (en) | 2014-06-05 | 2017-06-06 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US10093676B2 (en) | 2014-06-05 | 2018-10-09 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US10800781B2 (en) | 2014-06-05 | 2020-10-13 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US11179394B2 (en) | 2014-06-17 | 2021-11-23 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of Chk1 and ATR inhibitors |
US10131669B2 (en) | 2014-07-24 | 2018-11-20 | Pfizer Inc. | Pyrazolopyrimidine compounds |
US10669279B2 (en) | 2014-08-06 | 2020-06-02 | Pfizer Inc. | Imidazopyridazine compounds |
US9598421B2 (en) | 2014-08-06 | 2017-03-21 | Pfizer Inc. | Imidazopyridazine compounds |
US10077269B2 (en) | 2014-08-06 | 2018-09-18 | Pfizer Inc. | Imidazopyridazine compounds |
US11464774B2 (en) | 2015-09-30 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
US11718622B2 (en) | 2020-03-16 | 2023-08-08 | Exelixis Inc. | Heterocyclic adenosine receptor antagonists |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010059836A1 (en) | Substituted aza-bridged bicyclics for cardiovascular and cns disease | |
WO2010059838A2 (en) | Pde4 inhibitors selective for the long form of pde4 for treating inflammation and avoiding side effects | |
JP6236173B2 (en) | Compounds for treating spinal muscular atrophy | |
US8791267B2 (en) | Biaryl PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders | |
CN110437205B (en) | Pyridinonylpiperidine derivatives and use thereof | |
JP4248239B2 (en) | Pyrrolo [2,3-d] pyrimidines and their use as purinergic receptor antagonists | |
JP4284069B2 (en) | Purine derivatives as purinergic receptor antagonists | |
US8883833B2 (en) | Substituted benzoazole PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders | |
US7834014B2 (en) | A2a adenosine receptor antagonists | |
JP2018519273A (en) | Compounds for treating spinal muscular atrophy | |
CN111004214B (en) | Pyridylpiperidine derivatives and use thereof | |
CN107880038B (en) | [1,2,4] triazolo [1,5-a ] pyridine compound and preparation method and medical application thereof | |
US8877816B2 (en) | 4-(or 5-) substituted catechol derivatives | |
US20240101563A1 (en) | Novel compounds | |
JP2008501618A6 (en) | Pyridinylpyrazolopyrimidinone derivatives having PDE7 inhibitory action | |
CN111187251A (en) | Pyridylpiperidine derivatives and use thereof | |
CN110845402A (en) | Pyridylmethylenepiperazine derivatives and uses thereof | |
CN116262750A (en) | Aromatic heterocyclic compound and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09771443 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09771443 Country of ref document: EP Kind code of ref document: A1 |